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Summary
The human health status is co-determined by the interplay of body composition, metabolism,
and energy balance. In turn, these factors are influenced by genetic predispositions, a
multitude of environmental factors such as nutritional habits or physical activity, and
interactive effects between these parameters. Malnutrition and obesity reflect extreme
phenotypes of body composition, and lead to disturbances in metabolism. Especially obesity
as a prominent health problem in industrialised countries is linked to an increased risk
of morbidity and mortality. Important regulators of energy balance and metabolism are
thyroid hormones and disturbances of their homoeostasis are associated with serious health
problems.
Metabolomics is an evolving field which has the ability to represent a snapshot of the
current metabolic state. Disturbances of pathways can be captured and the utilisation
of closely connected metabolites ratios provides proxies for enzymatic reactions. In this
doctoral thesis, three projects are presented exploring the interplay of body composition,
metabolism, and energy homeostasis by focusing on gene–nutrition interactions and their
effect on obesity risk, the relationship between fat free mass and the serum metabolite
profile of adults, and the influence of thyroid hormones on the metabolism in euthyroid
adult participants.
The first project aims at improving the understanding of inter-individual variance and
susceptibility towards obesity. Common obesity is the result of a genetic predisposition in
combination with nowadays modern environment which encourages a sedentary lifestyle and
often leads to an imbalance in energy intake and expenditure, subsequently followed by weight
gain. To this end, adjusted logistic regression models are used to analyse the interaction
effects between single nucleotide polymorphisms (SNPs) of different candidate genes for
obesity and polyunsaturated fatty acids (PUFAs) analysed in erythrocyte membranes, which
are valid biomarkers for PUFA intake, on the obesity risk in adults participating in a cross-
sectional population-based study. Several significant SNP–PUFA interactions are identified,
indicating regulatory effects of PUFAs by gene variants of interleukin (IL)-2, IL-6, IL-18,
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tumour necrosis factor receptor superfamily (TNFRSF ) member 1B and 21, leptin receptor
(LEPR), and adiponectin (ADIPOQ). Due to the limited statistical power of this study,
these results have to be reproduced in a sufficiently sized prospective study. If replicated, our
results would indicate a beneficial effect of high PUFA supply for a substantial proportion
of the population with respect to obesity risk.
Aspiration of the second project is to provide a comprehensive picture of fat free mass induced
effects on the metabolite profile in blood samples of adults. Further, it is hypothesised that
a sedentary lifestyle leads to derangements in skeletal muscle metabolism, e.g., favouring
the development of obesity. Thus, the associations between the fat free mass index (FFMI)
and up to 190 serum metabolite concentrations - with a focus on amino acids, acylcarnitines,
phosphatidylcholines (PCs), and sphingomyelins - and all intra-class metabolite ratios are
investigated by means of adjusted linear regression models in cross-sectional analyses of
a cohort study. These analyses reveal 339 significant associations between FFMI and
various metabolites and metabolite ratios. Among the most prominent associations with
higher FFMI are increasing concentrations of the branched-chain amino acids (BCAAs),
ratios of BCAAs to glucogenic amino acids, and carnitine concentrations. These findings
are in agreement with the expected metabolic situation in fasted participants. Most of
these results are replicated in the follow-up survey of the analysed baseline study. In
order to draw a comprehensive picture of the FFMI effects, Gaussian graphical models
(GGMs) are computed. These models have previously been shown to reveal the true
relationships among metabolites. Further, genetic aspects are investigated. To this end, the
relationships between SNPs described to be associated with anthropometric characteristics
and the metabolite variables are analysed; however, no significant association is revealed.
Sensitivity and stratified analyses are carefully performed. Most interestingly, almost all
associations which are found for the entire sample are largely missing in the obese subgroup
supporting our hypothesis that the accumulation of body fat tissue may be accompanied
by a derangement in skeletal muscle metabolism.
The aim of the third project is to identify thyroid hormone related changes on metabolism
of fasting euthyroid participants in a cross-sectional analysis of a cohort study. To this end,
the associations between free tyroxine (FT4), thyrotropin (TSH), and 151 metabolites as
well as their pairwise intra-class metabolite ratios are analysed in adjusted linear regression
models. Increased serum FT4 levels are associated with an overall enhanced transport to
the mitochondria and β-oxidation of fatty acids which is reflected by significantly increased
serum acylcarnitine concentrations and decreased PC concentrations. Further, these findings
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are largely stable as they could be reproduced in different subsets of the population, including
obese versus non-obese participants. No significant associations are found between the
metabolite variables and the TSH concentrations.
In summary, this doctoral thesis provides indication of a beneficial effect of high PUFA
supply for specific genotype carriers with respect to obesity risk. An extensive image of
FFMI effects in a data-driven metabolic network is revealed and high body fat accumulation
is linked to a derangement in skeletal muscle metabolism. Further, this thesis broadens
our knowledge of FT4 triggered pathways in euthyroid participants. Thus, this thesis




Der Gesundheitszustand des Menschen wird neben anderen Faktoren durch das Zusam-
menspiel von Körperzusammensetzung, Stoffwechsel und Energiehaushalt bestimmt. Diese
Faktoren werden wiederum durch genetische Prädispositionen, eine Vielzahl von Umwelt-
faktoren, wie beispielsweise Ernährungsgewohnheiten oder körperliche Aktivität, sowie durch
Interaktionseffekte dieser Parameter beeinflusst. Unterernährung und Adipositas reflektieren
extreme Phänotypen der Körperzusammensetzung und führen zu Störungen im Stoffwech-
sel. Insbesondere Adipositas, ein prominentes Gesundheitsproblem in den industrialisierten
Ländern, erhöht das Morbiditäts- und Mortalitätsrisiko. Der Energiehaushalt und der
Stoffwechsel unterliegen einem starken Einfluss der Schilddrüsenhormone. Störungen ihrer
Homöostase sind mit schweren gesundheitlichen Problemen verbunden.
Die Metabolomforschung (englisch “metabolomics”) ist ein sich entwickelndes Forschungs-
gebiet, welches es an Hand der gemessenen Metaboliten ermöglicht, eine Momentaufnahme
der aktuellen Stoffwechsellage abzuzeichnen. Darüber hinaus bietet die Untersuchung der
Metaboliten die Möglichkeit, Störungen in Stoffwechselwegen zu erfassen und durch die Ver-
wendung von Metaboliten-Quotienten enzymatische Reaktionen zu identifizieren. In dieser
Dissertation werden drei Projekte vorgestellt, welche das Zusammenspiel von Körperzusam-
mensetzung, Stoffwechsel und Energiehaushalt erforschen. Die Schwerpunkte liegen dabei
auf Gen–Ernährungs–Interaktionen und ihre Auswirkungen auf das Adipositasrisiko, auf
der Beziehung zwischen der fettfreien Masse und den Serum–Metaboliten–Profilen Erwach-
sener, sowie auf dem Einfluss der Schilddrüsenhormone auf den Stoffwechsel; letzterer
widergespiegelt in den Serum–Metaboliten–Profilen euthyroider erwachsener Studienteil-
nehmer.
Das erste Projekt zielt darauf ab, das Verständnis der inter-individuellen Variabilität und
Empfänglichkeit gegenüber Adipositas zu verbessern. Adipositas ist das Ergebnis einer ge-
netischen Prädisposition in Kombination mit dem heutigen modernen Lebensumfeld. Dieses
ist oft geprägt von einer sitzenden Lebensweise und führt dadurch zu einem Ungleichgewicht
in Energieaufnahme und -verbrauch, welches letztendlich mit einer Gewichtszunahme
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verbunden ist. Bezüglich des Adipositasrisikos bei Erwachsenen werden die Wechsel-
wirkungen zwischen Einzelnukleotid-Polymorphismen (SNPs) unterschiedlicher Adipositas-
Kandidatengene und der Erythrozytenmembranzusammensetzung mehrfach ungesättigter
Fettsäuren (PUFAs), welche valide Biomarker für die PUFA–Zufuhr darstellen, mit Hilfe von
adjustierten logistischen Regressionsmodellen in einer populationsbasierten Querschnitts-
studie untersucht. Mehrere signifikante SNP-PUFA-Interaktionen werden gefunden, die auf
einen regulatorischen Effekt der PUFA auf Genvarianten von Interleukin (IL)-2, IL-6, IL-18,
Tumornekrosefaktor-Rezeptor-Superfamilie (TNFRSF ) Element 1B und 21, Leptin–Rezeptor
(LEPR) und Adiponektin (ADIPOQ) hinweisen. Aufgrund der begrenzten statistischen
Teststärke dieser Studie sollten diese Ergebnisse in einer ausreichend großen prospektiven
Studie repliziert werden. Bei Bestätigung der hier dargestellten Ergebnisse, würden diese eine
positive Wirkung einer hohen PUFA-Versorgung für einen erheblichen Anteil der Bevölkerung
im Hinblick auf das Adipositasrisiko anzeigen.
Im zweiten Projekt soll ein umfassendes Bild der durch die fettfreie Masse (als Proxy
für die Muskelmasse) induzierten Effekte auf das Stoffwechselprofil in Blutproben von
Erwachsenen ermittelt werden. Ebenso soll die Hypothese geklärt werden, ob eine sitzende
Lebensweise zu Störungen des Skelettmuskulatur–Stoffwechsels führen kann, welche z.B. die
Entwicklung von Adipositas begünstigen könnten. Dazu werden die Assoziationen zwischen
dem fettfreien Masse Index (FFMI) und bis zu 190 Serummetaboliten (unter anderem
Aminosäuren, Acylcarnitine, Phosphatidylcholine (PCs) und Sphingomyeline) sowie der
paarweisen Metaboliten-Quotienten innerhalb der einzelnen Klassen mit Hilfe von adjustier-
ten linearen Modellen in unabhängigen Querschnittsauswertungen einer Kohortenstudie
untersucht. Es werden 339 signifikante Assoziationen zwischen FFMI und den verschiedenen
Metaboliten und Metaboliten-Quotienten gefunden. Zu den prominentesten Assoziationen
mit höherem FFMI gehören steigende Konzentrationen der verzweigtkettigen Aminosäuren
(BCAA), Assoziationen mit Quotienten von BCAAs zu glukogenen Aminosäuren und mit
verschiedenen Carnitin-Konzentrationen. Diese Ergebnisse stimmen mit den Erwartungen
bezüglich des Stoffwechsels nüchterner Personen überein. Die meisten dieser Ergebnisse
werden auch im Follow-Up der analysierten Studie repliziert. Um ein umfassendes Bild
der FFMI-Effekte aufzuzeigen, werden Gauß’sche graphische Modelle (GGMs) gerechnet.
Vor kurzem wurde gezeigt, dass diese Modelle die wahren Beziehungen zwischen einzelnen
Metaboliten offenlegen können. In diesem Projekt werden ebenfalls genetische Aspekte
berücksichtigt. Dazu werden die Assoziationen zwischen SNPs, für die ein Zusammenhang
mit anthropometrischen Merkmalen beschrieben wurde, und den Metabolitenvariablen un-
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tersucht. Jedoch werden keine signifikanten Assoziationen gefunden. Sensitivitätsanalysen
und stratifizierte Analysen werden sorgfältig realisiert. Interessanterweise fehlen fast alle
Assoziationen, die für die gesamte Population vorhanden sind, in der adipösen Untergruppe.
Dieses Ergebnis unterstützt unsere Hypothese, dass eine Akkumulation von Fettgewebe
möglicherweise mit einer Störung im Skelettmuskulatur–Stoffwechsel einhergeht.
Die Zielsetzung des dritten Projektes ist es, die Auswirkungen der Schilddrüsenhormone
auf den Stoffwechsel bei nüchternen euthyroiden Teilnehmern einer Kohortenstudie in einer
unabhängigen Querschnittsauswertung zu analysieren. Zu diesem Zweck werden die Assozi-
ationen zwischen freiem Tyroxin (FT4), Thyreotropin (TSH), und 151 Metaboliten sowie
der paarweisen Metaboliten-Quotienten innerhalb der einzelnen Klassen mittels adjustierter
linearer Modelle untersucht. Eine erhöhte Serumkonzentration des FT4 ist mit einem
insgesamt verbesserten Transport in die Mitochondrien und einer gesteigerten β-Oxidation
der Fettsäuren verbunden, welche durch signifikant erhöhte Serum–Konzentrationen von
Acylcarnitinen und verringerte Konzentrationen von PCs angezeigt wird. Diese Ergebnisse
sind weitgehend stabil, da sie in verschiedenen Subgruppen, unter anderem in adipösen
versus nicht-adipösen Studienteinehmern, reproduziert werden können. Zwischen den TSH–
Konzentrationen und den Serum–Metaboliten-Profilen sind keine signifikanten Beziehungen
gefunden worden.
Zusammenfassend liefert diese Dissertation Hinweise auf einen positiven Effekt einer er-
höhten PUFA–Versorgung für spezifische Genotyp–Träger mit Bezug auf das Adipositas-
risiko. Sie zeigt ein umfangreiches Bild der FFMI–Effekte auf den Stoffwechsel in einem
datengesteuerten Netzwerk auf und gibt Hinweise darauf, dass eine hohe Körperfettakku-
mulation mit einer Störung des Skelettmuskulatur-Stoffwechsels verbunden ist. Darüber
hinaus wird unser Wissen über FT4–gesteuerte Stoffwechselwege in euthyroiden Personen
erweitert. Somit gewährt diese Arbeit einen tieferen Einblick in das Zusammenspiel von
Körperzusammensetzung, Stoffwechsel und Energiehaushalt.
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1 Introduction
Among the multitude of factors which influence the human health status are body compos-
ition, metabolism, and energy homeostasis. These factors do not only co-determine our
health status, they are also dependent on one another, and are themselves influenced by
many environmental and genetic parameters. This doctoral thesis aims at contributing new
aspects to this broad research area. Gene–Nutrition interactions and their effects on obesity
risk are explored. The relationship between the fat free mass and adult serum metabolite
profiles is investigated, and the influence of thyroid hormones on the metabolic makeup of
euthyroid participants is analysed.
For our research important topics such as body composition (1.1), blood metabolites (1.2),
and thyroid hormones (1.3) are introduced in this chapter. The three studies in which we
explored our research questions and the utilised analyses methods are described in chapter 2.
The results are given in chapter 3 and are followed by a comprehensive discussion. The last
chapter of this doctoral thesis provides future prospects in this scientific field.
1.1 Body Composition
The characterisation and classification of the human body in the context of health and
disease have been discussed ever since. There is hardly any epidemiological setting in which
anthropometric aspects of the human body or its composition are not involved, either as
adjustment parameters or as primary point of interest. The composition of the human
body can be measured at the atomic (oxygen, carbon, hydrogen, nitrogen, calcium, and
phosphorus), molecular (water, lipid, protein, mineral, and glycogen), cellular (extracellular
(EC) fluid, EC solids, and cell mass), tissue (skeletal muscle, adipose tissue, bone, and
blood), or at the whole body level (Wang et al., 1992) and over the past decades numerous
techniques have therefore evolved (Duren et al., 2008). The major components of the






























Whole Body   
Level (V) 
Figure 1.1: Body composition at different levels. Adapted by permission from the American
Society of Nutrition: Wang et al., copyright (1992).
Neutron activation, isotope dilution or total body counting are methods which assess the
body composition at the atomic, molecular or cellular level and have been described in more
detail by Beechy et al. (2012) and Duren et al. (2008). In this thesis we concentrate on
the body composition measured at the tissue level and the derived two compartment (body
fat mass and fat free mass) model of it. There are direct and indirect methods to assess a
person’s body composition at the tissue level. Direct methods such as computed tomography,
magnetic resonance imaging, dual-energy X-ray absorptiometry, or densitometry measure
the amount and distribution of at least one tissue or the body’s density. Indirect methods
include bioelectrical impedance analysis (BIA) and anthropometric measurements.
Anthropometry is the most basic instrument to assess a person’s body composition. It
is a universally applicable, non-invasive, and inexpensive method to describe body mass,
size, shape, and level of fatness (World Health Organization, 1995; Duren et al., 2008).
Measurements include amongst others weight, height, as well as circumferences of waist
and hip (Beechy et al., 2012). The most prominent anthropometric index, the body mass
index (BMI), was introduced in the late 1980s as a measurement of malnutrition and
obesity (Keys et al., 1972; James et al., 1988). The BMI is defined as the ratio of body
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Table 1.1: The World Health Organisation’s classification of underweight, overweight
and obesity of adults according to BMI. Adapted from the World Health
Organization by permission from the World Health Organization, copyright
(2000).
Classification BMI (kg/m2) Risk of Comorbidities
underweight < 18.5 low (but risk of other clinical
severe thinness < 16.0 problems increases)
moderate thinness 16.0 to < 17.0
mild thinness 17.0 to < 18.5
normal range 18.5 to < 25.0 average
overweight 25.0 to < 30.0 increased
obese ≥ 30.0
obese class I 30.0 to < 35.0 moderate
obese class II 35.0 to < 40.0 severe
obese class III ≥ 40 very severe
weight to squared body height (kg/m2). The World Health Organization (2000) divides
the BMI in four categories (underweight, normal range, overweight, and obese) with three
subcategories to classify each, the severity of underweight and obesity (Table 1.1).
The BMI is often regarded and used as a surrogate measurement of a person’s body
composition as it is presumed to represent the degree of fatness (Duren et al., 2008). For
adults, the correlation between excessive accumulation of body fat mass and a BMI in
the obesity range is quite modest. However, this relationship is influenced by a person’s
physical activity level, age, and race (Dulloo et al., 2010). For example athletes, in particular
bodybuilder, have a very low percentage of body fat, but a great amount of muscle mass
and according to their BMI, they would be classified as obese. Although, the BMI is seen as
a reasonable good predictor of disease risk and early mortality (World Health Organization,
2000), BMI and weight taken on their own are not sufficient to characterise underlying
changes in body composition during ageing or illness (Kyle et al., 2003b). The main
drawback of the BMI, however, is that the actual body composition, e.g., the distribution of
body fat mass and fat free mass, is not considered (Schutz et al., 2002). Nevertheless, the
accessibility to extensive national reference data in adult populations, and the established
relationships between BMI and degree of fatness, mortality and morbidity are considerable
advantages of the BMI (World Health Organization, 1995).
In BIA measurements, the human body functions as a conductor to a small alternating
electrical current (in general 50 kHz) and its resistance in combination with the phase angle
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allows the estimation of total body water. With the assumption of a constant hydration
of the fat free mass of 73.2 % (Wang et al., 1992) and the application of established
equations, e.g., Kyle’s equation (Kyle et al., 2001), body composition can be estimated
in two compartments: the fat free mass and the body fat mass. Because of its feasibility,
minimal cost, portability, and safety, BIA measurements are quite attractive for large-scale
studies (Lee & Gallagher, 2008). However, adequate equations have to be applied as the
accurateness of the calculated values is dependent on the healthy underlying population they
are derived from and on the assumptions made regarding the biological interrelationship
among the body compartments and their distribution (Duren et al., 2008). These equations
are influenced by age, gender, illness, race, or degree of fatness (Rush et al., 2006) and
most often they do not apply to or exist for sick or obese people (Beechy et al., 2012).
Research has indicated that body composition is a principal determinant of health (Segal
et al., 1987). Therefore, Kyle et al. (2003b) propose that the measurement of fat free
mass and body fat mass should be regularly included in health assessments. Depending on
the distribution of fat free mass and body fat mass, two individuals with the same weight
and height may look completely different. As fat free mass and body fat mass change
with weight, height and age it is difficult to classify if a person’s fat free mass or body
fat mass is in the higher or lower range. Therefore, similar to the BMI, the fat free mass
index (FFMI, kg/m2) and accordingly the body fat mass index (BFMI, kg/m2) have been
established and allow for height- and weight-independent interpretations and comparisons
between studies (Kyle et al., 2003b).
In an apparently healthy Caucasian population (n = 5635) aged 18 to 98 years, Schutz et al.
(2002) established the FFMI and BFMI for the 25th and 75th percentiles and different BMIs
(Table 1.2). Deviations from those values might indicate disease, derangement, or obesity
(Kyle et al., 2003b). Four extreme cases are shown in Figure 1.2 (Dulloo et al., 2010): (i)
Combination of low FFMI and low BFMI corresponds to chronic energy deficiency – people
having a low BMI and are probably suffering from anorexia or protein-energy malnutrition;
(ii) Combination of low BFMI and high FFMI corresponds to muscle hypertrophy – people
having a high BMI in the obesity range, without actually being overfat, such as bodybuilders;
(iii) Combination of low FFMI and high BFMI corresponds to sarcopenic elderly or sarcopenic
obesity – people are classified as overfat at different levels of BMI having a substandard
amount of muscle mass in relation to their body fat mass; and (iv) Combination of high
FFMI and high BFMI corresponds to the sumo wrestler type – people having a BMI in
the obese range representative of their excessive body fat and muscle mass. Schutz et al.
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Figure 1.2: Combinations of Fat Free Mass Index (kg/m2) and Body Fat Mass Index
(kg/m2) indicating various conditions. Adapted by permission of the Macmillan
Publishers Ltd.: Dulloo et al., copyright (2010).
(2002) proposed that men with a larger BFMI than 8.2 kg/m2 and women with a larger
BFMI than 11.8 kg/m2 are declared as overfat. In the following the two compartments fat
free mass and body fat mass are further discussed.
1.1.1 Fat Free Mass
In the two compartment model, fat free mass equals body weight minus body fat mass.
Thus, the fat free mass includes next to the skeletal muscles inter alia organs, blood, and
bones (Wang et al., 1992). It is the major contributor to the resting energy expenditure
(REE). This, however, is not so much due to the skeletal muscles, which accounts for about
20 to 30 % of REE, but it is the merit of the organs, such as brain, heart, liver, and kidneys
(Dulloo et al., 2010). Nevertheless, the largest fraction of the fat free mass is the skeletal
muscle (about 50 to 60 % (Dulloo et al., 2010)). It accounts for one-third to one-half of
total body protein, depending on gender, age, and health status (Heymsfield et al., 1990).
As the skeletal muscle mass itself is difficult to measure in most epidemiological studies,
data on fat free mass is often used as a proxy instead.
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Table 1.2: Fat Free Mass Index (FFMI) and Body Fat Mass Index (BFMI) for the 25th
and 75th percentile and different BMIs. Adapted by permission from Macmillan
Publishers Ltd.: Schutz et al., copyright (2002).
Percentiles BMI (kg/m2)
25% 75% 18.5 20.0 25.0
Men
FFMI (kg/m2) 18.2 20.0 16.7 17.5 19.8
BFMI (kg/m2) 3.5 5.9 1.8 2.5 5.2
Women
FFMI (kg/m2) 15.0 16.6 14.6 15.1 16.7
BFMI (kg/m2) 4.9 7.8 3.9 4.9 8.3
The skeletal muscle mass is a major determinant of overall energy requirement of the body.
It is a predictor of basal metabolic rate and especially of energy turn-over during physical
activity. In addition, it has recently been identified as an endocrine organ (Pedersen &
Febbraio, 2008); producing and releasing peptides and cytokines which exhibit various
biological effects on the muscle tissue itself and beyond (Pedersen, 2011). Among the
most important effects of muscle mass and activity with respect to chronic diseases are an
enhanced fat oxidation, improved insulin sensitivity, and a reduced body fat mass. Further,
the effects of the released myokines (peptides and cytokine) during regular exercise seem
to be protective against diseases with chronic inflammation (Pedersen, 2009), e.g., by
modulating the immune response. However, if these endocrine functions of the skeletal
muscles are not stimulated by physical activity, none of these positive effects will occur which
might result in malfunctioning of several organs and tissues and the risk of cardiovascular
disease, cancer, diabetes, or depression could rise (Pedersen & Febbraio, 2008). Pedersen
(2009) summarises those unfavourable health effects under the concept of the “diseasesome
of physical inactivity”. Further, a loss of fat free mass (sarcopenia) is associated with
increased mortality (Allison et al., 1997), especially in the elderly.
1.1.2 Body Fat Mass
Body fat mass is dividable into essential fat mass, the crucial amount of fat which our bodies
need to maintain life and reproductive functioning, and storage fat which is accumulated in
adipose tissue (Wang et al., 1992). Body fat is of multiple uses, e.g., as energy storage,
physical protection for organs, regulation of body temperature, and body fat is involved in
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the fabrication of cell membranes. For quite a while, adipose tissue was only seen as the
largest, inert energy reservoir in the human body. However, since the late 1980’s it has
started to be recognised as a highly active endocrine and metabolic organ (Siiteri, 1987;
Zhang et al., 1994; Ahima & Flier, 2000; Fruhbeck et al., 2001), producing cytokines and
a variety of bioactive peptides, known as adipokines. Further, a large number of receptors
are expressed in the adipose tissue enabling it to communicate with organs and the central
nervous system, as well as to influence a number of processes such as energy metabolism,
neuroendocrine functions, and immune response (Kershaw & Flier, 2004). However, the
excessive storage of body fat leads to obesity and high amounts of body fat, especially
visceral fat and fat in liver tissue (Pischon et al., 2008), are associated with an increased
risk of diseases such as type II diabetes, cardiovascular diseases, several types of cancer, or
renal failure (Galic et al., 2010).
Obesity
Obesity, defined as excessive fat accumulation, is in general measured by the BMI, and
represents a major health burden. By doubling its worldwide prevalence since 1980 (World
Health Organization, 2012), obesity has reached a pandemic state. In May 2012, the
World Health Organization reported, that more than one out of ten adults of the world
population is obese and that each year more than 2.8 million adults die as a consequence
of being obese or overweight (World Health Organization, 2012). Furthermore, obesity and
overweight are responsible for about 44 % of diabetes cases, 23 % of heart disease, and 7
to 41 % of certain cancers (World Health Organization, 2012). According to the National
Nutrition Survey II (Max Rubner-Institut – Bundesforschungsanstalt für Ernährung und
Lebensmittel, 2008), the obesity prevalence in German adults is about 20 % (20.5 % men,
21.2 % women).
Obesity is a multifactorial disorder reflecting complex interactions of genes, environment and
lifestyle (Newell et al., 2007). Industrialisation and modernisation encourage a sedentary
lifestyle with concomitantly increased energy intake, resulting in an imbalance of energy
intake and expenditure (Bell et al., 2005) and consequently in gaining surplus weight.
Further, about 40 to 70 % of the variance in the BMI is accounted for by genetic factors as
several studies of twins, adoptees and families have shown (Maes et al., 1997; Atwood et al.,
2002; Salsberry & Reagan, 2010). Screenings of candidate regions as well as genome-wide
scans have helped to identify single nucleotide polymorphisms (SNPs) which increase the
risk of becoming overweight or obese (Peeters et al., 2009).
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Thus, obesity is the result of an interaction between genetic predisposition and the modern
obesogenic environment (Bouchard, 1991). As it is spreading rather rapidly and representing
a major health problem, it is important to improve the understanding of inter-individual
variance and susceptibility.
1.2 Blood Metabolites
Our blood consists of erythrocytes, leukocytes, and platelets which are suspended in a liquid
straw-coloured carrier called plasma which is responsible for 50 to 55 % of our blood volume
(Fox, 1999; Psychogios et al., 2011). To separate plasma from the cellular part, whole blood
sample are mixed with anticoagulants, centrifuged and then the liquid (plasma) is lifted off
the separated cell mass. If no anticoagulants are added and whole blood samples are left to
clot before they are centrifuged then the liquid which separates from the cellular component
is called serum. Plasma as well as serum includes inter alia proteins, peptides, nutrients,
electrolytes, and organic wastes (Psychogios et al., 2011). The main difference between
plasma and serum is attributable to the (non-) clotting process. For example, eicosanoid
biosynthesis is fully stimulated during the clotting process and thus levels of those serum
metabolites are not reflective of the physiological concentration (Fischer, 1986).
Psychogios et al. (2011) described it in a nutshell: “. . . blood bathes every tissue and every
organ in the body, it essentially serves as a liquid highway for all the molecules that are being
secreted, excreted or discarded by different tissues in response to different physiological
needs or stresses.” As the functioning of our whole body seems to be reflected in our
blood, it is not surprising that its chemical analyses has been focused on for over 70 years
(Kekwick, 1939; Grant & Butt, 1970).
1.2.1 Fatty Acid Composition of the Erythrocyte Membranes
The assessment of dietary fat intake is a task which has not been resolved sufficiently for
many reasons (Arab & Akbar, 2002). Although our nutrition is in part reflected in our
blood constituents, good biomarkers for total fat intake have not yet been found, as our
blood is also reflective of the subsequent metabolism of those fatty acids. However, the
correlation between dietary intake of polyunsaturated fatty acids (PUFAs) and the PUFA
composition of the erythrocyte membranes is quite stable. Thus, the PUFA composition of
erythrocyte membranes is accepted as good biomarker of PUFA intake and metabolism.
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Type of Fatty Acid C:D Common Name  Mean ± SD 
Saturated  
Fatty Acids 
16:0 Palmitic Acid 25.17 ± 6.70 
18:0 Stearic Acid 20.27 ± 3.02 
Mono-unsaturated  




18:2 Linoleic Acid 11.06 ± 2.25 
18:3 γ-Linolenic Acid 0.04 ± 0.02 
20:3 Dihomo-γ-Linolenic Acid 1.54 ± 0.56 
20:4 Arachidonic Acid 13.98 ± 5.22 





18:3 α-Linolenic Acid 0.09 ± 0.05 
20:5 Eicosapentaenoic Acid 0.90 ± 0.71 
22:5 Docosapentaenoic Acid 2.21 ± 1.17 
22:6 Docosahexaenoic Acid 4.66 ± 2.51 
Figure 1.3: Mean and standard deviation (SD) of major fatty acids (% of total fatty acid
methyl ester) measured in the erythrocyte membranes of participants of the
BVS II.
In most cases, the fatty acid composition of the erythrocyte membranes is chromatographed
as fatty acid methyl esters. Different methods are described in more detail by Arab &
Akbar (2002). The fatty acid composition of the erythrocyte membranes of participants of
the second Bavarian Food Consumption Study (BVS II) which is part of the first project,
was analysed by means of gas chromatography (GC) coupled to a flame ionisation detector.
There, analyses were carried out on a polar column which separated the fatty acid methyl
esters based on carbon number and position of double bounds (C:D) and quantification
was done with the help of a flame ionisation detector (2.1.3).
Figure 1.3 shows the main fatty acids which were assessed in the BVS II. For the present
project, linoleic acid (LA, 18:2), arachidonic acid (AA, 20:4) as well as eicosapentaenoic
(EPA, 20:5) and docosahexaenoic acid (DHA, 22:6) were chosen. The PUFA composition
of the erythrocyte membranes reflects both PUFA intake and subsequent metabolism
of the fatty acids over a period of weeks and months (Arab & Akbar, 2002). There
is considerable evidence that not all fatty acids are obesogenic (Storlien et al., 2001).
Approximately 6.2 to 7.4 % of our average daily energy intake is accounted for by PUFAs
(n-3 PUFA 0.7 to 0.9 %; n-6 PUFA 5.5 to 6.5 %; (Linseisen et al., 2003)). PUFAs exert
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Figure 1.4: How PUFAs exert their influence on gene expression and metabolism. Adapted
by permission from S. Karger AG, Basel: Stulnig, copyright (2003).
their influence on cardiovascular function, insulin action, plasma lipid levels (Harris et al.,
1997), neuronal development and the immune system inter alia through modulation of
eicosanoid (prostaglandin and leukotrine) synthesis, activation of orphan nuclear receptor
and T-lymphocyte signalling (Harris et al., 1997; Stulnig, 2003). They also regulate the
transcription and activation of multiple genes (Jump, 2004; Pegorier et al., 2004; Sampath
& Ntambi, 2004). Figure 1.4 shows how PUFAs exert their influence on gene expression
and metabolism.
Hence, PUFAs affect several metabolic pathways, and thus may have an impact on the
development of a series of diseases, including obesity (Storlien et al., 1998; Sampath &
Ntambi, 2004) either directly or through interactive effects with the genetic background.
This hypothesis is supported by the results of different experimental studies (Reseland et al.,
2001; Iwaki et al., 2003; Verlengia et al., 2003; Merzouk et al., 2008).
1.2.2 Metabolomics
As outlines by Fiehn (2002) “Metabolites are the end products of cellular regulatory processes,
and their levels can be regarded as the ultimate response of biological systems to genetic
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Figure 1.5: Metabolomics among the “omics”. Courtesy: LipoFIT Analytic GmbH.
or environmental changes” . Metabolomics is the corresponding “new” research area which
deals with the measurement and quantification of those endogenous organic compounds in
body cells or fluids, thereby fitting well in the world of “omics” which includes genomics,
transcriptomics and proteomics (Figure 1.5). Though, on the basis of biochemical knowledge
the interpretation of metabolomics data is more refined (Krug et al., 2012). There are two
different approaches on the quantification of metabolites. The non-targeted approach aims
at measuring all metabolites within a biospecimen (most analyses are based on blood or
urine). Whereas the concept of targeted metabolomics is the quantification of a defined
set of metabolites in a body fluid, representing an image of the current metabolic state of
the organism (Altmaier et al., 2009). A series of high-throughput quantification methods
has been established inter alia liquid chromatography (LC) or gas chromatography (GC)
coupled to mass spectrometry (MS), or nuclear magnetic resonance spectroscopy. For
comprehensive comparison of these methods see Psychogios et al. (2011).
So far, with an enormous effort over 4000 serum and plasma metabolites belonging to more
than 50 different chemical classes have been identified, validated and characterised in the
Serum Metabolome Database (Psychogios et al., 2011). As this number exceeds the scope
of most studies, a targeted metabolomics approach was chosen for our studies. It has been
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shown previously that this method has the power to identify perturbations of the body’s
metabolic homeostasis and allows for the identification of and access to biomarkers of
metabolic pathways that are impacted for example by diseases (Watson, 2006; Dumas et al.,
2007; Altmaier et al., 2008; Assfalg et al., 2008; Vinayavekhin & Saghatelian, 2009; Suhre
et al., 2010). The analysis kits utilised in the Cooperative Health Research in the Region of
Augsburg (KORA) studies which are part of the second and third project, include amongst
others amino acids, acylcarnitines, phosphatidylcholines (PCs), hexose, sphingomyelins, and
biogenic amines as analytes (2.2.6).
1.3 Thyroid Hormones
Thyroid hormones such as thyroxine (T4) and triiodothyronine (T3) are major regulators
of energy metabolism, especially REE, and are therefore determinants of body weight
(Kim, 2008; Reinehr, 2010). The release of T4 and T3 by the thyroid gland is controlled
by thyroid stimulating hormone (thyrotropin; TSH) which is synthesised by the anterior
pituitary gland in response to TSH-releasing hormone (TRH), which in turn is secreted by
the hypothalamus (Figure 1.6). With a 40-fold higher production, T4 is the quantitatively
main product of the thyroid gland (Yen, 2001). Nevertheless, T3 is the biologically active
hormone and it is produced by local deiodination of T4 in peripheral tissues (Boelaert &
Franklyn, 2005; Moreno et al., 2008). Almost all of T3 and T4 in the circulation is bound to
proteins, such as T4-binding globulin or albumin (Boelaert & Franklyn, 2005). Only about
0.03 % and 0.3 % of total serum T4 and T3, respectively, are free or unbound (Yen, 2001).
However, it is the free thyroid hormones which enter target cells and trigger a biological
reaction (Yen, 2001). Free T3 (FT3) and free T4 (FT4) also exert a negative feed-back
on the production and release of TSH and TRH (Boelaert & Franklyn, 2005; Williams &
Bassett, 2011). Thus, TSH and FT4 have a log-linear relationship in which small changes
in FT4 concentration lead to great differences in TSH concentration (Panicker et al., 2010).
For the synthesis of thyroid hormones, micronutrients such as selenium or iodine are crucial
(Brix et al., 2011).
Thyroid hormones are responsible for the proper function of nearly all organ systems (Brix
et al., 2011). They do not only modulate the metabolism of carbohydrates and lipids,
influence protein synthesis, affect the cellular reaction to catecholamines in almost every
tissue, they are also unique in their ability to influence all over energy expenditure, in
particular the basal metabolic rate, e.g., via the regulation of thermogenesis (Kim, 2008;















Figure 1.6: Hypothalamic-Pituitary-Thyroid Axis. Adapted from Williams & Bassett;
©Society for Endocrinology (2011). Reproduced by permission.
Moreno et al., 2008; Panicker et al., 2010). Their main target tissues are the central
nervous system, cardiovascular system, as well as the skeleton (Brix et al., 2011) and they
are essential for the development (Panicker et al., 2010). With the increasing prevalence of
obesity, a better understanding of energy homeostasis has reclaimed focus (Obregon, 2008).
While it is accepted, that thyroid hormones are major determinants of energy expenditure,
the exact mechanisms concerning these effects are still unknown (Kim, 2008; Moreno
et al., 2008). The “uncoupling hypothesis”, i.e., the transformation of energy into heat
(thermogenesis) by uncoupling of the respiratory chain, is probably the oldest hypothesis,
and explains thyroid hormone effects by a direct action at the mitochondrial level (Moreno
et al., 2008). Since the successful molecular cloning of nuclear thyroid hormone receptors
(TR) (Wagner et al., 1995; Ribeiro et al., 1998), understanding of how thyroid hormone
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exert their effects has further increased (Yen, 2001; Flamant et al., 2007). Most of the
physiological effects of thyroid hormones are exerted through thyroid hormone receptor
complexes and the response elements of regulatory regions of target genes (Brix et al.,
2011; Biondi, 2012a). For example, in a recent microarray study on the transcriptome of
the vastus lateralis, a daily doses of 75 µg T4 was administered to healthy male volunteers
(Clement et al., 2002). As a result, 8 genes involved in the metabolism of glucose and lipids
and 22 genes related to the energy metabolism within the mitochondrion were up-regulated.
Important regulatory elements in these pathways are the different types of deiodinases
which are responsible for the availability of thyroid hormones in tissue (Tarim, 2011). For
example, the type two deiodinases (DIO2) increases local, intercellular T3 production from
T4 (Kim, 2008). Nevertheless, not all thyroid hormone effects are attributable to nuclear
mediated pathways (Moreno et al., 2008) and an increasing number of non-genetic effects
such as the transportation of ions, such as calcium, sodium, and potassium, or glucose and
amino acids across plasma membranes have been described recently (Biondi et al., 2002;
Fazio et al., 2004).The complexity of understanding thyroid hormone actions even increases
if the biological effects shown for metabolites derived from T4 and T3 are considered as
well (Moreno et al., 2008; Cheng et al., 2010; Williams & Bassett, 2011). However, the
proper supply of thyroid hormones is crucial in all phases of life (Brix et al., 2011).
Perturbations of thyroid hormone release and functioning belong to the most common
endocrine disorders and are connected to major health problems during development, in
disease or while ageing (Brix et al., 2011). The absence of thyroid hormones in the brain
can lead to impaired cognitive functioning (Bauer et al., 2008), the absence or abundance of
thyroid hormones in the central nervous system can result in agitation or mismanagement of
body temperature, and further an increased risk for cardiovascular morbidity and mortality
has been linked to an imbalance in thyroid hormones as well (Brix et al., 2011). This
imbalance leads to thyroid diseases such as hyperthyroidism, the excess of T3 and T4
hormones or hypothyroidism characterised by a deficit of T3 and T4 in the body. About
10 % of the population are affected by thyroid diseases (Panicker et al., 2010) and they are
more common in women than men. The pre-stages to hyper- and hypothyroidism are called
subclinical hyper- and hypothyroidism. There, FT3 and FT4 levels are in the reference
ranges, but the TSH concentrations are not (Boelaert & Franklyn, 2005). As a result
of the tremendous consequences of untreated thyroid dysfunction on the cardiovascular
functioning, much attention has been focused on possible links between subclinical thyroid
diseases and the cardiovascular system (Boelaert & Franklyn, 2005; Biondi, 2012b). With
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respect to body weight, hyperthyroidism results in weight loss despite increased appetite
due to the increased metabolic rate, whereas hypothyroidism is accompanied by a moderate
weight gain and a decrease in thermogenesis and metabolic rate (Reinehr, 2010). An
imbalance in thyroid hormones might also be associated with conditions, such as obesity or
low lean body mass. Weight status is the result of energy intake and energy consumption,
whereas the latter is distributable into REE and physical activity (Reinehr, 2010). T3 and
T4 are modulators of many pathways involved in REE and therefore it is not surprising that
an imbalance in thyroid hormones is associated with a change in weight. However, in most
cases obese subjects have a normal functioning thyroid with comparable T4 and FT4 levels
to non-obese subjects.
1.4 Aim of this Thesis
The main objective of this doctoral thesis was to contribute to the ongoing exploration of
genetic and environmental factors which influence the interplay between body composition,
metabolism, as well as energy homeostasis which co-determine our health status. Thus, we
explored the following topics in three different projects:
(i) Gene–PUFA interactions that are associated with obesity risk in adults
(ii) Serum metabolite profiles related to body fat free mass
(iii) Effects of thyroid hormones on the serum metabolite profile in euthyroid adults
In the first project, gene–environment interactions were analysed with respect to obesity
risk in adults. Obesity with a national prevalence of about 20 % has become a worldwide
major public health burden reaching a pandemic state (Max Rubner-Institut – Bundes-
forschungsanstalt für Ernährung und Lebensmittel, 2008; World Health Organization, 2012).
Obesity is considered co-responsible for conditions such as diabetes, certain types of cancers,
or heart diseases and is particular cost-intensive for the health care systems (World Health
Organization, 2012). Thus, expanding our knowledge about the individual susceptibility
towards common obesity is of great urgency. The western lifestyle is associated with
a decrease in physical activity and easy access to high calorie dense food (Bell et al.,
2005). This leads consequently to an imbalance in energy intake and expenditure and
therefore subsequent weight gain. Also, genome-wide scans of candidate genes have
helped to identify gene regions which increase the risk of becoming obese (Peeters et al.,
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2009). We hypothesised that common obesity is the result of a genetic predisposition in
combination with environmental factors. In this project we chose the PUFA composition of
the erythrocyte membranes which reflects PUFA intake as well as its metabolism as the
environmental component to be investigated. PUFAs are known to influence a variety of
body functions, such as the cardiovascular system, insulin action, the immune system, or
the activation and transcription of genes (Harris et al., 1997; Stulnig, 2003; Jump, 2004;
Pegorier et al., 2004; Sampath & Ntambi, 2004) and thus may influence the development
of obesity (Storlien et al., 1998). For this project, we carefully selected 21 genes including
cytokines, neurotransmitters, transcription factors and adipokines out of an existing genetic
dataset, for which a potential influence of PUFAs has been reported and calculated the
interaction effects with different PUFA concentrations of the erythrocyte membranes on
the obesity risk in adults by means of adjusted logistic regression models.
The second project incorporated metabolomics as well as genetics. The aim was to identify
fat free mass – a proxy for muscle mass – related characteristics of human metabolism and
to confirm the findings in a follow-up study. Lewis et al. (2010) investigated the metabolic
signature of physical activity on human plasma metabolites and demonstrated increased
lipolysis during and after exercise in participants with higher endurance as compared to less
fit participants. Hence, we hypothesised that a sedentary lifestyle leads to derangements in
skeletal muscle metabolism favouring the development of obesity and metabolic disease
which is supposedly reflected in the metabolic makeup. The associations between the FFMI
and up to 190 serum metabolites and pairwise intra-class metabolite ratios were analysed
in adjusted linear regression models, Gaussian graphical models (GGMs) were established
to map the true relationship among pairs of metabolites, and also genetic aspects were
investigated in this project. The associations between SNPs which were described to be
associated with anthropometric measurements in genome-wide association studies (GWAS)
and the different metabolite variables were investigated.
Thyroid hormones are involved in the proper function of most organ systems, they are major
modulators of carbohydrate, lipid, and protein metabolism, and they are highly engaged in
the regulation of energy expenditure (Kim, 2008; Moreno et al., 2008; Panicker et al., 2010).
Affecting metabolism and energy balance and thereby body composition thyroid hormones
influence three key factors determining our health status. Although, FT4, FT3, and TSH
are thought to have a strong heritable component, GWAS concerning FT4 or FT3 have
been few and not very fruitful (Panicker et al., 2010). Thus, for the third project we focused
on metabolomics aiming at the identification of pathways which are affected by thyroid
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hormones in euthyroid participants. To this end, the relationship between FT4 as well as
TSH and up to 151 serum metabolite concentrations as well as intra-class metabolite ratios
in thyroid-healthy participants were investigated by means of adjusted linear regression
models.
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2 Materials and Methods
2.1 Second Bavarian Food Consumption Survey
2.1.1 Study Design and Population
The BVS II is a cross-sectional study, representative of the Bavarian population and designed
to investigate dietary and lifestyle habits. German-speaking subjects (n = 1050) aged 13
to 80 years were recruited between September 2002 and June 2003 following a three-step
random route sampling procedure. A total of 42 communities served as sampling points
and were stratified by county and community characteristics. With a given start address, a
random walk (every third household) was conducted and one random household member
who met the inclusion criteria was selected. Information on the subjects’ characteristics,
lifestyle as well as health and socioeconomic status were collected during a personal
computer-assisted face-to-face interview at baseline. The participation rate was 71 %. A
non-responder analysis was performed. On average, non-responders had – among other
characteristics – a higher BMI than the study participants. Within the following two weeks,
data of the subjects’ dietary intake and physical activity were assessed by three 24 hours
dietary recalls (two weekdays and one weekend day), which were conducted via telephone
and by trained interviewers. For the 24 hours dietary recalls, the software EPIC-Soft
(International Agency for Research on Cancer, Lyon, France) was used (Voss et al., 1998;
Slimani et al., 1999, 2000). The participants had to recall their dietary intake as well as
their physical activity of the previous day. All adult subjects (≥ 18 years) who completed
at least one 24 hours recall (n = 879) were invited to their nearest public health office
for blood sampling and standardised anthropometric measurements within 6 weeks after
recruitment. Of these subjects, 65 % (n = 568) accepted this invitation and represented
the subgroup on which this evaluation is based on.
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Ethics Statement
The BVS II study was conducted according to the guidelines laid down in the Declaration
of Helsinki, and all procedures involving human subjects were approved by the Bavarian
Medical Association. Written informed consent was obtained from all study participants.
2.1.2 Anthropometric, Dietary and Physical Activity
Assessment
Height was measured to the nearest 0.5 cm and weight to the closest 0.5 kg. BMI was
calculated as weight/height2 (kg/m2). Participants were classified according to the definition
of the World Health Organization (2000) as obese (BMI ≥ 30 kg/m2) and non-obese
(BMI < 30 kg/m2). Hip size was determined as the widest circumference measured over
the buttocks and waist measurements were taken midway between the iliac crest and the
margin of the lower rip. The German food composition table (Bundeslebensmittelschlüssel,
version II.3; BgVV, Berlin, Germany) was used to calculate nutrient intake. Data were
weighted correspondingly to weekday or weekend day in order to calculate a mean daily
intake per participant. In the telephone interviews, participants were asked to recall their
physical activity of the last 24 hours. Standardised questions on type and duration of the
physical activity in the categories of sports, occupation and other strenuous activities during
leisure time as well as non-occupational television/personal computer use and duration of
sleeping were part of the computer-based interview. Metabolic equivalents (MET) were
matched to each activity and the energy expenditure (MET × h) of every individual was
estimated (Schaller et al., 2005).
2.1.3 Blood Analyses
Blood Sampling
Venous blood was drawn, chilled at 4 ◦C and further processed within 3 hours. Plasma and
buffy coat were separated from erythrocytes by centrifugation (2,000 g for 15 minutes)
before being divided into aliquots and stored at -80 ◦C for further analyses.
Fatty Acid Composition of Erythrocyte Membranes
Membrane fatty acid analysis was conducted using an aliquot of 0.5 ml erythrocyte
suspension. After cell lyses through addition of aqua destillata, the erythrocyte membranes
2.1 Second Bavarian Food Consumption Survey 21
were isolated via centrifugation (20,000 g for 20 minutes at 4 ◦C) and the pellet was
resuspended with Tris-buffer (11 mM-Tris, 1 mMNa-EDTA, pH 7.4); the washing procedure
was repeated twice before adding 800 ml aqua destillata (Golik et al., 1996). Fatty
acid extraction was performed using a mixture of chloroform and methanol (2:1, v/v)
according to a modification of the method described by Folch et al. (1957). The lipids
were extracted twice using a chloroform-methanol mixture with the added antioxidant
butylated hydroxytoluene (50 mg/l) (Wren & Szczepanowksa, 1964). The combination
of these extracts was washed with a CaCl2 solution. The organic phase was collected
and evaporated until dry. Resuspension of that extract was done using chloroform, and
via transesterification with trimethylsulphonium hydroxide, the fatty acid methyl esters
were obtained (Butte, 1983). A 100m CP-Sil-88 capillary column (Varian-Chrompack,
Darmstadt, Germany), which was installed in an HP 5890 series II gas chromatograph
with a flame-ionisation detector (Hewlett Packard, Munich, Germany), was used to identify
and separate the different fatty acid methyl esters. Authentic standards (Sigma-Aldrich,
Steinheim, Germany) were applied to assure a correct identification and quantification of
the fatty acid methyl ester peaks. As a result, the content of twenty-two types of fatty acids
was measured and is expressed as a percentage of the total identified fatty acid methyl
esters (Hoff et al., 2005). For each sample, data represent the mean of two injections.
Analysis of Plasma IL-6
Plasma IL-6 was measured by means of a commercial ELISA kit (Biosource, Brussels,
Belgium). The intra- and inter-assay coefficients of variance were below 7 and 9 %,
respectively.
2.1.4 SNP Selection, Genotyping and Quality Control
The genetic dataset was developed in 2006 and consists of different candidate genes, which
were chosen on the basis of an extensive literature research (Figure 2.1). SNPs covering
these genes as well as 100 kb of region 5’ and 50 kb of region 3’ were selected based on
hapmap data (www.hapmap.org; phases 1 and 2) with a minimum minor allele frequency
(MAF) of 0.05 according to the data of dbSNP Build 125 (a SNP database).
For our analyses, we carefully selected only genes for which an indication of a potential inter-
action with PUFAs was provided by the literature. These include different cytokines and their
receptors (interleukin (IL)-2, IL-6, IL-10, IL-18, tumour necrosis factor-α (TNF-α), TNF
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CHR 1 CHR 2 CHR 3 CHR 4 CHR 5 CHR 6 CHR 7 CHR 8 CHR 9 CHR 10 
IL-10 GCG ADIPOQ IL-2 CART TNF-α LEP ABCA1 
TNFRSF1B POMC GHRL NPY1R IL-4 TNFRSF21 INSIG1 
LEPR INSIG2 SCAP NPY5R GLP1R IL-6 
PPARγ PPARγC1A NPY 
ABCB1 
CHR 11 CHR 12 CHR 13 CHR 14 CHR 15 CHR 16 CHR 17 CHR 18 CHR 19 CHR 20 
IL-18 TNFRDF1A AGRP PYY MC4R RETN MC3R 
INS GNB3 PPY GNAS 
IGF1 SREBF1 
Figure 2.1: Genetic datatset of the obesity candidate genes across the chromosomes
(CHR) in 2006. For the project selected genes are printed in bold.
receptor superfamily 1A, 1B, and 21 (TNFRSF1A, TNFRSF1B, and TNFRSF21)), neuro-
transmitters and receptors (neuropeptide Y (NPY ), NPY receptors type 1, and 5 (NPY1R,
NPY5R), melanocortin 4 receptor (MC4R), proopiomelanocortin (POMC ), pancreatic
polypeptide (PPY ), and peptide YY (PYY )), transcription factors (peroxisome proliferator-
activated receptor gamma (PPARγ) and PPARγ coactivator 1-alpha (PPARγC1A)) and
adipokines (leptin (LEP), leptin receptor (LEPR), adiponectin (ADIPOQ), and resistin
(RETN)). For these genes, the genetic dataset holds a total number of 187 SNPs, consisting
of 180 tagging SNPs, eighteen coding SNPs and twelve candidate SNPs previously reported
to be associated with obesity. The median number of SNPs per gene locus is 11 with
a range of 2 to 16 SNPs. Genotyping was performed by GoldenGate Genotyping Assay
(Illumina, Inc., San Diego, CA, USA) according to the standard protocol of the manufacturer.
Additional inclusion criteria were a MAF of at least 5 % and genotyping call rate of not
less than 95 %, leaving 157 SNPs in the dataset.
2.1.5 Statistical Analyses
The descriptive data are presented as mean and standard deviation for continuous parameters
or as percentage and absolute frequency for qualitative variables. Comparisons between the
groups of obese and non-obese subjects were made by means of either the Mann–Whitney
U test or the Kruskal–Wallis test. Socioeconomic status was categorised based on the
values of three characteristics on a point scale including educational level, social position
and the households’ net income (Winkler & Stolzenberg, 1999). Physical activity data
represent the estimated overall energy expenditure (MET × h) of every individual (Schaller
et al., 2005).
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Departure from the Hardy–Weinberg equilibrium was tested with an exact test (Wigginton
et al., 2005). All selected SNPs were in the Hardy–Weinberg equilibrium except for rs1061624
(TNFRSF1B), rs16475 (NPY ), rs16480 (NPY region 5’) and rs17366743 (ADIPOQ),
applying a p-value of 3.09×10−4 (corrected for multiple testing) as the significance level. For
comparison of the allele frequencies between obese and non-obese subjects, an approximated
X2–test was used. The main effects of SNPs and PUFAs as well as their interaction effects
are derived from a logistic regression model assuming additive genetic effects, and are
presented as odds ratios (OR) with the corresponding 95 % confidence interval (CI). For
the genetic main effect models, SNPs were introduced as discrete parameters with either
three categories (homozygous wild type, heterozygous or homozygous mutant type) or two
categories (homozygous wild type and one or more mutant allele carriers), depending on
the number of subjects in the third category (homozygous mutant type; minimum of ten
subjects). As EPA and DHA were highly correlated, their sum (EPA&DHA) was used. The
fatty acid variables (presented as percentage of fatty acid methyl esters) were established as
continuous parameters. For the interaction models, both SNPs and PUFAs were introduced
as continuous parameters. A likelihood ratio test was used to compare the models with and
without an interaction term and a p-value of 0.05 was regarded as nominally statistically
significant. These p-values are denoted as Pint. The interaction models were adjusted for
sex, age, physical activity, and socioeconomic status and significant SNP–PUFA interactions
were analysed further. The effect of each PUFA with respect to obesity risk was estimated
within the gene strata (homozygous wild type and one or more mutant allele carriers)
of the SNPs using logistic regression models adjusted for sex, age, physical activity, and
socioeconomic status. As the analyses were done within the SNP strata and the number of
people carrying two minor alleles was often quite small, two categories were used for sample
size reasons. We tried different procedures, inter alia by Bonferroni, Holm, Hochberg,
Sidak or Benjamini and Hochberg, to correct our results for multiple testing. However, the
application of each procedure reduced the amount of significant results to zero. Therefore,
all p-values reported in context with the BVS II project are uncorrected and only nominally
significant at α = 5 %. The SNPs were tested for pairwise linkage disequilibrium (LD). If
SNPs were in high LD (r ≥ 0.7), one of them was selected as representative for the LD
block. We chose rs1800795 to represent the IL-6 LD block with rs1800797 (r = 0.935)
and rs2069833 (r = 0.967) and IL-18 SNP rs3882891 to represent rs1946519 (r = 0.77).
As five values of plasma IL-6 were declared as outliers (greater than mean plus five times
the standard deviation), they were excluded from analyses. While plasma IL-6 levels ranged
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between 0.25 and 11.64 pg/ml, the levels of those five outliers were substantially higher
(51.5, 61.8, 68.92, 93.62 and 620.6 pg/ml). The reason for those high values could neither
be clarified nor was a re-analysis of the samples possible. To account for skewness, the
parameter was log-transformed. Plasma IL-6 is presented as geometric mean and 95 % CI.
2.2 KORA S4 and KORA F4 Studies
2.2.1 Design and Study Population
KORA is a research platform performing population-based surveys and subsequent follow-
ups in the region of Augsburg in Southern Germany. The KORA S4 survey includes 4261
participants aged 25 to 74 years (response rate 67 %) and was conducted in 1999 to 2001
(Holle et al., 2005). The KORA F4 survey comprises of 3080 participants which participated
in the seven-year follow-up examination of the KORA S4 survey in 2006 to 2008. In
both studies, baseline information on sociodemographic variables, lifestyle factors, medical
history and medication use, amongst others, was gathered in an extensive standardised
face-to-face interview. Additionally, all participants underwent standardised examinations
such as anthropometric measurements and provieded blood samples.
The analyses in this thesis are based on the metabolically characterised participants of the
KORA S4 and KORA F4 studies and different subsamples of those. The metabolomic
profiles of 1614 participants in KORA S4 (aged 54 to 75 years at the time of examination)
and 3061 participants in KORA F4 (aged 31 to 82 years) were determined. The overlap in
participants is 1134.
The BIA measurements of the participants’ body composition (fat free mass and body fat
mass) were only conducted in KORA S4. As those measurements were also to be used
in connection with the analyses of the KORA F4 data, adjustments had to be made. For
this purpose the KORA F4 weight-stable dataset was generated. A person was defined as
weight-stable if their weight gain or loss did not exceed more than 0.5 % per year since
their body weight was measured in KORA S4 (Nimptsch et al., 2010).
Ethics Statement
The KORA S4 and F4 studies were approved by the ethics committee of the Bavarian
Medical Association. Written informed consent was obtained from each participant in
accordance with institutional requirements and the Declaration of Helsinki Principles.
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Samples for the Metabolomics and FFMI Analyses
The associations between serum metabolite concentrations and FFMI were analysed in
KORA S4 and the KORA F4 weight-stable datasets. Therefore, participants with a
known history of myocardial infarction, stroke, diabetes or cancer were excluded as well
as participants taking angiotensin-converting-enzyme (ACE) inhibitors or anti-lipidemic
drugs. This resulted in a sample size of n = 965 for KORA S4 and n = 890 for KORA F4
weight-stable subgroup with an overlap of n = 725 participants.
Samples for the Metabolomics and Thyroid Hormones Analyses
For this project only euthyroid participants were included. A person was defined as euthyroid
if their FT4 and TSH hormone levels were in the ranges of 9.8 to 18.8 pmol/l and 0.3
to 4.0 mIU/l, according to the assay manuals and Brabant et al. (2006) as well as Surks
et al. (2004), respectively, their thyroid peroxidase antibody level did not exceed 200 IU/ml
(Knudsen et al., 1999; Demers & Spencer, 2003) and there was no known history of
thyroid disease or thyroid medication use in accordance with the anatomical therapeutic
chemical code for thyroid therapy (H03). Further, participants also with a known history of
myocardial infarction, stroke, diabetes or cancer were excluded as well as subjects taking
ACE inhibitors or anti-lipidemic drugs, and women being pregnant at the time of blood
collection. For a subanalysis, data on the subjects’ body composition was used. The sample
sizes were n = 1469 for KORA F4 and of n = 621 for the KORA F4 weight-stable subgroup.
2.2.2 Blood Sampling
In both studies, fasting serum samples for metabolic analysis were collected during study
centre visits. For KORA S4, the blood drawing occurred after a period of overnight-
fasting (minimum of 8 hours) using S-Monovette® serum tubes (SARSTEDT AG & Co.,
Nümbrecht, Germany). Tubes were inverted two to three times, spent 5 minutes on the
universal shaker (SARSTEDT AG & Co., Nümbrecht, Germany) before being allowed to
rest for 40 minutes at 4 ◦C for total coagulation. Later on, tubes were centrifuged for 15
minutes at 2,660 g, serum was separated and filled into synthetic straws (Cryo Bio System,
Paris, France) which were stored in liquid nitrogen (-196 ◦C) until analysis. For KORA F4,
the blood drawing occured between 8 and 10 o’clock in the morning in order to control
variability by circadian rhythm and after a period of overnight fasting. S-Monovette®
serum gel tubes (SARSTEDT AG & Co., Nümbrecht, Germany) were used. After blood
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was drawn, tubes were inverted twice and then allowed to rest for 30 minutes at room
temperature (18 to 25 ◦C) to achieve total coagulation. Later, tubes were centrifuged for
10 minutes at 2,660 g at 15 ◦C and afterwards serum was divided into aliquots, chilled for
a maximum of 6 hours at 4 ◦C before being stored at -80 ◦C until analysis.
2.2.3 Anthropometric, Physical Activity, and BIA Assessment
Height and weight were measured to the nearest 0.1 cm and 0.1 kg, respectively. Waist
circumference was measured to the closest 0.1 cm at the smallest position between the
lower rip and the upper margin of the iliac crest. Hip size was determined exactly to 0.1 cm
as the widest circumference measured between the upper margin of the iliac crest and
the crotch. The BMI was calculated as the ratio of weight by squared height (kg/m2)
and obesity was defined as having a BMI ≥ 30 kg/m2 according to the World Health
Organization (2000).
In KORA S4 and KORA F4, physical activity was assessed on a four-level grated scale by
the amount of regular leisure time exercise per week during summer and winter. Based on
those assessments, Meisinger et al. (2007) defined four levels of physical activity: (i) ’No
sports activities in leisure time’ - almost no sports activity or no activity in summer and in
winter; (ii) ’Low level of sports activities in leisure time’ - irregular exercise of 1 hour per
week at least in summer or winter; (iii) ’Moderate level of sports activity in leisure time’ -
regular exercise of 1 hour per week at least in summer or winter; (iv) ’High level of sports
activities in leisure time’ - more than 2 hours per week of regular exercise in summer and
winter. Based on this variable, the physical activity variable which was used in the present
KORA projects was created representing two levels: ’physically inactive’ - category (i) or
(ii), and ’physically active’ - category (iii) or (iv).
For the assessment of body composition, two BIA measurements of resistance, reactance and
the phase angle were taken between the dominant hand wrist and dorsum, and the dominant
foot angle and dorsum (placement of the electrodes) by means of a body impedance analyser
(BIA 2000-S; Data Input GmbH, Frankfurt, Germany) while participants were spreading
their arms and legs and lying in a relaxed and supine position on a nonconductive surface
with 50 kHz. Fat free mass, body fat mass, and the appendicular skeletal muscle mass
were then calculated by means of Kyle’s equations (Kyle et al., 2001, 2003a) on which the
following indices are based: FFMI (fat free mass in kg/(height in m)2), BFMI (body fat
mass in kg/(height in m)2) and the appendicular skeletal muscle mass index (appendicular
skeletal muscle mass/(height in m)2).
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2.2.4 Genotyping, Imputation and SNP Selection
In KORA F4, genotyping was done by means of Affymetrix Human SNP Array 6.0. HapMap
CEU version 22 was used as population reference and as reference for the imputation of
the genotyped SNPs with IMPUTE v0.4.2. The complete procedure has been described
in more detail (Illig et al., 2010). For a subanalysis within the metabolomics and FFMI
project, 170 SNPs were investigated. The selection of these SNPs is based on an extensive
literature research of GWASs with an anthropometric characteristic, such as lean body
mass (Liu et al., 2009), waist-to-hip ratio (Heid et al., 2010), or BMI (Thorleifsson et al.,
2009; Willer et al., 2009; Speliotes et al., 2010), as outcome. A list of the selected SNPs is
found in Supplementary Table B4.
2.2.5 Measurement of Thyroid Hormones
Concentrations of TSH and FT4 were analysed by immunochemiluminescent procedures
(Dimension Vista System, Siemens, Germany). The functional sensitivity of the TSH assay
was 0.005 mIU/l; the TSH and FT4 working ranges were 0.005 to 100 mIU/l and 1.3 to
103 pmol/l, respectively. The (low or high) inter-assay coefficients of variations were 2.0
or 2.2 % for TSH, and 1.7 or 4.1 % for FT4. All assays were performed according to the
manufacturer’s recommendations. The thyroid peroxidase antibodies were determined by
an enzyme immunoassay (VARELISA, Elias Medizintechnik GmbH, Freiburg, Germany)
with a functional sensitivity of 1 IU/ml.
2.2.6 Metabolomics Datasets
Quantification
Metabolic characterisation of the KORA F4 serum samples was done in 2009 in three
batches of approximately 1000 samples at three time points with a recalibration of the
equipment in between; whereas the complete KORA S4 set was characterised in 2011 in
one batch. The targeted metabolomics approaches for KORA F4 and KORA S4 were based
on electrospray ionisation (ESI)-(LC-)tandem mass spectrometry (MS/MS) measurements
by the AbsoluteIDQTM p150 kit and p180 kit (BIOCRATES, Life Sciences AG, Innsbruck,
Austria), respectively. The assays allow simultaneous quantification of 163 (kit p150;
KORA F4) or 186 (kit p180; KORA S4) metabolites out of 10 µl serum in each case.
The AbsoluteIDQTM p150 kit has previously been described in detail (Illig et al., 2010;
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Römisch-Margl et al., 2012). The p180 kit is an extension of the p150 kit, using additional
LC-MS/MS separation. For both kits, sample handling was performed by a Hamilton Micro
Lab Star robot (Hamilton Bonaduz AG, Bonaduz, Switzerland) and a nitrogen evaporator
(Porvair, Ultravap). MS analyses were done on a 4000 QTRAP mass spectrometer (AB
Sciex) coupled to Promincence HPLC (Shimadzu) apparatus (KORA F4) and an API 4000
LC-MS/MS System (AB Sciex Deutschland GmbH, Darmstadt, Germany) equipped with
an Agilent 1200 Series HPLC and a HTC PAL auto sampler (CTC Analytics, Zwingen,
Switzerland) (KORA S4) controlled by the software Analyst 1.4 for kit p150 (KORA F4) 1.5.1
for kit p180 (KORA S4). Data evaluation for quantification of metabolite concentrations
and quality assessment was performed with the MetIDQTM software package, which is
an integral part of the AbsoluteIDQTM kits. Internal standards serve as reference for the
calculation of metabolite concentrations. The methods of the AbsoluteIDQTM p150 and
p180 kits have been proven to be in conformance with the FDA guideline (U. S. Department
of Health and Human Services and Food and Drug Administration and Center for Drug
Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), May 2001),
which implies proof of reproducibility within an given error range. Measurements were
performed as described in the manufacturer manuals. Concentrations are reported in µmol/l.
Metabolite Spectrum
In total, up to 190 different metabolites were quantified. Kit p150 (KORA F4; 163
metabolites) contains 14 amino acids (13 proteinogenic + ornithine), hexose (sum of
hexoses - about 90 to 95 % glucose), free carnitine and 40 acylcarnitines (Cx:y), 15
sphingomyelins (SMx:y), 77 phosphatidylcholines (PCs; aa = diacyl, ae = acyl-alkyl) and 15
lyso-phosphatidylcholines (lysoPCs). The lipid side chain composition is abbreviated as Cx:y,
with x denoting the number of carbons in the side chain and y denoting the number of double-
bonds. Kit p180 (KORA S4; 186 metabolites) includes 21 amino acids (19 proteinogenic,
citrulline, and ornithine), hexose, free carnitine, 39 acylcarnitines, 15 sphingomyelins, 90
phosphatidylcholines (14 lysoPCs and 76 PCs) as well as 19 biogenic amines. The overlap
of both kits is 159 metabolites. Full biochemical names and abbreviations are provided in
Supplementary Table B1.
Quality Control
The quality control of the metabolomics dataset of KORA F4 was done in a two-step
procedure. First, the quality of all metabolites was assessed using a reference blood which
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was measured five times on ten plates. With this data, a coefficient of variation was
calculated for every metabolite and plate. All metabolites having a mean coefficient of
variation over all ten plates greater than 25 % were removed from the dataset (eleven in
total). One further metabolite was excluded as the number of missing values exceeded
5 %. In the second step, the dataset was controlled for outliers. A participant’s metabolite
concentration was defined as an outlier if the concentration was greater or less than the mean
plus or minus five standard deviations of the particular metabolite over the whole population.
All participants having more than three independent outlying metabolite concentrations
were excluded from the dataset. An outlier was defined as independent if the correlation
with all other outliers was less than 70 %. If there were three or less independent outliers,
only the data points were removed. All missing values were imputed with the R-package
“mice” which uses a linear regression approach. For the quality control of the KORA S4
metabolite dataset, a new coefficient of variation was calculated using the reference blood
which was on all KORA S4 plates. The same quality criteria were applied to the KORA
S4 sample, resulting in 20 metabolites being excluded from the dataset. This left us with
151 metabolites for the KORA F4 dataset and 166 metabolites for KORA S4, with an
overlap of 141 metabolites. As the metabolic profile in KORA F4 samples was assessed
in three batches a so called batch variable was included in all analyses of the KORA F4
metabolomics dataset in order to avoid possible effects due to technical issues or different
time points of analyses. This step was not necessary for the KORA S4 dataset.
2.2.7 Statistical Analyses of the FFMI Project
The descriptive data is presented as mean and standard deviation for the continuous
variables and as absolute quantities and percentages for the qualitative parameters. The
KORA S4 and KORA F4 samples were analysed as independent cross-sectional studies.
Besides the absolute metabolite concentrations, all pairs of intra-metabolite class ratios
(n = 4629 for KORA S4 and n = 4518 for KORA F4) were part of the metabolomics
datasets. Associations between metabolite concentrations or metabolite ratios and the FFMI
were assessed by means of linear regression models. First, metabolite variables (absolute
concentrations and ratios) were standardised with an inverse log-normal transformation
to allow for comparison of the estimates derived from the linear regression models. Then,
linear regression models were applied with the metabolite parameters as dependent variables
and the FFMI as explanatory variable. The models for the KORA S4 metabolomics data
were adjusted for age and sex, whereas the models for KORA F4 were adjusted for age,
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sex, and batch. To control for multiple testing and with regard to the dependencies among
the various metabolites and metabolite ratios, a p-value of 3.12x10−4 for KORA S4 and a
p-value of 3.5x10−4 for KORA F4 were considered to be statistically significant at α = 5 %.
For an association with a metabolite ratio to be regarded as statistically significant, an
additional criterion (the p-gain) had to be fulfilled next to a significant p-value. The p-gain
is defined as the fold decrease in the p-value of association for the pair of metabolites
compared to the lowest of the two p-values for the single metabolites (Suhre et al., 2010).
Thus, an association between a metabolite ratio (M1/M2) and FFMI is considered to
be significant, if the p-value of this association is significant and the p-gain exceeds a
certain value. To calculate the p-gain we first have to determine the minimum p-value of
the associations between metabolite M1 and FFMI as well as metabolite M2 and FFMI.
The p-gain is the quotient of this minimum to the p-value of the association between the
metabolite ratio and FFMI. This p-gain had to exceed 170 for KORA S4 and 150 for KORA
F4 which are approximately the numbers of tested metabolite concentrations in each study.
These cut-offs are seen as Bonferroni related corrections in order to identify metabolite
concentration pairs for which the strength of association improves considerably by using
ratios (Suhre et al., 2010).
Subanalyses
Different subanalyses were performed. First, a different main explanatory variable was used.
Instead of FFMI, the appendicular skeletal muscle mass index was included in the linear
regression models with the same adjustments. Second, stratified analyses were conducted
by age, sex, physical activity, and obesity status as potential confounders or effect modifiers.
Gaussian Graphical Models
In addition to the linear regression analyses, we investigated the relationships between
metabolites as well as the propagation of FFMI effects through the metabolic network by
means of GGMs. In order to obtain a GGM, the partial correlation coefficients between all
pairs of metabolites were calculated (Krumsiek et al., 2011). For KORA S4 each partial
correlation coefficient was controlled for age, sex, FFMI, and the other 164 metabolites
and tested for significance. Bonferroni correction was applied, maintaining a significance
level of α = 1 %. In order to focus on particularly strong effects between metabolites a
cut-off of r = 0.3 (partial correlation coefficient) was applied to the network. Each node
represents a metabolite, whereas edges represent significant partial correlations. Nodes
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were coloured according to the β-estimates and the p-values from the linear models (red =
positive estimate; blue = negative estimate; white = not significant estimate). The same
procedures were applied to the KORA F4 metabolite concentrations including the batch
variable as a confounder.
Genetic Analyses
The associations between serum metabolite concentrations or metabolite ratios and SNPs
which are found to be associated with anthropometric characteristic were analysed using
linear models with the assumption of additive genetic effects. For the metabolite concen-
trations of the genotyped KORA S4 participants (n = 668), models were adjusted for age
and sex. For the analysis with KORA F4 metabolomics dataset (n = 890), adjustments
were made for age, sex and batch. A p-value of 4.73x10−6 for KORA S4 and 5.3x10−6 for
KORA F4 was considered as statistically significant at α = 5 %.
2.2.8 Statistical Analyses of the Thyroid Hormones Project
The descriptive data is presented as described in (2.2.7). For the analyses of the metabolom-
ics dataset (absolute metabolite concentrations (n = 151) and intra-metabolite class ratios
(n = 2188)) and the thyroid hormone levels (FT4 and TSH) linear regression models were
applied. For interpretational reasons, the amount of intra-PC class ratios, as used in (2.2.7),
was restricted to the sub-intra-PC class ratios, i.e., no mixed metabolite ratios between
the PC aa, PC ae, or lysoPC classes. The metabolite variables formed the dependent
parameters and the hormone levels constituted the explanatory variables. Before analyses,
the metabolite variables were standardised as well with an inverse log-normal transformation
to allow for comparison of the estimates. Models were adjusted for age, sex, BMI, and
batch. A p-value of 1.75x10−4 was considered to be statistically significant at α = 5 %
and additionally the ratios’ p-gain had to exceed 2.86x10+03. Since the metabolomics and
FFMI project, Petersen et al. (2012) established a formula to calculate p-gain cut-off values
which replaces the before used common rule of thumb.
Subanalyses
In a subanalysis, the effect of FFMI on the association between FT4 and the metabolomics
data was examined. Therefore, the weight-stable set was used and the applied linear models
were adjusted for FFMI instead of BMI. Stratified analyses of the entire sample were also
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conducted by sex, obesity status, and physical activity as potential confounder or effect
modifiers. The equality of the strata-specific regression coefficients was tested by means
of an approximately normally distributed test-statistic as described by Paternoster et al.
(1998). Further, the influence of different liver, kidney, and inflammation parameters on
the identified associations between the metabolites and FT4 were analysed by including an
interaction term between FT4 and those parameters in the described models.
3 Results and Discussions
3.1 Gene–PUFA Interactions and Obesity Risk
3.1.1 Background
Obesity is a multifactorial disease (Newell et al., 2007) and over the past decades it has
reached a pandemic state by doubling its worldwide prevalence (World Health Organization,
2012). Common obesity is not solely attributable to a genetic predisposition or to physical
inactivity in combination with excessive caloric intake. We hypothesised that common
obesity is the result of interacting environmental and genetic factors. In this project, we
set out to investigate the interaction effects between SNPs of obesity candidate genes and
the PUFA content of erythrocyte membranes, a good biomarker for PUFA intake, with the
aim at increasing our understanding of the individual susceptibility towards obesity. So far,
only a few studies have investigated SNP–PUFA interactions with respect to obesity risk.
We have mainly found human or animal cell studies or dietary intervention studies showing
PUFAs to have an increasing or decreasing effect on the expression of different candidate
genes for obesity. Reseland et al. (2001), for example, found n-3 PUFAs to decrease leptin
gene expression in a dose and time dependent manner within a human trophoblast cell
line. Alnajjar et al. (2006) described the effects of PUFAs on the interleukin production on
the basis of a dietary intervention study (Jordan population). A case-control study in the
European Prospective Investigation into Cancer and Nutrition by Nieters et al. (2002) has
obtained indications for possible interactive effects between dietary intake of PUFAs and
polymorphisms of different obesity candidate gene variants.
3.1.2 Results
Table 3.1 summarises the characteristics of the study population. Obese participants had a
mean BMI of 34.28 ± 4.18 kg/m2 and were on average about 8 years older than non-obese
participants (mean BMI of 24.82 ± 2.99 kg/m2). The mean hip and waist circumference
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Table 3.1: Characteristics (mean, SD, % or N) of obese (BMI ≥ 30 kg/m2) and non-obese
(BMI < 30 kg/m2) participants of the analysed sample of the second Bavarian
Food Consumption Survey (Jourdan et al., 2011).
Obese Subjects Non-Obese Subjects
20.07% 79.93%
Parameter Unit Mean SD Mean SD P-Valuea
Age years 54.86 13.90 46.87 15.17 < 0.001
Weight kg 94.55 13.52 70.85 11.39 < 0.001
Height cm 166.07 9.79 168.7 8.36 0.005
Body Mass Index kg/m2 34.28 4.18 24.82 2.99 < 0.001
Waist cm 113.05 9.94 89.81 10.99 < 0.001
Hip cm 119.74 8.77 104.51 6.18 < 0.001
Waist to Hip Ratio 0.95 0.07 0.86 0.08 < 0.001
Physical Activity MET*h/db 38.94 8.45 39.43 6.79 0.116
Erythrocyte Membranes
Linoleic Acid (% FAMEc) 10.61 2.42 11.17 2.19 0.004
Arachidonic Acid (% FAMEc) 13.30 5.59 14.16 5.12 0.344
EPA&DHAd (% FAMEc) 5.29 3.43 5.64 2.81 0.230
Dietary Intake
Energy Intake kJ/d 7841.53 2727.63 8447.79 2615.88 0.014
Linoleic Acid % en. 5.39 2.27 5.38 2.18 0.828
Arachidonic Acid ‰ en. 0.89 0.61 0.85 0.66 0.148
EPA&DHAd % en. 0.13 0.22 0.11 0.17 0.242
Plasma Concentratione
Interleukin-6 pg/ml 2.37 2.12-2.65 1.38 1.30-1.48 < 0.001
Parameter Category % N % N P-Valuef
Sex male 44.74 51 42.29 192 0.637
female 55.26 63 57.71 262
Age Groups 18 to < 30 years 5.26 6 11.45 52 < 0.001
30 to < 40 years 12.28 14 25.55 116
40 to < 50 years 14.91 17 23.79 108
50 to < 65 years 42.98 49 23.79 108
≥ 65 years 24.56 28 15.42 70
Socio-Economic lower class 22.81 26 33.26 151 < 0.001
Status lower middleclass 14.91 17 22.69 103
middleclass 5.26 6 10.79 49
upper middleclass 36.84 42 20.93 95
upper class 20.18 23 12.33 56
a Mann-Whitney U test; b energy expenditure per day; c fatty acids in % of total fatty acid methyl esters in red blood cell
membranes; d sum of eicosapentaenoic and docosahexaenoic acid; e given as geometric mean and 95 % CI; f Kruskal-Wallis
test.
of obese participants exceeded that of the non-obese participants by 15 cm and 24 cm, the
mean plasma IL-6 level of obese participants was also elevated. There was no significant
difference in sex distribution, physical activity or dietary fatty acid intake between the
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Table 3.2: Significant SNP–linoleic acid interactions on obesity risk, showing the adjusteda
relative risk of obesity (OR, 95 % CI) per 1 mol-% increase in linoleic acid (main
effecta: OR = 0.90, 95 % CI = [0.82, 0.99]) from erythrocyte membranes by
allelic variants (Jourdan et al., 2011).
Gene SNP Allele Non-Obese Obese OR [95 % CI] Pintb
(%) (%)
IL-2 rs2069779 CC 85.8 86.7 0.93 [0.85, 1.03] 0.0310
≥1 T allele 14.2 13.3 0.63 [0.42, 0.87]
IL-2 rs2069762 TT 49.6 51.8 0.84 [0.73, 0.96] 0.0381
≥1 G allele 50.4 48.2 0.96 [0.85, 1.10]
IL-2 region 5’ rs4833248 GG 48.3 50.9 0.81 [0.70, 0.94] 0.0192
≥1 A allele 51.7 49.1 0.96 [0.85, 1.10]
IL-6 rs1800795 GG 33.6 35.4 0.98 [0.84, 1.14] 0.0341
≥1 C allele 66.4 64.6 0.86 [0.76, 0.96]
IL-6 region 3’ rs10242595 AA 49.2 50.0 0.81 [0.71, 0.93] 0.0229
≥1 G allele 50.8 50.0 0.98 [0.87, 1.12]
IL-18 rs3882891 AA 35.0 32.5 1.03 [0.88, 1.22] 0.0237
≥1 C allele 65.0 67.5 0.83 [0.74, 0.94]
LEPR rs1805096 CC 37.5 36.8 1.01 [0.85, 1.20] 0.0084
≥1 T allele 62.5 63.2 0.83 [0.74, 0.93]
a adjusted for age, sex, physical activity, and socioeconomic status; b p-value of the likelihood ratio test (adjusted continuous
interaction model).
Table 3.3: Significant SNP–arachidonic acid interactions on obesity risk, showing the
adjusteda relative risk of obesity (OR, 95 % CI) per 1 mol-% increase in
arachidonic acid (main effecta: OR = 0.97, 95 % CI = [0.94, 1.01]) from
erythrocyte membranes by allelic variants (Jourdan et al., 2011).
Gene SNP Allele Non-Obese Obese OR [95 % CI] Pintb
(%) (%)
IL-2 rs2069779 CC 85.8 86.7 1.00 [0.95, 1.04] 0.0104
≥1 T allele 14.2 13.3 0.83 [0.72, 0.94]
IL-6 rs1800795 GG 33.6 35.4 1.01 [0.94, 1.08] 0.0315
≥1 C allele 66.4 64.6 0.96 [0.91, 1.01]
LEPR rs1805096 CC 37.5 36.8 1.01 [0.94, 1.10] 0.0459
≥1 T allele 62.5 63.2 0.95 [0.91, 1.00]
a adjusted for age, sex, physical activity, and socioeconomic status; b p-value of the likelihood ratio test (adjusted continuous
interaction model).
two groups. The LA, AA, and EPA&DHA compositions of erythrocyte membranes were
higher for non-obese than obese participants but only the difference in LA content reached
statistical significance. The following results are not corrected for multiple testing and
therefore are only nominally significant at α = 5 %. Table A1 in the appendix shows the
distribution of the alleles within the two groups of obese and non-obese participants, the
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Table 3.4: Significant SNP–EPA&DHA interactions on obesity risk, showing the adjusteda
relative risk of obesity (OR, 95 % CI) per 1 mol-% increase in EPA&DHA (main
effecta: OR = 0.95, 95 % CI = [0.89, 1.02]) from erythrocyte membranes by
allelic variants (Jourdan et al., 2011).
Gene SNP Allele Non-Obese Obese OR [95 % CI] Pintb
(%) (%)
IL-2 rs2069779 CC 85.8 86.7 1.00 [0.93, 1.09] 0.0021
≥1 T allele 14.2 13.3 0.66 [0.48, 0.85]
IL-6 rs2069861 CC 80.4 86.8 1.00 [0.92, 1.08] 0.0219
≥1 T allele 19.6 13.2 0.74 [0.57, 0.94]
TNFRSF1B rs3766730 CC 71.0 69.9 1.01 [0.93, 1.11] 0.0237
≥1 T allele 29.0 30.1 0.86 [0.74, 0.99]
TNFRSF1B rs2275416 GG 67.9 62.8 1.02 [0.93, 1.11] 0.0341
≥1 A allele 32.1 37.2 0.88 [0.77, 1.00]
TNFRSF21 region 3’ rs9381530 TT 30.7 35.1 0.79 [0.68, 0.91] 0.0065
≥1 G allele 69.3 64.9 1.03 [0.95, 1.13]
TNFRSF21 rs2236039 AA 53.3 49.1 0.87 [0.78, 0.96] 0.0482
≥1 G allele 46.7 50.9 1.06 [0.95, 1.17]
ADIPOQ rs2241766 TT 77.8 85.1 0.92 [0.85, 1.00] 0.004
≥1 G allele 22.2 14.9 1.19 [0.96, 1.52]
ADIPOQ rs1063539 GG 72.7 80.5 0.92 [0.85, 1.00] 0.0316
≥1 C allele 27.3 19.5 1.09 [0.92, 1.32]
a adjusted for age, sex, physical activity, and socioeconomic status; b p-value of the likelihood ratio test (adjusted continuous
interaction model).
p-values of the used test and the main effects of all analysed SNPs on the risk of obesity.
Risk estimates were calculated for models with either three categories (homozygous wild
type, heterozygous and homozygous mutant type) or two categories (homozygous wild type
and one or more mutant allele carriers). The p-value of the continuous model is given as
Ptrend. A nominal p-value of less than 0.05 was reached by rs4719714 and rs12700386 (IL-6
region 5’), rs2069849 (IL-6), rs1061628 (TNFRSF1B) and rs1116656 (LEP region 3’).
The crude main effects for LA (OR = 0.90, 95 % CI = [0.83, 0.98]), AA (OR = 0.97, 95
% CI = [0.93, 1.01]) and EPA&DHA (OR = 0.96, 95 % CI = [0.89, 1.03]) in erythrocytes
showed an indication of an inverse association with obesity, but only for LA, the statistical
significance was reached. SNPs for which the interaction terms with PUFAs reached nominal
statistical significance (α = 5%) were stratified by genotype (two categories: homozygote
wild type and one or more mutant allele carriers), and risk estimates were calculated for
the corresponding PUFAs within these strata (Tables 3.2 to 3.4). Concerning cytokine
genes, we found several SNP–PUFA interactions in relation to obesity risk. For IL-2, the
interaction term between rs2069779 and all three PUFAs as well as between rs2069762,
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Table 3.5: Plasma IL-6 concentrations (pg/ml; geometric mean values and 95 % CI)
by tertiles of linoleic acid, arachidonic acid, and EPA&DHA in erythrocyte
membranes by allelic variants of IL-6 SNPs: re1800795, rs10242595, and
rs2069861 (Jourdan et al., 2011).
SNP Allel PUFA Tertile Obese Non-Obese
rs1800795 GG LA 1 3.04 [2.72, 3.40] 1.63 [1.53, 1.74]
2 2.46 [2.20, 2.75] 1.40 [1.31, 1.49]
3 1.59 [1.42, 1.77] 1.15 [1.08, 1.22]
≥1 C allele 1 2.21 [1.98, 2.47] 1.63 [1.53, 1.74]
2 2.96 [2.65, 3.30] 1.36 [1.27, 1.45]
3 2.16 [1.93, 2.41] 1.23 [1.15, 1.31]
rs10242595 AA LA 1 2.61 [2.33, 2.92] 1.56 [1.46, 1.66]
2 3.31 [2.96, 3.70] 1.31 [1.23, 1.40]
3 2.27 [2.03, 2.54] 1.21 [1.13, 1.29]
≥1 G allele 1 2.24 [2.00, 2.50] 1.73 [1.63, 1.85]
2 2.25 [2.01, 2.51] 1.50 [1.41, 1.60]
3 1.71 [1.53, 1.92] 1.19 [1.12, 1.27]
rs1800795 GG AA 1 2.78 [2.49, 3.11] 1.62 [1.52, 1.73]
2 1.80 [1.61, 2.01] 1.21 [1.14, 1.29]
3 2.50 [2.24, 2.79] 1.32 [1.24, 1.40]
≥1 C allele 1 2.39 [2.14, 2.67] 1.42 [1.33, 1.51]
2 2.59 [2.32, 2.90] 1.50 [1.41, 1.60]
3 2.25 [2.01, 2.51] 1.25 [1.18, 1.33]
rs2069861 CC EPA&DHA 1 2.55 [2.29, 2.85] 1.52 [1.42, 1.61]
2 2.37 [2.13, 2.65] 1.37 [1.28, 1.46]
3 2.20 [1.97, 2.45] 1.39 [1.30, 1.48]
≥1 T allele 1 2.60 [2.33, 2.90] 1.19 [1.12, 1.27]
2 1.65 [1.48, 1.84] 1.34 [1.25, 1.42]
3 3.34 [2.99, 3.72] 1.18 [1.11, 1.26]
Tertiles LA: (I) 2.7-10.7, (II) 10.7-12.2, (III) 12.2-16.8 ; Tertiles AA: (I) 1.0-14.5, (II) 14.5-17.1, (III) 17.1-21.1 ; Tertiles
EPA&DHA: (I) 0.00-4.8, (II) 4.8-7.1 (III)7.1-14.0.
rs4833248 (IL-2 region 5’) and LA were statistically significant. Each PUFA associated
with rs2069779 had a decreasing effect on obesity risk for minor allele carriers (Figure
3.1). In this gene stratum, the risk decreased for each mol-% increase in erythrocyte
membrane-bound PUFAs with OR of 0.63 (LA), 0.83 (AA) and 0.66 (EPA&DHA). For
rs4833248 as well as rs2069762, homozygous wild-type carriers benefited from increased
LA content in erythrocyte membranes. Analyses for IL-6 revealed three SNPs: rs1800795,
rs10242595, and rs2069861. The first two showed a significant interaction effect with LA
with Pint = 0.0341 and 0.0315, respectively. For each percentage increase in erythrocyte
membrane-bound LA, obesity risk decreased in carriers of at least one minor allele of
rs1800795 with an OR of 0.86 (95 % CI = [0.76, 0.96]); a similar effect was found for
the rs1800795–AA interaction (Figure 3.2). In the case of rs10242595, the relative risk
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decreased for carriers of the homozygous wild-type alleles with increasing LA content (OR
= 0.81, 95 % CI = [0.71, 0.93]). The interaction effect of rs2069861 and EPA&DHA was
significant as well. Here, the obesity risk decreased with each mol-% increase of erythrocyte
membrane-bound EPA&DHA for minor allele carriers (OR = 0.74, 95 % CI = [0.57, 0.94]).
For IL-18, one SNP (rs3882891) interacted significantly with LA when analysing obesity
risk. Minor allele carriers of this SNP had a reduced obesity risk with increasing LA content
in erythrocyte membranes (OR = 0.84, 95 % CI = [0.75, 0.94], Pint = 0.0203). We
also obtained evidence for SNP–EPA&DHA interaction effects of the TNFRSF1B gene.
Participants carrying at least one minor allele of rs3766730 (OR = 0.86, 95 % CI = [0.75,
0.98], Pint = 0.0225) or rs2275416 (OR = 0.88, 95 % CI = [0.78, 0.99], Pint = 0.0455)
had a lower obesity risk than homozygous wild-type carriers. In relation to obesity risk,
two SNPs of TNFRSF21 were shown to interact with EPA&DHA; rs9381530 (region 3’)
with an OR of 0.79 (95 % CI = [0.68, 0.91], Pint = 0.0065) and rs2236039 with an OR of
0.87 (95 % CI = [0.78, 0.96], Pint = 0.0482). In each case, obesity risk decreased with
increasing PUFA content in participants carrying two major alleles.
Among the selected adipokine genes, few significant results were obtained. The interaction
terms of two ADIPOQ SNPs (rs1063539 and rs2241766) and membrane EPA&DHA
content were significantly associated with obesity risk. In homozygous wild-type carriers,
obesity risk decreased with increasing EPA&DHA content (Table 3.4). Concerning a LEPR
polymorphism (rs1805096), an inverse association with obesity risk existed in carriers of
the minor allele, with an increasing erythrocyte membrane content of LA (OR = 0.83, 95
% CI = [0.74, 0.93], Pint = 0.0084; Table 3.2) or AA (OR = 0.95, 95 % CI = [0.91, 1.00],
Pint = 0.0459; Table 3.3).
Table 3.5 gives the geometric means and the 95 % CI of plasma IL-6 stratified by IL-6
SNPs rs1800795, rs10242595 and rs2069861 (homozygote wild type and one or more
mutant alleles) and tertiles of LA, AA and EPA&DHA for obese and non-obese participants.
The plasma IL-6 concentrations were generally higher in obese participants compared
with non-obese participants (Table 3.1) and decreased with increasing PUFA content in
erythrocyte membranes (tertiles). These results lend credit to the identified IL-6 SNP–PUFA
interactions and obesity risk derived from the statistical models.
3.1.3 Discussion
This project aimed at investigating the additional effect on obesity brought on by the
interaction of selected genetic variants and PUFA content of erythrocyte membranes. Out




















Figure 3.1: The effect of LA (Pint = 0.0310), AA (Pint = 0.0104) and EPA&DHA (Pint
= 0.0022) on the risk of obesity, stratified by genotype of IL-2 (rs2069779).
Estimates are adjusted for age, sex, physical activity, and socioeconomic status
(Jourdan et al., 2011).
of the four different groups of genes, including cytokines, adipokines, neurotransmitters and
transcription factors, we obtained significant interaction effects between the SNPs of IL-2,
IL-6, IL-18, TNFRSF1B, TNFRSF21, LEPR, or ADIPOQ and PUFA content in erythrocyte
membranes. We found a reduced obesity risk for minor allele carriers of most variants
with high PUFA content in erythrocyte membranes, except for the SNPs of TNFRSF21,
ADIPOQ, rs2069762 (IL-2), rs4833248 (IL-2 region 5’) and rs10242595 (IL-6 region 3’).
With the latter genes, participants, homozygote for the major allele, benefited from an
increased PUFA content of erythrocyte membranes. In the case of IL-6, the analysed plasma
IL-6 protein concentration supports the statistical findings.
PUFAs and Cytokines
Obesity has been described as a state of chronic low-grade inflammation (Engstrom et al.,
2003; Festa et al., 2001). Thus, polymorphisms in different cytokines were included in the



















Figure 3.2: The effect of LA (Pint = 0.0341), AA (Pint = 0.0315) and EPA&DHA (Pint
= 0.0878) on the risk of obesity, stratified by genotype of IL-6 (rs1800795).
Estimates are adjusted for age, sex, physical activity, and socioeconomic status
(Jourdan et al., 2011).
analyses of gene–PUFA interactions. Cytokines are a group of modulatory proteins which
respond to various stimuli, thereby activating second messengers and signal transduction
pathways within the cells (Smith & Humphries, 2009). Several cell studies and also dietary
intervention studies have shown a reduced production of IL-2 in response to PUFAs (Merzouk
et al., 2008; Verlengia et al., 2003; Alnajjar et al., 2006; von Schacky, 2007); however,
the exact mechanism behind this phenomenon still remains unclear (Calder & Grimble,
2002; Gorjao et al., 2007). Here, obesity risk decreased with increasing PUFA content of
the erythrocyte membranes, and thus confirms the expected direction. PUFA eicosanoid
derivates, such as prostaglandin E2 (PGE2), are involved in the modulation of the intensity
and duration of inflammatory processes and suppress the production of IL-6 (Stulnig, 2003).
Adipose tissue in human participants releases IL-6 and serum levels are positively correlated
with body fat mass (Vozarova et al., 2001). Himmerich et al. (2006) confirmed this relation
for the present population. IL-6 gene transcription was found to be influenced in vitro by the
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rs1800795 polymorphism within the promoter region (Fishman et al., 1998). The G allele of
this SNP was described as to be more common in lean participants (Berthier et al., 2003);
additionally, a lower BMI was measured in participants with the CC genotype (Kubaszek
et al., 2003), which might eventually predispose to weight gain; this hypothesis has been
supported by some studies but not confirmed in two meta-analyses of the association of this
SNP with BMI (Huth et al., 2009; Qi et al., 2007). Our findings on SNP–PUFA interactions
may provide an explanation for the diverging results since they consider the possible interplay
between SNPs and the PUFA supply status. For the other IL-6 SNP, rs10242595, the A
variant was found to be significantly associated with decreased body fat mass in young adult
men, a result which was replicated in two other population-based studies of elderly men
(Andersson et al., 2010). The interaction effect between this SNP and PUFAs in this study
is indicative towards the importance of this SNP for the development of obesity. Variations
in the IL-18 gene have been associated with IL-18 plasma concentrations and measures
of obesity (Thompson et al., 2007). Obese participants show higher levels of IL-18 than
lean participants (Skurk et al., 2005), and IL-18 has been associated with excess adiposity
(Hung et al., 2005). Our IL-18 variant is in complete LD with rs5744292, an IL-18 SNP
whose minor allele has been reported to be associated with lower circulating IL-18 levels
and lower mRNA expression in immortalised lymphocytes (Barbaux et al., 2007; Tiret et al.,
2005)). Furthermore, a suppressing effect of PGE2 on the expression of IL-18 has been
shown in cell studies (Suk et al., 2001). The finding of an IL-18–PUFA interaction in the
present study fits well with these data. Even though the production of TNFα by monocytes
and macrophages is also suppressed by PGE2 (Stulnig, 2003), no significant interactions
were detected. However, we found evidence for significant interaction effects for SNPs from
its receptors, TNFRSF1B and TNFRSF21. Overall, all identified (significant) interactions
between cytokine SNPs and PUFAs indicate an inverse association with obesity risk for
minor allele carriers, with increasing PUFA content in erythrocyte membranes, except for
SNPs of TNFRSF21, rs4833248 (IL-2 region 5’) and rs10242595 (IL-6 region 3’).
PUFAs and Adipokines
Besides its role for lipid storage, adipose tissue functions as an endocrine organ, regulating
metabolism and different vital functions related, among others, to inflammation (Saltiel,
2001; Spiegelman & Flier, 2001). Thus, different adipokines have been included in this
project. Adiponectin is exclusively secreted by adipose tissue and serum levels are inversely
correlated with body fat mass (Arita et al., 1999). The mRNA expression is reduced in obese
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individuals (Hu et al., 1996). Serum adiponectin levels are highly heritable (approximately
50 %) and are linked to the ADIPOQ gene locus (Chuang et al., 2004; Comuzzie et al.,
2001; Vasseur et al., 2002). Different cell and dietary intervention studies found EPA&DHA
to stimulate the expression of ADIPOQ and to increase plasma adiponectin levels (Itoh
et al., 2007; Flachs et al., 2006; Yu et al., 2008); however, findings differ (Lorente-Cebrian
et al., 2006). EPA&DHA might possibly up-regulate ADIPOQ by acting through PPARγ,
affecting the ADIPOQ promoter (Iwaki et al., 2003). The present results are in line with
these findings and show a significantly decreased obesity risk for carriers of two major
alleles of rs2241766 or rs1063539, with increasing EPA&DHA concentrations in erythrocyte
membranes. Different animal, human and cell studies have shown an inverse effect of
PUFAs on the LEP mRNA expression (Reseland et al., 2001; Phillips et al., 2010). The
present analyses resulted in one significant interaction for a variant of the LEPR gene,
which is in line with these findings.
Sensitivity Analyses
We see two major mechanisms of how PUFAs may in conjunction with genetic variants
affect obesity risk: either via direct modification of gene transcription or by products of the
eicosanoid pathway. To compare the direction of the different effects of PUFAs on the risk
of obesity within the SNP strata of the significant interaction models, we also estimated
the effects of the remaining PUFAs by the given SNP strata for which the interaction term
with those SNPs was not significant (e.g., Figure 3.2). We observed quite similar effects
(direction and estimates) over the different PUFAs in the various SNP strata (data not
shown). A high erythrocyte membrane content of LA, AA, or EPA&DHA thereby did either
show no association or an inverse association with obesity risk in each of the SNP strata. In
mutually adjusted analyses, we have also not received any indication for changes of effects
of n-3 PUFA-adjusted n-6 PUFAs and vice versa.
Strength and Limitations
A limitation of the first project is obviously the small sample size (n = 621). Studies of
genetic associations with complex diseases need thousands of cases and controls (Colhoun
et al., 2003); however, this requirement is not easily fulfilled with respect to the costly
fatty acid analyses. The small number of cases and controls and consequently the limited
statistical power strongly argue for a careful interpretation of the results and a replication
in a second, larger and independent study. Because of the small sample size and the
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resulting limited power, we did not correct for multiple testing. The observational nature
of this project does not allow for interpreting causal associations, and we cannot rule out
the possibility of reverse causation. However, we controlled for potential confounding by
adjusting for sex, age, physical activity, and socioeconomic status. The genetic dataset of
the BVS II was comprised in 2006 and was based on an extensive literature research for
obesity candidate genes. This was shortly after the first GWAS and thus, in the meantime
newly identified SNPs and genes associated with obesity are not part of the dataset.
The major strength of this project is the use of erythrocyte membranes to assess biologically
available PUFAs at the cellular level and its association with genetic variants influencing
the risk of obesity. With the utilisation of biomarkers as an objective metabolic correlate
of dietary PUFA intake, misclassifications can be largely avoided. A further strength of
the present study is its population-based design aiming at representativeness for the adult
Bavarian population and the strict quality control in the analyses.
Conclusion
We conclude that PUFAs exert their effects rather via modification of gene transcription
than through metabolites derived during eicosanoid synthesis, since the latter would have
led to differential effects of n-3 and n-6 PUFAs. Further, it is important to mention that
the frequency of these SNPs for which we observed interactive effects with PUFAs is fairly
high, except for IL-2 SNP (rs2069779). This implicates that a substantial part of the
population would benefit from a high PUFA intake with respect to obesity risk.
3.2 Metabolomics and Fat Free Mass
3.2.1 Background
This project aimed at providing a comprehensive picture of fat free mass induced effects on
the metabolite profile in blood samples of adults. The human serum metabolome is currently
characterised in many studies using different analytic approaches (Psychogios et al., 2011),
including the method applied here. To the best of our knowledge, the association of FFMI
or fat free mass and serum metabolites was not explored before in an epidemiologic setting
involving healthy participants. Rather, metabolomics signatures of exercise (before, during
and afterwards) in human plasma were investigated showing that subjects who were in
better shape exhibited more lipolysis during and after exercise than did the less fit subjects
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Table 3.6: Characteristics (mean, SD, % or N) of male and female participants of the
analysed samples of KORA S4 and KORA F4 (Jourdan et al., 2012).
KORA S4 KORA F4
(n = 965) (n = 890)
Men Women Men Women
(n = 485) (n = 480) (n = 423) (n = 467)
Parameter Unit Mean SD Mean SD Mean SD Mean SD
Age years 63.2 5.5 63.3 5.3 53.8 12.0 54.7 12.5
Weight kg 83.2 11.4 71.6 12.0 83.2 11.4 69.0 13.1
Height cm 172.3 6.4 159.3 6.00 176.7 7.0 162.9 6.6
Body Mass Index kg/m2 28.0 3.6 28.2 4.7 26.6 3.3 26.0 4.7
Waist cm 100.0 9.4 89.6 11.1 95.9 9.9 85.2 12.6
Hip cm 104.7 6.5 107.2 9.9 104.2 6.2 104.2 9.4
Waist to Hip Ratio 1.0 0.1 0.8 0.1 0.9 0.1 0.8 0.1
Fat Free Massa kg 58.5 5.7 43.1 5.1 60.8 6.1 43.6 5.4
Body Fat Massb % 29.3 4.7 39.2 4.8 26.3 5.0 36.0 5.7
FFMIa,b kg/m2 19.7 1.7 17.0 1.9 19.6 1.6 16.5 1.8
BFMIa,c kg/m2 8.3 2.3 11.2 3.1 7.2 2.1 9.6 3.2
Parameter Category % N % N % N % N
Body Mass Index < 18.5 - - - - 0.2 1 0.6 3
18.5 to < 25 17.1 83 25.6 123 30.5 129 45.8 214
25 to < 30 56.5 274 43.3 208 52.7 223 34.9 163
≥ 30 26.2 127 30.6 147 16.6 70 18.6 87
Physical Activityd active 38.76 188 46.7 224 59.8 253 61.2 286
inactive 60.4 293 52.9 254 40.0 169 38.8 181
Age Groups 31 to 40 years - - - - 14.7 62 15.4 72
41 to 50 years - - - - 29.6 125 24.2 113
51 to 60 years 38.1 185 35.4 170 23.9 101 27.0 126
61 to 70 years 48.5 235 52.1 250 22.0 93 21.2 99
71 to 80 years 13.4 65 12.5 60 9.5 40 11.6 54
≥ 81 years - - - - 0.5 2 0.6 3
a Parameter derived from the bioelectrical impedance analysis measurements which were only conducted in KORA S4; b Fat
Free Mass Index; c Body Fat Mass Index; d Physical Activity (active: > 1 h leisure time of sports per week on a regular
basis; inactive: less than 1h per week).
(Lewis et al., 2010). Thus, we hypothesised that a sedentary lifestyle leads to derangements
of skeletal muscle metabolism favouring, e.g., the development of obesity.
3.2.2 Results
Table 3.6 summarises the anthropometric data of the KORA S4 and KORA F4 participants.
Selected statistically significant associations of FFMI with different metabolite concentrations
for the KORA S4 population are given in Table 3.7. Different parameters such as the
direction of the β-estimate derived from the adjusted linear models are given, as is the
3.2 Metabolomics and Fat Free Mass 45
agreement between the KORA S4 and KORA F4 results. The full list of statistically
significant associations obtained in KORA S4 and KORA F4 are found in the Supplementary
Tables B2 and B3, respectively. The GGMs established in KORA S4 and KORA F4 are
displayed in Figure 3.4, 3.5, and B1, completing the results of the linear regression models
by illustrating the underlying relationships between the metabolite concentrations.
Amino Acids
With higher FFMI, increasing serum concentrations of the branched-chain amino acids
(BCAAs) valine, isoleucine, and leucine as well as of the sum of BCAAs were observed.
Furthermore, other serum amino acids increased with higher FFMI, including the glucogenic
amino acid alanine, and the aromatic amino acids tyrosine and phenylalanine. With respect
to metabolite ratios, strong positive associations were found between FFMI and the ratios
of isoleucine to glycine and leucine to glycine. In addition, the ratio of all BCAAs to
all glucogenic amino acids (sum of alanine, glycine, and serine) was positively related to
FFMI, supporting the notion of increasing BCAAs concentrations in relation to glucogenic
amino acids in serum samples of participants with higher FFMI. Inspecting the GGM results
(Figure 3.4), we also observe these strong correlations between BCAAs. Based on these
results, we illustrated the association between the sum of BCAAs and quintiles of FFMI in
Figure 3.3, and described the anthropometric characteristics of the KORA S4 participants
by quintiles of BCAAs (Table 3.8). These findings are replicated in the KORA F4.
Acylcarnitines
Serum concentrations of free carnitine (C0) and short-chain odd-numbered acylcarnitines,
such as propionylcarnitine (C3) and valerylcarnitine (C5), were found to be positively
associated with FFMI while octadecanoylcarnitine (C18) decreased with increasing FFMI.
This is also reflected in the results for the ratios of C18 to C0, C3, or C5. These findings in
KORA S4 are supported by the KORA F4 results. The acylcarnitines form a separate group
within the partial correlation networks and a particularly strong correlation exists between
the metabolites C0 and C3.
Phosphatidylcholines
The group of phosphatidylcholines consists of different PC diacyl (aa), PC acyl-alkyl (ae),
and lysoPC acyl (a) compounds. Numerous associations between FFMI and PCs or PC
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Table 3.7: Selected metabolic traits significantly associated with FFMIa in a linear regres-
sion adjusted for age and sex in KORA S4 (Jourdan et al., 2012).
Trait Mean SD Dirb P-Value R2 P-Gaine F4f
(µmol/l) Adj.c Adj.d
Val 227.26 53.13 pos. 4.75x10−16 0.16 *
Glu 80.13 32.04 pos. 1.22x10−15 0.11 n.a.
Ile 72.14 20.22 pos. 1.96x10−11 0.22 #
Leu 160.51 44.33 pos. 2.57x10−08 0.18 #
Ala 417.99 101.40 pos. 8.95x10−06 0.03 n.a.
Tyr 72.09 20.06 pos. 4.77x10−10 0.06 *
Phe 76.73 17.19 pos. 2.53x10−07 0.05 n.s.
Σ aromatic AAs 208.98 43.75 pos. 3.37x10−09 0.07 *
Σ BCAAs 459.91 113.06 pos. 2.07x10−13 0.19 *
Ile/Gly 0.29 0.11 pos. 1.61x10−14 0.30 1.22x10+03 #
Leu/Gly 0.65 0.25 pos. 1.46x10−12 0.29 1.75x10+04 #
Σ BCAAs / Σ glucogenic AAs 0.58 0.14 pos. 1.49x10−08 0.26 *
C5 0.16 0.06 pos. 3.49x10−05 0.17 *
C3 0.47 0.15 pos. 4.85x10−05 0.13 *
C0 40.52 8.49 pos. 1.19x10−02 0.13 *
C18 0.06 0.01 neg. 3.96x10−02 0.10 n.s.
C18/C5 0.37 0.14 neg. 1.44x10−09 0.08 2.42x10+04 n.s.
C18/C3 0.13 0.05 neg. 3.65x10−09 0.05 1.33x10+04 n.s.
C18/C0 0.001 0.0004 neg. 5.44x10−07 0.05 2.19x10+04 n.s.
PC aa C38:3 57.77 14.01 pos. 7.02x10−06 0.06 *
PC ae C42:3 0.85 0.19 neg. 5.10x10−18 0.10 *
PC ae C36:2 15.33 3.88 neg. 2.42x10−15 0.19 *
lysoPC a C18:2 28.46 9.04 neg. 8.19x10−16 0.16 *
lysoPC a C18:1 21.61 6.10 neg. 2.30x10−10 0.11 *
Σ PC ae 181.45 30.52 neg. 1.38x10−04 0.10 *
Σ lysoPC 229.29 47.21 neg. 4.36x10−04 0.07 *
PC aa C38:3/PC aa C42:6 97.71 21.87 pos. 1.04x10−17 0.09 6.73x10+11 *
PC aa C38:3/PC aa C42:0 111.66 41.58 pos. 1.06x10−15 0.07 3.68x10+06 *
PC aa C38:3/PC aa C42:2 297.65 96.51 pos. 1.72x10−16 0.10 1.69x10+09 *
lysoPC a C14:0/lysoPC a C18:2 0.24 0.08 pos. 1.04x10−20 0.18 7.88x10+04 n.s.
PC ae C36:4/PC ae C40:1 12.99 3.34 pos. 1.70x10−07 0.04 3.57x10+02 *
PC aa C38:3/lysoPC a C18:1 2.27 0.99 pos. 3.37x10−20 0.19 2.43x10+04 *
PC aa C38:3/lysoPC a C18:2 2.87 1.03 pos. 1.38x10−19 0.17 1.66x10+09 *
PC aa C38:3/PC ae C42:3 70.43 21.88 pos. 3.12x10−26 0.12 1.63x10+08 *
PC aa C38:3/PC ae C42:2 93.08 24.28 pos. 3.73x10−23 0.11 7.97x10+15 *
SM C16:0/SM C16:1 6.40 0.76 neg. 1.52x10−11 0.29 3.13x10+08 *
SM (OH) C16:1/SM C18:1 0.31 0.06 neg. 3.51x10−10 0.05 4.94x10+07 *
SM C16:0/SM C18:1 9.36 1.83 neg. 5.71x10−08 0.24 8.33x10+04 *
SM (OH) C16:1/SM C18:0 0.16 0.03 neg. 3.28x10−10 0.10 5.27x10+07 *
SM (OH) C22:2/SM C18:1 1.00 0.19 neg. 4.14x10−07 0.05 2.93x10+05 *
a Fat Free Mass Index; b direction of the association (positive or negative); c for multiple testing adjusted p-value; d adjusted
R2 of the linear model; e p-gain, fold decrease in the p-value of association for the pair of metabolites, compared to the
lowest of two p-values for the single metabolites; f confirmed in KORA F4, * for significance and direction; # confirmed
for xLeu in KORA F4, n.a. metabolite was not available in KORA F4, n.s. not significant; AAs amino acids; Σ aromatic
amino acids is the sum of tyrosine, phenylalanine, and tryptophan; Σ BCAAs is the sum of valine, isoleucine, and leucine; Σ
glucogenic amino acids is the sum of alanine, glycine, and serine.




































Figure 3.3: Boxplot of serum BCAA concentrations (µmol/l), by quintiles of FFMI, for
the KORA S4 population. (Jourdan et al., 2012).
ratios could be observed. An increase in FFMI was associated with (i) a higher serum
concentration of PC aa in relation to PC ae, (ii) a decrease in chain length of the fatty
acid residues, and (iii) a decrease in saturation (i.e., a higher number of double bonds) of
the fatty acid moieties. Significant results for single PC compounds were all negatively
associated with FFMI, such as PC ae C42:3 or PC ae C36:2, lysoPC a C18:2 or lysoPC
a C18:1; the only exception is PC aa C38:3 which increased with higher FFMI. Ratios
within subgroups (aa/aa, ae/ae, lyso/lyso) demonstrated that increasing FFMI is associated
with a shift towards shorter fatty acids and fatty acids with more double bonds. Examples
are ratios of PC aa C38:3/PC aa C42:6, PC aa C38:3/PC aa C42:2, PC aa C38:3/PC
aa C42:0, PC ae C36:4/PC ae C40:1 or lysoPC a C14:0/lysoPC a C18:2. This is most
likely a consequence of the associations observed for the single compounds (e.g., PC aa
C38:3 increased and lysoPC a C18:1 decreased with increasing FFMI). Ratios of PC aa
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Table 3.8: Different characteristics (mean, SD, %, or N) of the KORA S4 sample stratified
by quintiles of the BCAAsa serum concentration (Jourdan et al., 2012).
Quintiles of the sum of BCAA (µmol/l)
1 2 3 4 5
(163.5-363.7) (364.1-418) (418.2-476.9) (477-542.2) (542.3-963)
Parameter Mean SD Mean SD Mean SD Mean SD Mean SD
Age 63.1 5.4 63.3 5.4 63.5 5.6 63.6 5.4 62.9 5.3
Weight 69.5 11.8 75.5 12.7 76.1 11.2 81.6 12.4 84.3 11.9
Height 161.4 7.5 164.7 8.7 165.8 9.1 168.9 8.8 168.5 8.4
Body Mass Index 26.6 4.1 27.9 4.3 27.8 4.0 28.6 3.8 29.8 4.2
Fat Free Mass (kg) 44.1 7.3 49.4 9.1 50.2 8.7 54.8 8.8 55.7 8.1
Body Fat Mass (%) 36.1 6.3 34.4 6.9 34.0 7.2 32.7 6.8 33.7 6.7
FFMIb 16.9 2.0 18.1 2.3 18.2 2.1 19.1 1.9 19.6 1.9
BFMIc 9.8 2.9 9.7 3.1 9.6 3.2 9.5 3.0 10.3 3.2
FFM/BFMd 1.9 0.8 2.1 0.7 2.1 0.7 2.2 0.7 2.1 0.7
Parameter % N % N % N % N % N
Male 19.7 38 42.5 82 49.7 96 67.9 131 71.5 138
Female 80.3 155 57.5 111 50.3 97 32.1 62 28.5 55
Physical activitye 47.2 91 35.8 69 52.3 101 40.9 79 37.3 72
a BCAAs is the sum of valine, isoleucine, and leucine; b Fat Free Mass Index; c Body Fat Mass Index; d
Fat Free Mass divided by Body Fat Mass; e Physical Activity (active: > 1 h leisure time of sports per week
on a regular basis; inactive: less than 1h sports per week).
to PC ae were significantly associated with FFMI, such as PC aa C38:3/PC ae C42:3 or
PC aa C38:3/PC ae 42:2. There are three large groups of PCs which were identified in
the network analyses (Figure 3.5). PC aa C38:3 is the centre of the largest cluster which
includes mainly PC aa and shorter PC ae; the second cluster is very similar to the former.
The third cluster consists of mostly long-chain PCs. These findings are also supported by
the results obtained in the KORA F4 sample.
Sphingomyelins
With higher FFMI an increased concentration of sphingomyelins (SM) as compared to
hydroxysphingomyelins (SM (OH)) was observed. This is reflected e.g., by the ratios of SM
(OH) C16:1/SM C18:1, SM (OH) C16:1/SM C18:0 or SM (OH) C22:2/SM C18:1. Also,
the results of sphingomyelin ratios, such as SM C16:0/SM C16:1 or SM 16:0/SM C18:1,
demonstrate a decrease in saturation of the fatty acids with increasing FFMI. The same
associations are found in KORA F4. The GGM results show that almost all sphingomyelin
are interrelated and the strong relationship between SM (OH) C16:1 and SM (OH) C14:1
is present in both GGMs (Figure 3.5 and Figure B1).
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Table 3.9: Selected metabolic traits significantly associated with FFMIa in a linear regres-
sion model adjusted for age, and sex for the non-obese (BMI < 30 kg/m2)
and obese (BMI ≥ 30 kg/m2) participants in the KORA S4 sample (Jourdan
et al., 2012).
Obese Non-Obese
(n = 274) (n = 691)
Trait Beta Adj. P-Valueb Adj.c R2 Beta Adj. P-Valueb Adj.c R2
Val 0.08 1.00 0.03 0.14 1.70x10−04 0.17
Ile 0.06 1.00 0.12 0.13 3.94x10−04 0.25
Leu 0.04 1.00 0.08 0.13 3.77x10−04 0.22
Ala 0.02 1.00 0.00 0.12 0.0409 0.02
Tyr 0.04 1.00 0.00 0.14 2.09x10−03 0.05
Phe 0.06 1.00 0.00 0.10 0.2377 0.04
Σ aromatic AAs 0.05 1.00 0.02 0.12 0.014 0.06
Σ BCAAs 0.06 1.00 0.07 0.15 5.10x10−05 0.21
Ile/Gly 0.03 1.00 0.26 0.13 2.42x10−04 0.30
Leu/Gly 0.02 1.00 0.22 0.13 9.29x10−05 0.30
Σ BCAAs/Σ glucogenic AAs 0.05 1.00 0.15 0.10 0.0353 0.30
C5 0.06 1.00 0.13 0.14 1.34x10−04 0.19
C3 0.06 1.00 0.06 0.13 2.52x10−03 0.16
C0 0.06 1.00 0.08 0.09 0.2550 0.16
PC aa C38.3 0.00 1.00 0.02 0.08 1.00 0.04
PC ae C42.3 -0.14 0.3100 0.04 -0.16 7.30x10−05 0.06
PC ae C36.2 -0.07 1.00 0.13 -0.09 0.4180 0.17
lysoPC a C18.1 -0.08 1.00 0.08 -0.07 1.00 0.05
lysoPC a C18.2 -0.14 0.2100 0.13 -0.07 1.00 0.08
Σ PC ae -0.04 1.00 0.05 -0.05 1.00 0.09
Σ lysoPC -0.04 1.00 0.06 -0.02 1.00 0.04
PC aa C38:3/PC aa C42:6 0.03 1.00 0.01 0.18 2.69x10−06 0.05
PC aa C38:3/PC aa C42:2 0.05 1.00 0.03 0.14 7.49x10−04 0.05
lysoPC a C14:0/lysoPC a C18:2 0.18 0.0030 0.17 0.10 0.1130 0.09
PC aa C38:3/lysoPC a C18:1 0.07 1.00 0.11 0.11 0.0377 0.10
PC aa C38:3/lysoPC a C18:2 0.10 1.00 0.13 0.10 0.1580 0.11
PC aa C38:3/PC ae C42:3 0.10 1.00 0.01 0.18 8.77x10−07 0.05
PC aa C38:3/PC ae C36:2 0.06 1.00 0.04 0.14 1.48x10−03 0.06
PC aa C38:3/PC ae C42:2 0.07 1.00 0.00 0.17 1.02x10−05 0.04
SM C16:0/SM C16:1 -0.02 1.00 0.23 -0.06 1.00 0.27
SM (OH) C16:1/SM C 18:1 0.01 1.00 0.01 -0.08 1.00 0.02
SM C 16:0/SM C 18:1 -0.02 1.00 0.17 -0.06 1.00 0.23
SM (OH) C16:1/SM C 18:0 0.02 1.00 0.17 -0.10 0.1700 0.05
SM (OH) C22:2/SM C 18:1 0.00 1.00 0.05 -0.07 1.00 0.01
a Fat Free Mass Index; b for multiple testing adjusted p-value; c adjusted R2 of the linear model; Σ AAs amino acids; Σ
aromatic amino acids is the sum of tyrosine, phenylalanine, and tryptophan; Σ BCAAs is the sum of valine, isoleucine, and
leucine; Σ glucogenic amino acids is the sum of alanine, glycine, and serine.
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Appendicular Skeletal Muscle Mass Index
For both, KORA S4 and KORA F4, the results for the appendicular skeletal muscle mass
index were largely comparable to the results with FFMI (data not shown). However, the
p-values in the linear regression models did not decrease and also the adjusted R2 did not
improve as compared to the FFMI based results. Therefore, FFMI remained as primary
explanatory variable.
Stratifications
In stratified analyses, very similar results could be observed for men and women. With
respect to physical activity, there was only a slight difference between both groups (active
versus inactive participants) for the associations with the acylcarnitine metabolites. Most
of the statistically significant associations between FFMI and the acylcarnitines found for
the entire group and the physically active group were not present in the inactive group.
Regarding age (> 65 years versus ≤ 65 years; KORA S4), there were no distinct differences
between groups. With respect to the associations between FFMI and the metabolites in
obese and non-obese participants in KORA S4 we did observe significant differences. Most
associations described for the whole population and also noted for the non-obese subgroup
are not present in obese participants (Table 3.9).
Genetic Analyses
No significant associations were found between the selected genetic variants (Supplementary

















Figure 3.4: Gaussian graphical model of serum amino acids and acylcarnitine metabolite concentrations in KORA
S4. Each node represents a metabolite, whereas edges represent significant partial correlations. Nodes were coloured
according to the β-estimate and the p-value from the linear models (red = positive association with FFMI; blue =












Figure 3.5: Gaussian graphical model of serum glycerophospholipids and sphingolipid metabolite concentrations
in KORA S4. Each node represents a metabolite, whereas edges represent significant partial correlations. Nodes
were coloured according to the β-estimate and the p-value from the linear models (red = positive association with
FFMI; blue = negative association with FFMI; white = not significant association with FFMI). Yellow highlights
the large clusters within the glycerophospholipid metabolites (Jourdan et al., 2012).
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3.2.3 Discussion
In this population-based study, strong associations between FFMI and serum metabolite
concentrations were found in KORA S4 and reproduced in KORA F4. With higher FFMI,
BCAA serum concentrations and the ratio of BCAAs to glucogenic amino acids increased.
Free carnitine levels were also positively associated with FFMI, and for the various PCs we
found a decrease in chain length and/or saturation of the fatty acid residues in combination
with higher concentrations of PC aa in expense of PC ae and lysoPC. In obese participants
of KORA S4, however, these associations were lacking.
Sedentary Lifestyle leads to Derangements in Skeletal Muscle Metabolism
As described in 3.2.1 we hypothesised that a sedentary lifestyle leads to derangements in
skeletal muscle metabolism thereby favouring the development of obesity and metabolic
diseases. The fact that we observed a lack of associations between FFMI and serum
metabolites in obese participants at baseline (KORA S4) fits well to this hypothesis. As
observed by Lewis et al. (2010), a decreased capability to stimulate lipid oxidation during
exercise could be reflected in the missing associations between FFMI and the various lipid
metabolites in obese participants. For the non-obese participants, we find evidence for
an enhanced β-oxidation with higher FFMI which is reflected in the carnitine and PC
metabolite results.
BCAAs and Muscle Metabolism
In contrast to a study with physical activity intervention, it was not clear how strong
the associations between FFMI and serum concentrations of amino acids, acylcarnitines,
glycerophospholipids, and sphingolipids could be in a cross-sectional study with collection of
serum samples after short-term fasting of at least eight hours. However, our results fit well
to biological pathways that are related to skeletal muscle metabolism, namely amino acid
metabolism and fatty acid metabolism (reflected by acylcarnitines and glycerophospholipids).
BCAAs are described as preferred substrates for muscle tissue, and BCAA supplementation
can suppress protein degradation (Tom & Nair, 2006). During short-term fasting, glucose
released from glycogen stores of the liver is provided as fuel for tissues that need glucose,
e.g., the brain. Muscle protein degradation provides amino acids that are used by the liver
for gluconeogenesis (Layman & Walker, 2006), with alanine being the most important one.
BCAAs are a major source of nitrogen for muscle synthesis of glucogenic amino acids such
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as alanine (Ruderman, 1975; Layman, 2003). This has been shown in studies with 1 to 3
days of starvation. Levels of BCAAs rise in fasting state parallel to an increased protein
degradation. In this state, the only source of BCAAs is appearance from protein degradation,
which is a key process for maintenance of protein quality and repair process of tissues.
Thus, during overnight fasting, BCAA serum concentrations are increased proportional to
the muscle mass of the body. Furthermore, alanine concentration levels rise with increasing
protein degradation during starving (Tom & Nair, 2006). Thus, our findings of increasing
serum concentrations of BCAAs and alanine that are strongly associated with FFMI are in
line with the expectations.
Acycarnitines reflect Upregulation of β-Oxidation
Several other studies reported that acylcarnitines are also found in circulation (Psychogios
et al., 2011). Acylcarnitines are intra-cellularly synthesised for the transport of fatty acids
into the mitochondria for β-oxidation. In the present analyses an increase of acylcarnitine
concentrations could be observed which argues for an upregulated β-oxidation of fatty acids
in participants with higher muscle mass. One explanation for the origin of propionylcarnitine
is oxidative degradation (β-oxidation, γ-oxidation) of BCAAs, releasing propionylcarnitine
units. Another source of propionyl residues may be the intestinal production by gut
microbiota; however a relationship with plasma propionylcarnitine or FFMI is not established.
Possibly altered Activity of ELOVL or FADS
Our phospholipid results point towards a decrease in chain length and degree of saturation
of the lipid side chains. The concentrations of lysoPC and PC ae decrease with increasing
FFMI and PC aa C38:3 is the only PC positively associated with higher FFMI. Considering
the GGM results, PC aa C38:3 is central in one cluster of PC metabolites, while the other
cluster consists of long-chain PCs. Overall, our results implicate that FFMI is associated
with lower plasma concentrations of very long-chain PCs (GGM cluster 2), while the
concentration of PC aa C38:3 increased. Thus, a higher FFMI may indicate a higher activity
of enzymes involved in fatty acid oxidation, especially in the oxidation of very long-chain fatty
acids. In addition, an altered activity of enzymes involved in chain elongation (ELOVL) or
desaturation (FADS) could contribute to these findings. Earlier studies using metabolomics
and genetic data demonstrated that genetic effects (mediated by the expression of enzymes)
are reflected in the serum metabolic profile, lending credibility to the approach of identifying
enzyme activities by means of serum metabolites or metabolite ratios (Illig et al., 2010;
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Gieger et al., 2008). The shift from PC ae and lysoPC towards PC aa could also be
explained by modifications in expression or activity of relevant enzymes (Illig et al., 2010).
However, our analyses between SNPs associated with anthropometric characteristics and
metabolite variables did not reveal any significant results.
Greater Muscle Mass might affect SCD
In addition, a higher FFMI was associated with an increased concentration of sphingomyelins
as compared to hydroxysphingomyelins. Recently, Wang-Sattler et al. (2008) reported a
reduced concentration of sphingomyelins and an increased concentration of hydroxysphin-
gomyelins in smokers. This finding was explained as a consequence of smoking on the
activity of the peroxisomal enzyme alkylglycerone phosphate synthase (alkyl-DHAP). Fol-
lowing this argumentation, FFMI is probably associated with an increase of the activity of
alkyl-DHAP. The negative association of the SM C16:0/SM C16:1 ratio with FFMI might
be explained by regulatory processes in the fatty acid biosynthesis pathway. In particular,
stearoyl-CoA desaturase (SCD), which catalyses the desaturation of C16 and C18 fatty
acids, might be a target enzyme/gene affected by greater muscle mass and/or activity.
Sensitivity Analyses
For the current analysis, subjects with a diagnosis of diabetes or hypertension or medication
for both diseases were excluded. However, obese subjects are more likely to develop
derangements in glucose or lipid metabolism as compared to normal-weight subjects which
are in a subclinical state and have not led to a clinical diagnosis yet. An analysis of serum
glucose (hexose) and triacylglycerol indicated significantly different means between non-
obese and obese subjects. In non-obese subjects, mean ± standard deviation serum glucose
concentration was 5.18 ± 0.76 mmol/l and mean serum triacylglycerol concentration was
1.4 ± 0.81 mmol/l; the corresponding values in obese subjects were 5.6 ± 1.11 mmol/l
and 1.70 ± 1.05 mmol/l, respectively. However, the higher glucose and triacylglycerol
concentrations in obese do not indicate a catabolic status and thus are not sufficient to
explain the missing association between FFMI and serum metabolites.
Stratified Analyses
Stratified analyses by gender, age, and physical activity were conducted in order to detect
potential confounders and effect modifiers. Similar results were found for men and women
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separately. P-values increased, as the sample size within the strata (slightly more for men)
was smaller. However there was no improvement of the model fit, represented by the
adjusted R2. In addition, the FFMI is independent of height (Kyle et al., 2003a) thus taking
one difference between men and women into account. Furthermore, analysing the whole
sample increases the power and we were able to cover a wider range of the FFMI. With
respect to physical activity, slight differences were found for the acylcarnitine metabolite
group. These effects were no longer present within the inactive participants. However, as
physical activity and FFMI are correlated and FFMI covers the long-term sports effect as
representative of the muscle mass, physical activity was not included as a covariate in the
main analyses.
Strength and Limitations
The participants of our studies represent random samples of the underlying population. In
such a population with a heterogeneous metabolic makeup influenced by different environ-
mental factors, genetic predispositions, and lifestyles, the interpretation of metabolic profiling
is quite ambitious (Suhre et al., 2010). The metabolite concentrations which are reported
in the present paper were identified by means of two slightly different AblsoluteIDQTM kits
p150 and p180. These two kits are not identical (190 different metabolites were measured
with an overlap of 141) and the measurement method of the amino acids slightly differs.
However, this technology allows the automated quantification of hundreds of metabolites
for many samples at a time which is very helpful for future studies (Altmaier et al., 2011).
Furthermore, the side chain composition of the different PCs, lysoPCs, sphingomyelins and
acylcarnitines carries many information on the different fatty acid pools in the human body,
such as n-3 and n-6 PUFAs or saturated and mono-saturated short and medium-chain fatty
acids (Wenk, 2005). Thus, the kit is well oriented to map out the human lipidome and
therefore particular for the purpose of this project.
The BIA measurements did only take place in KORA S4. For the analyses of associations
between FFMI and the metabolite concentrations in KORA F4 only the results of the
BIA measurements at baseline examination (KORA S4) were available. Assuming that
the participants’ body composition is fairly stable in weight-stable subjects, the KORA F4
based analyses were restricted to the weight-stable subjects in order to account for this.
No significant associations were detected between the different SNPs and metabolite
variables. However, at the time of our analyses only one GWAS with lean body mass as
phenotype has been published.
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The GGMs present low levels of linkage between the metabolites which is in line with
findings from Krumsiek et al. (2011) who demonstrated that GGMs omit indirect correla-
tions. Nevertheless, the GGMs complete the linear regression results with the underlying
relationships between the metabolites.
Conclusion
We found strong associations between serum amino acids, acylcarnitines, and glycerophos-
pholipids with the FFMI in a population-based sample. These findings were stable as they
could be reproduced in a follow-up study of this population. Most interestingly, such asso-
ciations were largely missing in obese subjects. The latter finding supports the hypothesis
that a sedentary lifestyle associated with accumulation of fat tissue may be accompanied
by a derangement in skeletal muscle metabolism, especially a limited inducibility of fatty
acid oxidation.
3.3 Metabolomics and Thyroid Hormones
3.3.1 Background
Thyroid hormones are responsible for the proper function of nearly all organ systems (Brix
et al., 2011) and disturbances are associated with major health problems. For example, the
non-treatment of hyperthyroidism bears a high risk of death from cardiovascular disease
(Boelaert & Franklyn, 2005). The circulating concentrations of TSH, FT4 and FT3 have a
strong heritable component and are supposed to be controlled by multiple genes (Panicker
et al., 2010). However, in case of FT4 these genes are still unknown. So far, one GWAS
has been conducted but with little success (Panicker et al., 2010). In this project, we
therefore decided not to focus on the genetics, but to focus on the thyroid hormone effects
on the actual metabolism with a scope on euthyroid participants. We hypothesised that
the effects of FT4 and TSH on substrate oxidation and the activity of involved enzymes are
reflected in serum metabolite concentrations. Therefore, we took a targeted quantitative
metabolomics approach to identify FT4 and TSH triggered pathways.
3.3.2 Results
Table 3.10 summarises the characteristics of all euthyroid KORA F4 participants and the
weight-stable subsample. On average, men and women were 51 ± 12 years old and had a
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Table 3.10: Characteristics (mean, SD, % or N) of male and female participants in the
analysed samples of KORA F4 sample and the weight-stablea subset.
All Weight-Stablea
(n = 1496) (n = 621)
Men Women Men Women
(n = 792) (n = 677) (n = 343) (n =278)
Parameter Unit Mean SD Mean SD Mean SD Mean SD
Age years 50.9 12.1 51.0 12.4 53.3 12.1 54.1 12.7
Weight kg 85.3 13.0 69.8 13.1 83.3 11.5 67.9 12.5
Height cm 177.1 6.9 162.9 6.7 176.7 7.0 162.4 6.4
Body-Mass-Index kg/m2 27.2 3.7 26.4 5.0 26.7 3.3 25.8 4.7
Waist cm 97.2 11.4 85.3 12.2 95.9 10.1 84.1 12.2
Hip cm 105.6 8.1 104.9 9.9 104.3 6.3 103.6 9.4
Waist-to-Hip Ratio 0.9 0.1 0.8 0.1 0.9 0.1 0.8 0.1
FT4 pmol/l 13.5 1.7 13.5 1.6 13.4 1.6 13.6 1.6
TSH mlU/l 1.4 0.7 1.5 0.7 1.4 0.6 1.5 0.7
Fat Free Massb kg 60.9 6.1 43.3 5.2 60.8 6.1 43.2 5.2
Body Fat Massb % 26.3 5.0 35.6 5.7 26.4 4.9 35.6 5.6
FFMIb,c kg/m2 19.6 1.6 16.4 1.8 19.6 1.6 16.4 1.8
BFMIb,d kg/m2 7.2 2.2 9.5 3.2 7.21 2.1 9.4 3.2
Parameter Category % N % N % N % N
Body-Mass-Index <18.5 0.13 1 0.1 3 0.3 1 0.4 1
18.5 to < 25 28.3 224 28.3 321 30.6 105 50.7 141
25 to < 30 52.5 416 52.5 217 51.6 177 32.7 91
≥ 30 19.1 151 19.1 135 17.5 60 16.2 45
Physical Activitye active 58.0 459 58.0 379 60.4 207 60.4 168
inactive 42.1 333 42.1 298 39.7 136 39.6 110
Age Groups 31 to 40 years 23.2 184 25.0 169 18.4 51 15.2 52
41 to 50 years 30.6 242 30.0 203 23.4 65 31.8 109
51 to 60 years 23.0 182 23.0 156 26.6 74 23.3 80
61 to 70 years 15.5 123 12.9 87 20.14 56 19.8 68
71 to 80 years 7.5 59 8.7 59 10.4 29 9.3 32
≥ 81 years 0.3 2 0.4 3 1.1 3 0.6 2
a weight-stable subjects of KORA F4, whose weight gain or loss did not exceed more than 0.5% per year since their body
weight was measured in KORA S4 (on average seven years prior F4 examination); b Parameters derived from the BIA-
measurements which were only conducted in KORA S4; c fat free mass index; d body fat mass index; e Physical Activity
(active: >1h sport per week on a regular basis; inactive: less than 1h sport per week).
BMI of 27 ± 4 kg/m2 and 26 ± 5 kg/m2, respectively. About 19 % of men and women
were classified as obese. Mean serum TSH and FT4 concentrations were 1.40 ± 0.65 mIU/l
and 13.45 ± 1.67 pmol/l in men and 1.51 ± 0.71 mIU/l and 13.54 ± 1.62 pmol/l in
women. Comparing serum FT4 and TSH hormone concentrations across different categories
of age, sex, BMI, and physical activity for all KORA F4 participants and the two subsets,
weight-stable and obese participants, we hardly detected any differences (Table 3.11 and
3.12). Applying ANOVA and pairwise t-tests, mean FT4 values of all KORA F4 participants
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Table 3.11: Mean and SD of FT4 hormone concentration (pmol/l) across different strata
of age, BMI (kg/m2), sex or physical activity for the KORA F4 participants
(n = 1469), the weight-stablea subset (n = 621) and the obese participants
(BMI ≥ 30 kg/m2; n = 286).
KORA F4 Weight-Stablea Obese Subset
(n = 1469) (n = 621) (n = 286)
Parameter Category Mean SD Mean SD Mean SD
Age 31 to 40 years 13.34 1.59 13.43 1.59 13.00 1.54
41 to 50 years 13.23 1.61 13.10 1.64 13.34 1.64
51 to 60 years 13.41 1.54 13.34 1.35 13.34 1.45
61 to 70 years 13.88 1.67 * 13.80 1.60 *of 2 13.95 1.70 *of 1
71 to 80 years 14.45 1.72 * 14.43 1.70 *of 1-3 14.49 1.85 *of 1-3
≥ 81 years 14.22 2.05 14.22 2.05 15.45 3.18
Body Mass < 18.5 16.65 1.04 * 16.90 1.41 *
Index 18.5 to < 25 13.50 1.62 13.49 1.66
25 to < 30 13.43 1.63 13.49 1.50
≥ 30 13.56 1.69 13.46 1.72
Physical active 13.45 1.57 # 13.54 1.54 # 13.50 1.54
Activityb inactive 13.55 1.73 13.41 1.71 13.60 1.80
a weight-stable subjects of KORA F4, whose weight gain or loss did not exceed more than 0.5% per year since their body
weight was measured in KORA S4 (on average seven years prior KORA F4 examination); b Physical Activity (active: >1h
sport per week on a regular basis; inactive: less than 1h sport per week); * pairwise t-test was significant; # leven test
resulted in rejection of equal variances.
for the age strata 61 to 70 years and 71 to 80 years were significantly different to the other
strata. Also the mean FT4 value in the BMI category <18.5 was significantly higher as
compared to the other BMI categories. No differences among categories were found for the
TSH concentrations (Table 3.12).
After correction for multiple testing we obtained 152 statistically significant associations
between various serum metabolite concentrations, metabolite ratios, and FT4. Significant
associations between metabolites and TSH concentrations were entirely lacking. Selected
statistically significant associations of FT4 with different metabolite concentrations for the
KORA F4 population are shown in Table 3.13. Different parameters such as the direction of
the beta estimate derived from the adjusted linear model are given, as well as the adjusted
p-value, the adjusted R2 and the p-gain. The full list of all obtained statistically significant
associations can be found in Supplementary Table C2.
FT4 and Acylcarnitines
For a series of different serum acylcarnitines, statistically significant associations with serum
FT4 concentrations were detected, and all of them showed a positive direction (of the
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Table 3.12: Mean and SD of TSH hormone concentration (mIU/l) across different strata
of age, BMI (kg/m2), sex or physical activity for the KORA F4 participants
(n = 1469), the weight-stablea subset (n = 621) and the obese participants
(BMI ≥ 30 kg/m2; n = 286).
KORA F4 Weight-Stablea Obese Subset
(n = 1469) (n = 621) (n = 286)
Parameter Category Mean SD Mean SD Mean SD
Age 31 to 40 years 1.54 0.67 1.52 0.54 1.44 0.66
41 to 50 years 1.47 0.67 1.46 0.68 1.54 0.58
51 to 60 years 1.40 0.70 1.42 0.71 1.48 0.61
61 to 70 years 1.42 0.64 1.35 0.63 1.60 0.69
71 to 80 years 1.33 0.70 1.25 0.66 1.48 0.80
≥ 81 0.91 0.59 0.91 0.59 0.43 0.01
Body Mass Index < 18.5 1.23 0.59 1.23 0.89
18.5 to < 25 1.46 0.73 1.41 0.71
25 to < 30 1.41 0.65 1.36 0.58
≥ 30 1.51 0.65 1.55 0.70
Physical Activity active 1.44 0.69 1.38 0.65 1.49 0.61
inactive 1.45 0.67 1.47 0.67 1.52 0.69
a weight-stable subjects of KORA F4, whose weight gain or loss did not exceed more than 0.5% per year since their body
weight was measured in KORA S4 (on average seven years prior KORA F4 examination); b Physical Activity (active: >1h
sport per week on a regular basis; inactive: less than 1h sport per week).
β-estimate), strongly indicating an overall elevated β-oxidation of fatty acids with higher
serum FT4 concentration. For acetylcarnitine (C2) as the quantitatively most important
serum acylcarnitine the adjusted p-value was 3.23x10−10. Similarly strong associations were
detected for single acylcarnitine concentrations such as C18:1, C16:1, C18:2, the sums of all
acylcarnitines, long-chain acylcarnitines, even-numbered acylcarnitines, and acylcarnitines
carrying monounsaturated or polyunsaturated fatty acids. Special ratios, such as C2 by
C0 or the sum of C2 and C3 by C0 were suggested as valid measures of β-oxidation of
fatty acids (Pande, 1975; Roschinger et al., 2000) and they were both positively associated
with FT4 hormone concentrations in our project (Table 3.13, Figure 3.6). The activity of
carnitine palmitoyltransferase I, reflected by the ratio of (C16 + C18) by C0 as described
by the manufacturer of the metabolite analysis kit, increased with higher FT4 hormone
concentrations. These results are strongly representative of the effects that higher FT4
concentrations exert on fatty acid oxidation.
FT4 and Phosphatidylcholines
The group of phosphatidylcholines consists of different PC diacyl (aa), PC acyl-alkyl (ae),
and lysoPC acyl (a) compounds. Numerous associations between FT4 and PCs or PC ratios

















































Figure 3.6: Boxplot of serum C2/C0 concentrations by quintiles of the FT4 (pmol/l), for
the KORA F4 population
were observed. Generally, an increase in FT4 levels was associated with lower concentrations
of PCs. This was reflected by the sum of all PCs, and the different sums of PCs containing
saturated, monounsaturated, polyunsaturated, or short-chain fatty acides. These results
are in line with the associations found for the sums of PC aa, PC ae, or lysoPC with
FT4 concentrations. Furthermore, single PCs such as PC aa C34:4, PC aa 36:1, PC ae
C40:1, PC ae C40:0, lysoPC a C14:0, or lysoPC a C16:1 were all inversely associated
with increasing serum FT4 concentrations. Regarding metabolite ratios, we received some
indication for an increase in saturation and chain length for PC aa by PC aa ratios, such as
PC aa C36:6 by PC aa C42:0, PC aa C36:5 by PC aa C42:0 or PC aa 36:0 by PC aa C38:0
with elevated FT4 levels. For PC ae by PC ae ratios, an increase in desaturation and chain
length with higher FT4 concentrations was observed, e.g., PC ae C42:2 by PC ae C42.5,
PC ae C40:1 by PC ae C40:5 or PC ae C38:2 by PC ae C42:5.
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Table 3.13: Selected metabolic traits significantly associated with FT4 in a linear regression
model adjusted for age, sex, BMI, and batch in the KORA F4 sample.
Trait Mean SD Dir.a P-Value R2 P-Gaind
(µmol/l) Adj.b Adj.c
Σ AC 10.81 3.24 pos. 9.02x10−11 0.14
Σ even. AC 9.97 3.16 pos. 9.35x10−11 0.14
Σ long. AC 0.40 0.09 pos. 9.56x10−11 0.21
Σ med. AC 1.12 0.36 pos. 2.82x10−06 0.14
Σ mono AC 1.73 0.46 pos. 1.92x10−08 0.16
Σ poly AC 8.32 2.85 pos. 1.74x10−10 0.13
C18:1 0.13 0.04 pos. 5.15x10−14 0.18
C16:1 0.04 0.01 pos. 4.29x10−11 0.17
C2 7.86 2.77 pos. 3.23x10−10 0.13
C14:2 0.03 0.01 pos. 3.58x10−10 0.14
C18:2 0.05 0.01 pos. 7.09x10−07 0.18
C12:1 0.14 0.05 pos. 1.10x10−06 0.12
C12 0.13 0.05 pos. 1.70x10−06 0.12
C10 0.34 0.16 pos. 3.72x10−05 0.10
C10:1 0.16 0.06 pos. 2.72x10−04 0.14
C14:1 0.14 0.05 pos. 1.59x10−02 0.25
C8 0.21 0.09 pos. 2.55x10−02 0.10
C2/C0 0.23 0.08 pos. 2.18x10−10 0.15
(C2+C3)/C0 0.24 0.08 pos. 1.19x10−10 0.14
CPT1: (C16+C18)/C0 0.001 0.001 pos. 2.35x10−02 0.07
Σ PCs 1985.90 355.32 neg. 3.66x10−11 0.14
Σ mono PCs 348.23 86.27 neg. 1.08x10−10 0.07
Σ poly PCs 1593.43 279.51 neg. 9.44x10−10 0.15
Σ sat. PCs 44.23 7.91 neg. 2.83x10−06 0.12
Σ short. PCs 759.58 161.54 neg. 3.58x10−11 0.25
PC aa
Σ PC aa 1788.09 333.40 neg. 8.32x10−12 0.14
Σ long. PC aa 47.14 12.35 neg. 1.24x10−02 0.07
Σ mono PC aa 323.62 83.10 neg. 1.25x10−10 0.07
Σ poly PC aa 1436.75 261.65 neg. 2.23x10−10 0.15
Σ sat. PC aa 27.72 5.60 neg. 9.50x10−06 0.11
Σ short. PC aa 721.28 156.91 neg. 2.97x10−11 0.25
PC aa C34:4 2.26 0.83 neg. 2.08x10−16 0.07
PC aa C36:1 53.44 13.59 neg. 1.23x10−14 0.10
PC ae
Σ mono PC ae 24.61 5.00 neg. 7.52x10−04 0.17
Σ sat. PC ae 16.51 2.81 neg. 8.24x10−05 0.12
Σ short. PC ae 38.30 8.25 neg. 9.24x10−03 0.19
PC ae C40:1 1.69 0.40 neg. 1.84x10−10 0.08
PC ae C40:0 10.27 1.63 neg. 8.27x10−03 0.11
lysoPC a
Σ lysoPCs 191.41 40.73 neg. 6.92x10−05 0.19
Σ sat. lysoPCs 127.77 26.44 neg. 2.33x10−03 0.14
Σ unsat. lysoPCs 63.64 17.36 neg. 2.95x10−05 0.23
lysoPC a C14:0 3.23 0.84 neg. 2.84x10−06 0.04
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Trait Mean SD Dir.a P-Value R2 P-Gaind
(µmol/l) Adj.b Adj.c
lysoPC a C16:1 2.92 1.00 neg. 2.19x10−05 0.06
PC aa C36:6/ PC aa C42:0 1.95 0.80 neg. 1.45x10−15 0.06 5.08x10+05
PC aa C36:5/ PC aa C42:0 51.17 24.93 neg. 5.52x10−14 0.10 4.10x10+04
PC aa C36.0/ PC aa.C38.0 0.83 0.13 neg. 2.79x10−09 0.04 1.51x10+08
PC ae C42:2/ PC ae C42:5 0.29 0.06 neg. 1.23x10−19 0.07 4.37x10+12
PC ae C40:1/ PC ae C40:5 0.48 0.10 neg. 1.97x10−17 0.09 9.35x10+06
PC ae C38:2/ PC ae C42:5 0.92 0.22 neg. 3.80x10−16 0.08 9.04x10+06
a direction of the association (positive or negative); b for multiple testing adjusted p-value; c adjusted R2 of the linear model;
d p-gain, fold decrease in the p-value of association for the pair of metabolites, compared to the lowest of two p values for
the single metabolites; AC, acylcarnitines; CPT1, carnitine palmitoyltransferase I; even., even numbered; long., long-chain;
med., medium-chain; short, short-chain; sat., saturated; unsat., unsaturated.
Subanalyses
Weight-Stable Subsample. Restricting our sample to the weight-stable subset and adjusting
for FFMI instead of BMI resulted in a substantial loss of significant associations with
FT4 as compared to the results in the entire sample (Supplementary Table S3). Although
β-estimates are similar in both analyses, statistical power was lower due to the smaller size of
the weight-stable group. Still, long-chain acylcarnitines, the sums of long-chain acylcarnitines
and of monounsaturated acylcarnitines were significantly positively associated with FT4
levels in this subsample. The significant associations between single PC concentrations
and FT4 were similar to the results of the entire sample. However, significant associations
with PC ratios are largely missing, indicating loss of statistical power as a consequence
of the reduced sample size. Adjusting the linear models for BMI instead of FFMI in the
weight-stable subsample resulted in almost the same significant associations with FT4,
suggesting no distinct effect of the more precise adjustment for lean body mass.
Physical Activity. The acylcarnitine results for physically inactive participants paralleled the
results in the whole sample, showing an enhanced oxidation activity with no preference of
acylcarnitine type. The results for the active participants varied slightly (Supplementary
Table C4). Here, the positive associations with most sums of acylcarnitines were also
present, but regarding individual compounds, only C18:1, C14:2, C18:2 and C2 were still
positively associated with elevated FT4 hormone concentrations. Testing for differences
of the estimated coefficients between groups revealed no statistical significance. The
associations between PCs and FT4 levels in active and inactive participants were in line
with the results for the entire study population. For the inactive participants, however,
most associations regarding metabolite ratios were missing.
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Males versus Females. The acylcarnitine results for men were very much comparable to
the results in the whole sample while the results for the female participants varied slightly
(Supplementary Table C5). Here, the positive associations with the sums of acylcarnitines
were still present, but regarding the single concentrations, only C18:1, C14:2 and C18:2 are
positively associated with elevated FT4 hormone concentrations. Testing for differences of
the estimated coefficients between men and women revealed no statistical significance. The
associations between PCs and FT4 levels in men and women were in line with the results
for the entire study population.
Obese versus Non-Obese. The associations with FT4 levels found for the entire population
and the non-obese participants were similar for both, the acylcarnitine and the PC concen-
trations (see Supplementary Table C6). In the obese group, many significant associations
identified in the entire group were lacking which is likely due to sample size reasons. This
is supported by the results of the β-estimates which were largely comparable in size and
direction to those obtained in the entire group or the non-obese participants, although
not reaching statistical significance (data not shown). Still, significant associations were
identified for long-chain acylcarnitines with FT4 in the group of obese participants.
Influence of Liver, Kidney, or Inflammation Parameters. Almost all identified associations
between FT4 and different metabolite variables were independent of parameters such as
glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, gamma-glutamyl
transpeptidase, cystatin C, albumin, creatinine, C-reactive protein, or white blood cell count,
indicating liver or kidney insufficiency or underlying inflammation. Only the associations
between FT4 and PC aa C38:5, PC aa C40:4, PC aa C40:5, PC aa C42:6, PC ae C40:0,
and PC ae C42:1 were influenced by gamma-glutamyl transpeptidase, and the association
between FT4 and lysoPC a C18:2 was affected by C-reactive protein.
3.3.3 Discussion
In this population-based study, after overnight fasting, strong associations between serum
FT4 and serum metabolite concentrations were found. With higher FT4 levels, the
concentration of acylcarnitines as well as the ratio of C2 by C0 increased, indicating an
overall increase of β-oxidation of fatty acids. In addition, the inverse associations between
FT4 and PC metabolites are reflective of a uniform decline in serum PC concentrations.
These results were supported by the associations found in stratified analyses and strengthened
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by their independency of different liver, kidney, and inflammation parameters, indicative
for liver or kidney insufficiency, or underlying inflammation. In euthyroid adults, TSH
concentrations were not associated with serum metabolites. Also, no effect of FT4 on
serum amino acids concentrations was found.
Possible Direct Effects of FT4 on the Mitochondrial Level
Knowledge of how thyroid hormones exert their effects has further increased since the
successful molecular cloning of nuclear thyroid hormone receptors in the mid 90’s (Yen,
2001; Flamant et al., 2007; Wagner et al., 1995; Ribeiro et al., 1998). Most of the
physiological effects of thyroid hormones are exerted through thyroid hormone receptor
complexes and the response elements of regulatory regions of target genes (Brix et al.,
2011; Biondi, 2012a). Nevertheless, not all thyroid hormone effects are attributable to
nuclear mediated pathways (Moreno et al., 2008) and an increasing number of non-genetic
effects such as the transportation of ions, e.g., calcium, sodium, and potassium across
plasma membranes or glucose and amino acids have been described lately (Biondi et al.,
2002; Fazio et al., 2004). From a clinical point of view, it is clear that minor changes in
thyroid hormone concentrations cause distinct metabolic effects (Kim, 2008). In a recent
microarray study by Clement et al. (2002) on the transcriptome of the vastus lateralis, a
daily dosage of 75 µg of T4 was administered to healthy male volunteers with the result of
22 genes involved in mitochondrial energy metabolism being up-regulated. At the cellular
level, T4 is converted to T3, and T3 is considered the active hormone. It is evident that
intracellular T3 concentrations do not necessarily correspond to blood T3 concentrations.
Although serum FT3 concentrations were measured in our study as well, the applied analytic
method did not fulfil the strict quality control criteria in the end (Thienpont et al., 2010).
Thus, FT3 data could not be used in this project. However, our results and the findings of
the microarray study argue for an independent effect of FT4 on the mitochondrial level.
β-Oxidation increases with FT4
In a human experimental setting, it has recently been described that all plasma acylcarnitines
(except for C3, C4, and C5) showed a strong increase in times of elevated β-oxidation, e.g.,
during fasting and or exercise (Krug et al., 2012). Concomitantly, plasma free carnitine (C0)
decreases. In this project blood samples from all participants were drawn in fasting state, i.e.,
after overnight fast (minimum of 8 hours). Thus, all study participants were in a catabolic
metabolic state which is characterised by low plasma insulin concentrations, increased
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plasma concentrations of non-esterified fatty acids and ketone bodies, and an enhanced
gluconeogenesis. Under this fasting condition, our results strongly indicate elevated β-
oxidation with increasing plasma FT4 concentrations. Results from single acylcarnitine
concentrations, sums of different acylcarnitine groups, as well as the ratio of C2 by C0
support this conclusion (Pande, 1975; Roschinger et al., 2000). The observed decreasing
serum PC concentrations with higher FT4 levels are probably the consequence of this
enhanced lipid oxidation, and therefore underline our hypothesis.
No Effect of FT4 on Gluconeogenesis
Krug et al. (2012) further demonstrated that plasma concentrations of specific amino
acids, especially branched-chain amino acids, increased during fasting status, indicating
enhanced gluconeogenesis. Although, a strong relationship between branched-chain amino
acid serum concentrations and fat free mass in fasted state has been described for the
present population (3.2), we did not observe significant associations between serum amino
acid concentrations and FT4 levels in this project. Thus, we conclude that FT4 does not
affect gluconeogenesis in euthyroid and fasting subjects. This finding affirms the notion
that we do not simply see the effects of fasting status in our study but a specific effect
attributable to the thyroid hormone FT4 which is characterised by enhanced transport of
fatty acids in form of carnitine acylesters to the mitochondrion and subsequent β-oxidation.
To the best of our knowledge no study directly comparable to ours has been performed so
far. Most recent studies using transcriptomics or proteomics techniques investigated effects
of T3 administration. In these studies effects of T3 on proteins of gluconeogenic pathways
have been described; a review is given by Silvestri et al. (2011).
Independency of FT4 and β-Oxidation Association
For treatment of obesity, T3 and T4 in varying doses and duration have been administered to
euthyroid obese subjects during caloric deprivation to enhance weight loss and a systematic
review on this issue is given by Kaptein et al. (2009). The authors summarised that available
studies are insufficient to draw conclusions on beneficial or adverse effects of T3 or T4
administration; however, because of possible side-effect they do not advise on treatment
of obesity with T4 or T3 (Kaptein et al., 2009). The results of the subanalyses presented
here did not suggest specific differences by fat free mass (analysis in weight-stable subjects)
or between obese and non-obese subjects. Also, subanalyses by sex and physical activity
provided largely similar results across subgroups. Thus, we conclude that the positive
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association between FT4 and β-oxidation of fatty acids after overnight fast is not dependent
on lean body mass, body fat mass, sex, or habitual physical activity. In other words, we
gained no indication for obesity being a consequence of altered fatty acid oxidation in fasting
status as related to serum FT4 concentrations in euthyroid subjects. Further, no impact of
liver or kidney insufficiency or underlying inflammation on the associations between FT4
and β-oxidation could be observed. This supports the stability of our results and argues for
an independent effect of FT4.
Strength and Limitations
The human serum metabolome is currently characterised in many studies using different
analytic approaches (Psychogios et al., 2011), including the method applied here. To
the best of our knowledge, the association of FT4, TSH, and serum metabolites was not
explored before in a population-based setting. The participants of our study represent a
random sample of the underlying population. In such a population with a heterogeneous
metabolic makeup influenced by different environmental factors, genetic predispositions,
and lifestyles, the interpretation of metabolic profiling is quite ambitious (Suhre, Meisinger
et al. 2010). The metabolite concentrations which are reported in the present paper were
identified by means of the AbsoluteIDQTM p150 kit. This technology allows the automated
quantification of many metabolites with a focus on amino acids, acylcarnitines, and PCs for
many samples at a time (Wenk, 2005; Altmaier et al., 2011). Thus, the kit is well suitable
to assess a suggested impact of thyroid hormones on energy metabolism, especially lipid
metabolism. The BIA measurements did only take place in KORA S4. For the analyses
of associations with FT4 and the metabolite concentrations in the linear models with the
FFMI instead of the BMI as adjustment variable only the results of the BIA measurements
at baseline examination (KORA S4) were available. Assuming that the participants’ body
composition is fairly stable in weight-stable subjects, those analyses were restricted to the
weight-stable subjects in order to account for this.
Conclusion
Our results indicate that in a euthyroid population after overnight fast, serum FT4 concen-
trations are strongly linked to serum acylcarnitines and PCs, indicating enhanced transport
of fatty acids to the mitochondrion and subsequent β-oxidation. These findings were stable
as they could be largely reproduced in different subsets of the population.
68 3 Results and Discussions
4 Future Prospects
In this thesis three projects are presented exploring different aspects of body composition,
metabolism, and energy balance, and their interplay which are co-determining the health
status of human beings. These factors are themselves influenced by a multitude of
environmental factors and genetics. The projects in this thesis are utilising genetics and
metabolomics data for analysing gene–diet interactions and serum metabolite patterns
related to variation in fat free mass as proxy for skeletal muscle mass or thyroid hormones.
In the first project, we concluded that a large portion of the population would benefit from
a high PUFA intake with respect to obesity risk. Nevertheless, the study was not sufficiently
powered for the analyses of interaction effects. Hence, a replication of our results in a larger
prospective study is warranted. However, until today there has not been a comparable
project (Vliet-Ostaptchouk et al., 2012). Conventional analyses of fatty acids as, e.g.,
described in this thesis are expensive and time consuming. A possible further exploration of
this topic could be on the basis of a GWAS in combination with a metabolomics approach.
A prerequisite would be the identification and validation of metabolomics pattern indicative
for the intake of specific fatty acids, such as PUFAs. Then, a GWAS could be conducted
analysing the interaction effects between the SNPs and those identified sets of metabolites
with respect to obesity risk. Studies with genome wide data and metabolomics often are
large in size and thus more suitable for the analyses of interaction effects.
The second project incorporated metabolomics as well as genetics. We received an extensive
picture of the fat free mass related metabolic makeup of adults and the interrelation
between the metabolites. The genetic approach aimed at identifying significant associations
between different metabolites and SNPs described to be associated with anthropometric
measurements. The idea was to incorporate the genetic background and therewith sharpen
the picture of fat free mass induced effects. Unfortunately, no significant association was
found for the selected SNPs. However, stratified analyses supported our hypothesis that the
excessive accumulation of body fat tissue may be accompanied by a derangement in skeletal
muscle metabolism, especially a limited inducibility of fatty acid oxidation. Lifestyle factors
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favouring the development of obesity, especially low physical activity over a longer time
period, may be causally related to this modified skeletal muscle metabolism. Further large
prospective studies have to explore in more detail the interrelationships between lifestyle
factors and derangements of muscle mass metabolism. From a public health perspective, it
would be important to know whether this metabolic status is reversible and how much of
regular physical activity is necessary to avoid such derangement.
In the third project, we identified a set of metabolites which indicates an overall enhanced
transport to the mitrochondria and β-oxidation of fatty acids with higher FT4 concentrations
in fasted euthyroid adults. No associations were found for TSH. The results for FT4 were
quite stable throughout stratified analyses and no differences between obese versus non-
obese subjects were identified. However, the situation might be different in an anabolic
status or during phases of increased energy expenditure. Studies considering these aspects
should be performed as well and additionally in different populations with abnormal thyroid
hormone concentrations (subclinical derangements, thyroid diseases). The number of
participants with hormone concentrations above or below the normal range was too small
in our study to perform statistically meaningful subanalyses.
The results described in this thesis give a taste of the values, possibilities and potentials
of “new” data obtained by means of “omics” techniques and the possible combination of
different “omics” approaches such as genomics and metabolomics. Ideas for meaningful
follow-up projects are described and suggested above. However, there are many research
opportunities and projects, either in the field of gene–diet interactions or in applying
metabolomics data in observational and intervention studies. Also, obesity is only one of the
important chronic diseases which have to be addressed. This thesis with the incorporation
of gene–environment interactions and the utilisation of metabolomics data shows promising
perspectives in the development of new measures to prevent, early detect or treat metabolic
diseases and other chronic diseases.
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Table A1: Genotype distribution and crude main effects of the different SNPs on the risk
of obesity in the BVS II study (Jourdan et al., 2011).
Gene SNP MAFa Allele Obese Non- P-valueb OR [95% CI] P-trendc
Obese
IL-2 region 5’ rs4833248 0.30 GG 50.90 48.30 0.8876 1.00 0.6606
AG 40.90 43.10 0.90 [0.58-1.39]
AA 8.20 8.60 0.91 [0.39-1.91]
IL-2 rs2069779 0.07 CC 86.70 85.80 0.8649 1.00 0.7599
CT 13.30 14.00 0.93 [0.49-1.65]
TT 0.00 0.20
IL-2 rs2069778 0.16 CC 69.40 71.00 0.923 1.00 0.7846
CT 28.80 27.00 1.09 [0.68-1.72]
TT 1.80 2.00 0.93 [0.14-3.69]
IL-2 rs2069763 0.35 GG 38.90 43.20 0.0835 1.00 0.8331
GT 54.00 43.90 1.37 [0.89-2.12]
TT 7.10 12.90 0.61 [0.25-1.31]
IL-2 rs2069762 0.29 TT 51.80 49.60 0.9149 1.00 0.7005
GT 40.20 42.00 0.91 [0.59-1.41]
GG 8.00 8.40 0.91 [0.40-1.92]
IL-6 region 5’ rs1880241 0.50 AA 30.70 26.00 0.5736 1.00 0.3146
AG 45.60 47.30 0.82 [0.50-1.33]
GG 23.70 26.70 0.75 [0.43-1.32]
IL-6 region 5’ rs4719714 0.22 AA 59.80 61.60 0.0284 1.00 0.2056
AT 30.40 34.60 0.90 [0.57-1.42]
TT 9.80 3.80 2.68 [1.17-5.94]
IL-6 region 5’ rs12700386 0.19 CC 76.30 63.40 0.0327 1.00 0.0184
CG 20.20 31.80 0.53 [0.31-0.86]
GG 3.50 4.90 0.60 [0.17-1.62]
IL-6 rs1800797 0.42 GG 35.10 33.60 0.9132 1.00 0.6772
AG 47.40 47.30 0.96 [0.61-1.52]
AA 17.50 19.10 0.88 [0.48-1.58]
IL-6 rs1800795 0.43 GG 35.40 33.60 0.8814 1.00 0.6257
CG 46.90 46.80 0.95 [0.60-1.52]
CC 17.70 19.60 0.86 [0.46-1.54]
IL-6 rs2069840 0.35 CC 46.90 43.00 0.4942 1.00 0.8148
CG 38.10 44.10 0.79 [0.50-1.24]
GG 15.00 12.90 1.07 [0.56-1.96]
IL-6 rs2069861 0.10 CC 86.80 80.40 0.1825 1.00 0.2004
CT 11.40 18.40 0.62 [0.33-1.10]
TT 1.80 1.10
IL-6 rs2069833 0.43 TT 35.10 32.90 0.8205 1.00 0.5411
CT 48.20 48.10 0.94 [0.60-1.49]
CC 16.70 19.00 0.82 [0.44-1.49]
IL-6 region 3’ rs10242595 0.30 AA 50.00 49.20 0.6341 1.00 0.7851
AG 37.50 41.00 0.90 [0.57-1.40]
GG 12.50 9.80 1.26 [0.63-2.40]
IL-10 region 5’ rs17015767 0.19 GG 70.20 65.90 0.6464 1.00 0.5015
CG 24.60 29.00 0.80 [0.49-1.27]
CC 5.30 5.10 0.97 [0.35-2.31]
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Gene SNP MAFa Allele Obese Non- P-valueb OR [95% CI] P-trendc
Obese
IL-10 region 5’ rs3122605 0.16 AA 63.20 72.10 0.1351 1.00 0.0477
AG 33.30 26.20 1.45 [0.92-2.26]
GG 3.50 1.80 2.26 [0.59-7.37]
IL-10 rs3024498 0.22 AA 66.70 60.70 0.4964 1.00 0.306
AG 28.10 33.60 0.76 [0.48-1.20]
GG 5.30 5.70 0.84 [0.30-1.98]
IL-10 rs1554286 0.20 CC 59.60 63.70 0.5686 1.00 0.5872
CT 37.70 32.70 1.23 [0.80-1.89]
TT 2.60 3.50 0.79 [0.18-2.47]
IL-10 rs3021094 0.10 AA 84.20 79.90 0.3698 1.00 0.2204
AC 15.80 19.00 0.74 [0.42-1.27]
CC 0.00 1.10
IL-10 rs1800896 0.44 AA 25.40 31.30 0.3532 1.00 0.5466
AG 57.90 50.60 1.41 [0.87-2.31]
GG 16.70 18.20 1.13 [0.59-2.12]
IL-10 region 3’ rs3024505 0.16 CC 63.20 70.40 0.1416 1.00 0.0783
CT 33.30 28.30 1.31 [0.84-2.03]
TT 3.50 1.30 2.94 [0.74-10.57]
IL-18 rs3882891 0.42 AA 32.50 35.00 0.7613 1.00 0.8617
AC 50.90 47.00 1.17 [0.74-1.86]
CC 16.70 18.00 1.00 [0.53-1.83]
IL-18 rs5744280 0.33 CC 45.10 43.80 0.9581 1.00 0.8547
CT 45.10 46.70 0.94 [0.61-1.45]
TT 9.70 9.60 0.98 [0.45-1.98]
IL-18 rs549908 0.30 TT 44.20 49.10 0.6455 1.00 0.367
GT 46.00 42.40 1.20 [0.78-1.86]
GG 9.70 8.50 1.27 [0.59-2.59]
IL-18 rs5744256 0.26 TT 54.00 54.70 0.9818 1.00 0.9464
CT 39.80 38.90 1.04 [0.67-1.59]
CC 6.20 6.40 0.97 [0.38-2.21]
IL-18 rs360722 0.11 CC 82.50 77.50 0.5139 1.00 0.2638
CT 16.70 21.40 0.73 [0.42-1.22]
TT 0.90 1.10
IL-18 rs795467 0.27 GG 51.80 53.10 0.9414 1.00 0.7426
AG 40.40 39.80 1.04 [0.67-1.60]
AA 7.90 7.10 1.14 [0.49-2.44]
IL-18 rs1946519 0.39 CC 38.10 36.70 0.7115 1.00 0.5333
AC 48.70 46.90 1.00 [0.64-1.57]
AA 13.30 16.40 0.78 [0.40-1.46]
TNF-α rs3093662 0.07 AA 87.60 85.90 0.8051 1.00 0.5965
AG 12.40 13.90 0.86 [0.45-1.55]
GG 0.00 0.20
TNF-α rs3093668 0.05 GG 92.90 90.00 0.5996 1.00 0.329
CG 7.10 9.70 0.69 [0.29-1.43]
CC 0.00 0.20
TNFRSF1A rs4149579 0.06 GG 90.40 88.30 0.6836 1.00 0.4742
AG 9.60 11.30 0.81 [0.39-1.54]
AA 0.00 0.40
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Obese
TNFRSF1A rs4149577 0.48 TT 28.10 24.30 0.4424 1.00 0.216
CT 55.30 54.10 0.88 [0.55-1.44]
CC 16.70 21.60 0.67 [0.35-1.24]
TNFRSF1A rs4149576 0.45 GG 24.60 31.20 0.354 1.00 0.3468
AG 55.30 48.90 1.44 [0.88-2.38]
AA 20.20 19.90 1.29 [0.69-2.37]
TNFRSF1A rs4149570 0.39 GG 43.40 34.40 0.2057 1.00 0.1269
GT 44.20 51.40 0.68 [0.44-1.06]
TT 12.40 14.20 0.69 [0.35-1.31]
TNFRSF1B rs652625 0.05 AA 88.60 91.20 0.3895 1.00 0.5686
AT 11.40 8.20 1.33 [0.66-2.51]
TT 0.00 0.70
TNFRSF1B rs496888 0.32 AA 49.10 46.70 0.7928 1.00 0.5235
AG 41.20 41.60 0.94 [0.61-1.45]
GG 9.60 11.70 0.78 [0.37-1.55]
TNFRSF1B rs3766730 0.16 CC 69.90 71.00 0.1012 1.00 0.4355
CT 25.70 27.70 0.94 [0.58-1.49]
TT 4.40 1.30 3.38 [0.95-11.48]
TNFRSF1B rs1061622 0.21 TT 61.10 62.90 0.1445 1.00 0.3269
GT 31.90 34.00 0.97 [0.61-1.50]
GG 7.10 3.10 2.36 [0.91-5.74]
TNFRSF1B rs2275416 0.18 GG 62.80 67.90 0.2342 1.00 0.1668
AG 31.90 29.70 1.16 [0.73-1.81]
AA 5.30 2.50 2.34 [0.78-6.36]
TNFRSF1B rs235219 0.10 GG 82.10 81.40 0.9817 1.00 0.8626
AG 17.00 17.70 0.95 [0.54-1.60]
AA 0.90 0.90
TNFRSF1B rs1061624 0.41 GG 42.90 38.20 0.6605 1.00 0.4479
AG 37.50 40.80 0.82 [0.51-1.30]
AA 19.60 21.00 0.83 [0.47-1.45]
TNFRSF1B rs1061628 0.40 CC 32.10 36.40 0.0219 1.00 0.5483
CT 58.90 46.10 1.45 [0.92-2.29]
TT 8.90 17.50 0.58 [0.26-1.18]
TNFRSF21 rs9473029 0.05 GG 92.00 90.10 0.6198 1.00 0.4332
CG 8.00 9.30 0.78 [0.35-1.59]
CC 0.00 0.70
TNFRSF21 rs2236039 0.28 AA 49.10 53.30 0.6287 1.00 0.6086
AG 43.00 38.10 1.23 [0.80-1.89]
GG 7.90 8.60 0.99 [0.43-2.09]
TNFRSF21 rs2295266 0.19 CC 61.90 66.40 0.6331 1.00 0.4735
CG 34.50 29.90 1.24 [0.79-1.92]
GG 3.50 3.80 1.01 [0.28-2.83]
TNFRSF21 rs714373 0.36 AA 44.70 40.30 0.649 1.00 0.5459
AG 41.20 45.80 0.81 [0.52-1.26]
GG 14.00 13.90 0.91 [0.47-1.67]
TNFRSF21 rs9473045 0.34 GG 45.10 43.00 0.7653 1.00 0.9333
AG 41.60 45.20 0.88 [0.56-1.36]
AA 13.30 11.80 1.08 [0.55-2.03]
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TNFRSF21 rs16875844 0.08 GG 81.60 86.30 0.3809 1.00 0.274
AG 17.50 12.60 1.42 [0.81-2.42]
AA 0.90 1.10
TNFRSF21 rs2017424 0.48 CC 29.80 27.60 0.5536 1.00 0.8808
CG 43.90 49.40 0.82 [0.51-1.34]
GG 26.30 23.00 1.06 [0.61-1.85]
TNFRSF21 rs6458555 0.34 GG 44.20 46.80 0.8817 1.00 0.6226
AG 41.60 40.10 1.10 [0.70-1.71]
AA 14.20 13.10 1.14 [0.59-2.12]
TNFRSF21 region 3’ rs9381530 0.43 TT 35.10 30.70 0.6516 1.00 0.3818
GT 49.10 51.70 0.83 [0.53-1.32]
GG 15.80 17.70 0.78 [0.41-1.44]
NPY region 5’ rs16480 0.32 TT 56.30 52.90 0.3693 1.00 0.2632
CT 30.40 28.00 1.02 [0.63-1.62]
CC 13.40 19.10 0.66 [0.35-1.19]
NPY rs16148 0.34 TT 43.40 43.50 0.3535 1.00 0.5282
CT 48.70 43.90 1.11 [0.72-1.72]
CC 8.00 12.60 0.64 [0.28-1.32]
NPY rs16141 0.49 AA 25.00 23.60 0.6322 1.00 0.78
AC 50.00 54.80 0.86 [0.52-1.45]
CC 25.00 21.60 1.09 [0.60-1.98]
NPY rs9785023 0.50 AA 23.70 23.20 0.7098 1.00 0.6878
AG 50.90 54.60 0.91 [0.55-1.54]
GG 25.40 22.10 1.13 [0.62-2.04]
NPY rs16138 0.26 GG 56.10 53.00 0.4733 1.00 0.3394
CG 40.40 40.60 0.94 [0.61-1.43]
CC 3.50 6.40 0.52 [0.15-1.37]
NPY rs16135 0.07 CC 90.40 84.70 0.2342 1.00 0.099
CT 9.60 14.40 0.59 [0.29-1.11]
TT 0.00 0.90
NPY rs16131 0.15 AA 68.40 73.70 0.4935 1.00 0.2354
AG 28.10 23.80 1.27 [0.79-2.01]
GG 3.50 2.40 1.56 [0.42-4.69]
NPY rs16475 0.11 TT 86.70 86.50 0.498 1.00 0.7838
CT 2.70 4.90 0.54 [0.13-1.61]
CC 10.60 8.60 1.22 [0.59-2.36]
NPY region 3’ rs2023890 0.22 TT 57.70 61.70 0.3871 1.00 0.2594
CT 35.10 34.10 1.10 [0.70-1.71]
CC 7.20 4.20 1.82 [0.72-4.22]
NPY region 3’ rs16472 0.08 CC 84.70 83.30 0.7242 1.00 0.724
CT 15.30 16.70 0.90 [0.49-1.57]
NPY region 3’ rs17374047 0.15 AA 73.20 70.80 0.6333 1.00 0.4807
AG 25.90 27.00 0.93 [0.57-1.47]
GG 0.90 2.20 0.39 [0.02-2.08]
NPY region 3’ rs16468 0.40 CC 33.00 33.90 0.8188 1.00 0.8685
AC 54.50 51.70 1.08 [0.69-1.72]
AA 12.50 14.50 0.88 [0.44-1.72]
XLVIII Appendix
Gene SNP MAFa Allele Obese Non- P-valueb OR [95% CI] P-trendc
Obese
NPY region 3’ rs16110 0.50 GG 26.50 23.70 0.8191 1.00 0.6479
CG 50.40 52.80 0.85 [0.52-1.42]
CC 23.00 23.50 0.87 [0.48-1.58]
NPY1R region 5’ rs4234955 0.23 AA 59.30 60.10 0.1041 1.00 0.3521
AG 31.00 35.20 0.89 [0.56-1.40]
GG 9.70 4.70 2.11 [0.94-4.51]
NPY1R region 5’ rs4691076 0.23 CC 58.40 59.00 0.2458 1.00 0.4733
CT 32.70 36.10 0.91 [0.58-1.42]
TT 8.80 4.90 1.83 [0.80-3.96]
NPY1R rs9764 0.27 TT 53.60 50.60 0.8303 1.00 0.6456
TC 42.00 45.20 0.88 [0.57-1.34]
CC 4.50 4.30 0.99 [0.32-2.57]
NPY1R rs4691075 0.11 TT 78.60 80.10 0.3085 1.00 0.4762
CT 18.80 19.00 1.10 [0.65-1.80]
CC 2.70 0.90
NPY1R rs7687423 0.35 GG 40.40 41.30 0.9668 1.00 0.9305
AG 48.20 46.90 1.05 [0.68-1.64]
AA 11.40 11.80 0.99 [0.48-1.93]
NPY1R rs12507653 0.30 AA 53.10 47.90 0.6132 1.00 0.3763
AT 38.10 42.40 0.81 [0.52-1.25]
TT 8.80 9.80 0.82 [0.37-1.66]
NPY5R rs4632602 0.10 TT 74.60 82.10 0.1896 1.00 0.0779
CT 24.60 17.20 1.57 [0.95-2.52]
CC 0.90 0.70
NPY5R rs7678265 0.08 CC 85.00 85.20 0.969 1.00 0.9122
CT 14.20 14.20 1.02 [0.56-1.78]
TT 0.90 0.70
NPY5R rs11100494 0.08 CC 89.40 82.90 0.169 1.00 0.0692
AC 10.60 15.70 0.58 [0.29-1.06]
AA 0.00 1.30
NPY5R region 3’ rs6536721 0.34 GG 47.80 43.50 0.2032 1.00 0.9922
AG 36.30 44.80 0.74 [0.47-1.15]
AA 15.90 11.70 1.24 [0.66-2.26]
POMC region 5’ rs874401 0.18 CC 73.70 65.60 0.1012 1.00 0.2296
CT 22.80 32.50 0.63 [0.38-1.00]
TT 3.50 2.00 1.57 [0.42-4.96]
POMC rs6713532 0.21 TT 69.90 60.00 0.1127 1.00 0.1282
CT 24.80 35.10 0.61 [0.37-0.96]
CC 5.30 4.90 0.94 [0.34-2.26]
POMC rs934778 0.30 TT 50.40 46.80 0.6555 1.00 0.699
CT 40.70 45.50 0.83 [0.54-1.28]
CC 8.80 7.80 1.06 [0.47-2.19]
MC4R region 5’ rs8097783 0.06 GG 89.50 87.60 0.7778 1.00 0.5455
AG 10.50 12.20 0.83 [0.41-1.56]
AA 0.00 0.20
MC4R region 5’ rs8091237 0.23 CC 54.90 59.70 0.5989 1.00 0.4611
CG 39.80 34.70 1.25 [0.81-1.92]
GG 5.30 5.50 1.05 [0.38-2.50]
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MC4R region 5’ rs1943225 0.26 TT 53.10 58.30 0.3252 1.00 0.6525
GT 39.80 32.60 1.34 [0.86-2.07]
GG 7.10 9.20 0.85 [0.35-1.82]
MC4R region 5’ rs7228573 0.31 CC 45.90 47.50 0.503 1.00 0.825
CT 47.70 43.20 1.14 [0.74-1.76]
TT 6.30 9.30 0.70 [0.27-1.56]
MC4R region 5’ rs1943228 0.22 AA 56.90 61.40 0.4261 1.00 0.6171
AG 40.40 34.30 1.27 [0.82-1.96]
GG 2.80 4.30 0.70 [0.16-2.13]
MC4R rs8087522 0.32 GG 42.50 45.20 0.5264 1.00 0.9645
AG 50.40 45.20 1.19 [0.77-1.83]
AA 7.10 9.50 0.79 [0.33-1.71]
MC4R region 3’ rs17066829 0.35 TT 41.60 42.90 0.7242 1.00 0.9011
AT 47.80 44.20 1.11 [0.72-1.73]
AA 10.60 12.80 0.85 [0.41-1.67]
MC4R region 3’ rs1943226 0.10 TT 85.00 80.50 0.3931 1.00 0.2191
GT 15.00 18.60 0.73 [0.40-1.26]
GG 0.00 0.90
PPY rs231471 0.44 AA 39.50 29.90 0.0621 1.00 0.3392
AG 38.60 50.60 0.58 [0.36-0.92]
GG 21.90 19.50 0.85 [0.48-1.48]
PPY rs1642603 0.34 CC 46.00 43.40 0.7247 1.00 0.4614
CT 43.40 43.40 0.94 [0.61-1.46]
TT 10.60 13.30 0.75 [0.36-1.46]
PYY region 5’ rs17611995 0.18 CC 66.70 68.10 0.8208 1.00 0.9245
AC 29.80 27.40 1.11 [0.70-1.74]
AA 3.50 4.40 0.81 [0.23-2.22]
PYY region 5’ rs497847 0.07 AA 87.60 86.70 0.5218 1.00 0.9523
AG 11.50 13.10 0.92 [0.48-1.68]
GG 0.90 0.20
PYY rs9907468 0.10 CC 81.40 80.10 0.5998 1.00 0.6236
CT 18.60 19.00 0.92 [0.53-1.54]
TT 0.00 0.90
PYY rs918242 0.34 TT 43.80 43.00 0.8146 1.00 0.6827
CT 46.40 45.00 1.01 [0.65-1.57]
CC 9.80 12.00 0.81 [0.38-1.61]
PYY rs1684668 0.24 CC 58.40 57.40 0.9807 1.00 0.8464
CT 36.30 37.10 0.96 [0.62-1.48]
TT 5.30 5.50 0.95 [0.34-2.26]
PYY rs1859223 0.15 CC 71.10 71.70 0.7638 1.00 0.9592
CG 28.10 26.50 1.03 [0.65-1.61]
GG 0.90 1.80
PYY region 3’ rs1662754 0.47 AA 23.90 28.40 0.2685 1.00 0.95
AT 58.40 49.90 1.39 [0.85-2.32]
TT 17.70 21.70 0.97 [0.51-1.82]
PYY region 3’ rs8079623 0.13 CC 74.60 76.10 0.9068 1.00 0.6876
CG 23.70 22.60 1.09 [0.67-1.73]
GG 1.80 1.30
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LEP rs2167270 0.40 GG 36.00 36.20 0.8447 1.00 0.738
AG 45.60 47.60 0.97 [0.61-1.53]
AA 18.40 16.20 1.14 [0.62-2.05]
LEP rs2278815 0.46 AA 27.20 32.20 0.5427 1.00 0.2784
AG 47.40 45.60 1.23 [0.76-2.03]
GG 25.40 22.10 1.36 [0.77-2.40]
LEP rs11763517 0.47 CC 29.80 28.20 0.7577 1.00 0.945
CT 46.50 50.30 0.87 [0.54-1.42]
TT 23.70 21.50 1.04 [0.58-1.84]
LEP rs7795794 0.05 GG 89.50 91.40 0.1278 1.00 0.3672
AG 9.60 8.60 1.25 [0.61-2.40]
AA 0.90 0.00
LEP rs10954173 0.40 GG 36.00 36.10 0.6991 1.00 0.6587
AG 44.70 47.80 0.94 [0.59-1.49]
AA 19.30 16.20 1.20 [0.66-2.14]
LEP region 3’ rs10954176 0.47 TT 24.60 30.60 0.1173 1.00 0.8758
CT 55.30 44.40 1.55 [0.95-2.57]
CC 20.20 25.00 1.00 [0.54-1.84]
LEP region 3’ rs1116656 0.46 GG 27.20 30.80 0.0144 1.00 0.3721
AG 59.60 45.80 1.48 [0.92-2.40]
AA 13.20 23.40 0.64 [0.32-1.22]
LEPR rs3790433 0.25 GG 50.90 58.10 0.3229 1.00 0.1334
AG 40.40 35.80 1.29 [0.83-1.98]
AA 8.80 6.20 1.62 [0.71-3.42]
LEPR rs4655811 0.34 GG 44.60 42.30 0.8564 1.00 0.5812
CG 45.50 46.50 0.93 [0.60-1.44]
CC 9.80 11.30 0.82 [0.38-1.65]
LEPR rs1327120 0.41 GG 32.50 32.70 0.5787 1.00 0.6174
AG 55.30 51.30 1.08 [0.69-1.72]
AA 12.30 16.00 0.77 [0.38-1.49]
LEPR rs1327116 0.27 CC 50.40 52.10 0.7634 1.00 0.5888
AC 42.50 42.60 1.03 [0.67-1.58]
AA 7.10 5.30 1.37 [0.55-3.10]
LEPR rs1782763 0.05 TT 89.30 91.30 0.5182 1.00 0.5185
CT 10.70 8.70 1.25 [0.61-2.41]
LEPR rs6673324 0.48 AA 21.10 26.00 0.542 1.00 0.4375
AG 57.00 52.70 1.34 [0.81-2.28]
GG 21.90 21.30 1.27 [0.68-2.37]
LEPR rs3790428 0.28 CC 50.90 49.00 0.6817 1.00 0.9737
AC 42.10 45.70 0.89 [0.58-1.36]
AA 7.00 5.30 1.26 [0.51-2.85]
LEPR rs1137101 0.46 AA 29.80 26.40 0.367 1.00 0.1988
AG 55.30 53.00 0.92 [0.58-1.49]
GG 14.90 20.60 0.64 [0.33-1.20]
LEPR rs4655537 0.33 GG 41.20 43.70 0.8253 1.00 0.5467
AG 48.20 47.30 1.08 [0.70-1.68]
AA 10.50 9.00 1.24 [0.59-2.50]
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LEPR rs3790419 0.22 AA 65.80 60.00 0.5004 1.00 0.3475
AG 28.90 34.70 0.76 [0.48-1.19]
GG 5.30 5.30 0.90 [0.32-2.15]
LEPR rs8179183 0.20 GG 62.70 65.40 0.6831 1.00 0.8065
CG 33.60 29.80 1.17 [0.74-1.83]
CC 3.60 4.80 0.79 [0.23-2.16]
LEPR rs1938484 0.19 CC 69.30 64.70 0.5503 1.00 0.2901
AC 28.90 32.20 0.84 [0.53-1.31]
AA 1.80 3.10 0.53 [0.08-1.94]
LEPR rs1805096 0.39 CC 36.80 37.50 0.9541 1.00 0.9855
CT 48.20 46.70 1.05 [0.67-1.66]
TT 14.90 15.70 0.97 [0.50-1.79]
ADIPOQ region 5’ rs1648707 0.34 AA 45.90 43.10 0.7352 1.00 0.818
AC 41.40 45.50 0.85 [0.55-1.33]
CC 12.60 11.40 1.04 [0.52-1.98]
ADIPOQ region 5’ rs10937273 0.44 GG 30.10 31.60 0.9484 1.00 0.7506
AG 50.40 49.80 1.06 [0.66-1.72]
AA 19.50 18.60 1.10 [0.59-1.99]
ADIPOQ rs16861194 0.07 AA 89.50 86.70 0.5573 1.00 0.3562
AG 10.50 12.60 0.77 [0.38-1.43]
GG 0.00 0.70
ADIPOQ rs822391 0.21 TT 63.20 61.90 0.7309 1.00 0.6241
CT 33.30 32.70 1.00 [0.64-1.54]
CC 3.50 5.30 0.65 [0.19-1.74]
ADIPOQ rs16861210 0.09 GG 83.30 83.40 0.9751 1.00 0.9711
AG 15.80 15.50 1.01 [0.57-1.71]
AA 0.90 1.10
ADIPOQ rs822395 0.35 AA 47.40 41.40 0.3662 1.00 0.1607
AC 43.00 44.90 0.84 [0.54-1.29]
CC 9.60 13.70 0.61 [0.29-1.21]
ADIPOQ rs822396 0.19 AA 68.50 65.20 0.7134 1.00 0.4385
AG 28.80 30.70 0.89 [0.56-1.41]
GG 2.70 4.10 0.63 [0.15-1.93]
ADIPOQ rs12495941 0.35 GG 41.20 43.20 0.8475 1.00 0.5893
GT 44.70 44.60 1.05 [0.68-1.64]
TT 14.00 12.20 1.21 [0.62-2.26]
ADIPOQ rs17366568 0.12 GG 78.90 77.00 0.9051 1.00 0.6962
AG 19.30 21.20 0.89 [0.52-1.47]
AA 1.80 1.80 0.97 [0.14-3.95]
ADIPOQ rs2241766 0.11 TT 85.10 77.80 0.2306 1.00 0.1049
GT 14.00 21.10 0.62 [0.34-1.05]
GG 0.90 1.10
ADIPOQ rs1501299 0.28 CC 51.80 51.70 0.9954 1.00 0.9557
AC 40.40 40.20 1.00 [0.65-1.54]
AA 7.90 8.20 0.96 [0.42-2.03]
ADIPOQ rs3821799 0.45 CC 37.70 28.50 0.1589 1.00 0.1004
CT 43.90 50.10 0.66 [0.42-1.05]
TT 18.40 21.40 0.65 [0.36-1.15]
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ADIPOQ rs17366743 0.11 TT 84.10 81.70 0.8112 1.00 0.6611
CT 11.50 13.80 0.81 [0.41-1.49]
CC 4.40 4.50 0.97 [0.31-2.46]
ADIPOQ rs6773957 0.39 GG 42.10 36.80 0.5817 1.00 0.3651
AG 43.90 47.90 0.80 [0.51-1.25]
AA 14.00 15.30 0.80 [0.42-1.48]
ADIPOQ rs1063539 0.13 GG 80.50 72.70 0.1881 1.00 0.0755
CG 19.50 26.60 0.64 [0.38-1.06]
CC 0.00 0.70
RETN region 5’ rs2081075 0.27 GG 59.30 54.40 0.5533 1.00 0.5421
AG 31.00 36.40 0.78 [0.49-1.22]
AA 9.70 9.10 0.98 [0.46-1.95]
RETN rs1862513 0.28 GG 54.90 50.30 0.6693 1.00 0.3745
CG 38.90 42.20 0.85 [0.55-1.30]
CC 6.20 7.50 0.76 [0.30-1.70]
RETN rs3745367 0.23 GG 64.90 56.40 0.2546 1.00 0.1083
AG 31.60 38.70 0.71 [0.45-1.10]
AA 3.50 4.90 0.63 [0.18-1.70]
RETN rs3745369 0.50 GG 25.40 26.30 0.86 1.00 0.8851
CG 50.90 48.10 1.09 [0.67-1.82]
CC 23.70 25.60 0.96 [0.53-1.71]
PPARγ rs2972164 0.47 CC 24.10 28.10 0.5491 1.00 0.2757
CT 51.80 51.80 1.17 [0.71-1.95]
TT 24.10 20.10 1.40 [0.77-2.54]
PPARγ rs6809631 0.29 AA 53.50 50.00 0.5309 1.00 0.3255
AT 40.40 40.70 0.93 [0.60-1.42]
TT 6.10 9.30 0.62 [0.24-1.36]
PPARγ rs17793951 0.31 AA 44.10 47.80 0.3464 1.00 0.2421
AG 42.30 43.30 1.06 [0.68-1.65]
GG 13.50 9.00 1.63 [0.82-3.14]
PPARγ rs12497191 0.14 AA 78.10 73.20 0.5658 1.00 0.2914
AG 20.20 24.30 0.78 [0.46-1.27]
GG 1.80 2.40 0.68 [0.10-2.58]
PPARγ rs1801282 0.15 CC 72.80 72.60 0.9028 1.00 0.9392
CG 24.60 25.40 0.96 [0.59-1.54]
GG 2.60 2.00 1.32 [0.29-4.53]
PPARγ rs12629751 0.09 CC 83.90 82.80 0.9115 1.00 0.7262
CT 15.20 15.80 0.92 [0.51-1.59]
TT 0.90 1.40
PPARγ rs2028759 0.48 AA 29.50 26.40 0.6772 1.00 0.8333
AG 45.50 50.10 0.81 [0.50-1.34]
GG 25.00 23.50 0.95 [0.54-1.68]
PPARγ rs1151996 0.36 TT 38.60 41.70 0.8223 1.00 0.6575
GT 48.20 45.20 1.15 [0.74-1.80]
GG 13.20 13.10 1.09 [0.55-2.06]
PPARγ rs7645903 0.18 AA 67.90 66.50 0.7513 1.00 0.6389
AT 30.40 30.40 0.98 [0.62-1.53]
TT 1.80 3.10 0.56 [0.09-2.08]
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PPARγ rs1175540 0.34 CC 39.80 44.40 0.3925 1.00 0.7579
CA 51.30 44.40 1.29 [0.84-2.00]
AA 8.80 11.30 0.88 [0.39-1.79]
PPARγ rs6782475 0.17 TT 69.00 68.10 0.6231 1.00 0.6289
GT 29.20 28.30 1.02 [0.64-1.59]
GG 1.80 3.60 0.49 [0.08-1.77]
PPARγ rs3856806 0.14 CC 72.60 73.80 0.4017 1.00 0.5333
CT 23.90 24.60 0.99 [0.60-1.59]
CC 3.50 1.60 2.30 [0.59-7.80]
PPARγC1 rs6821591 0.48 CC 21.90 25.80 0.6696 1.00 0.5795
CT 56.10 52.30 1.26 [0.76-2.14]
TT 21.90 21.90 1.18 [0.64-2.19]
PPARγC1 rs3736265 0.05 GG 89.50 90.20 0.8394 1.00 0.8647
AG 10.50 9.50 1.09 [0.53-2.07]
AA 0.00 0.20
PPARγC1 rs3755863 0.40 GG 35.10 34.70 0.8476 1.00 0.7283
AG 51.80 50.00 1.02 [0.66-1.62]
AA 13.20 15.30 0.85 [0.43-1.62]
PPARγC1 rs8192678 0.35 GG 39.80 43.60 0.7172 1.00 0.6385
AG 48.70 44.50 1.20 [0.77-1.87]
AA 11.50 11.90 1.05 [0.51-2.05]
PPARγC1 rs2970849 0.33 TT 48.20 42.50 0.4445 1.00 0.2045
CT 43.90 46.50 0.83 [0.54-1.28]
CC 7.90 10.90 0.64 [0.28-1.32]
PPARγC1 rs2932976 0.27 GG 59.60 51.80 0.2763 1.00 0.1101
AG 35.10 40.30 0.76 [0.49-1.16]
AA 5.30 8.00 0.57 [0.21-1.33]
PPARγC1 rs4697046 0.33 TT 39.50 45.60 0.3565 1.00 0.1567
CT 46.50 44.20 1.21 [0.78-1.89]
CC 14.00 10.20 1.58 [0.81-3.01]
PPARγC1 rs4235308 0.41 TT 30.10 34.80 0.3145 1.00 0.1555
CT 49.60 50.30 1.14 [0.71-1.84]
CC 20.40 14.90 1.59 [0.86-2.88]
PPARγC1 rs7677000 0.16 CC 71.90 69.90 0.9124 1.00 0.6985
CT 26.30 28.30 0.90 [0.56-1.43]
TT 1.80 1.80 0.96 [0.14-3.93]
PPARγC1 rs4469064 0.08 AA 81.60 84.10 0.7239 1.00 0.4678
AG 17.50 15.50 1.19 [0.69-2.01]
GG 0.90 0.40
PPARγC1 rs3774902 0.05 CC 91.20 89.60 0.7184 1.00 0.5342
CT 8.80 10.00 0.83 [0.38-1.63]
TT 0.00 0.40
a minor allele frequency; b p-value of the main effect models incorporating SNPs as categorical variables
with two or three categories; c p-value of the main effect models assuming additive genetic effects.
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Table B1: Full biochemical names, abbreviation, mean ± standard deviation of all meta-
bolite concentrations measured in µmol/l with the Biocrates AbsoluteIDQ kits
p150 (KORA F4, n = 890) and p180 (KORA S4, n = 965) (Jourdan et al.,
2012).
Abbrevation Full biochemical name KORA S4 KORA F4
Mean ± SD Mean ± SD
C0 Carnitine 40.52 ± 8.49 35.05 ± 7.36
C2 Acetylcarnitine 8.62 ± 2.86 8.08 ± 2.78
C3 Propionylcarnitine 0.47 ± 0.15 0.38 ± 0.12
C3-OH Hydroxypropionylcarnitine 0.12 ± 0.06 *
C3:1 Propenonylcarnitine * *
C4 Butyrylcarnitine 0.22 ± 0.10 0.22 ± 0.09
C4-OH (C3-DC) Hydroxybutyrylcarnitine 0.06 ± 0.02 0.09 ± 0.05
C4:1 Butenylcarnitine 0.02 ± 0.01 *
C5 Valerylcarnitine 0.16 ± 0.06 0.11 ± 0.04
C5-DC (C6-OH) Glutarylcarnitine * 0.03 ± 0.01
C5-M-DC Methylglutarylcarnitine * 0.03 ± 0.01
C5-OH (C3-DC-M) Hydroxyvalerylcarnitine
(Methylmalonylcarnitine)
0.03 ± 0.01 0.04 ± 0.02
C5:1 Tiglylcarnitine 0.05 ± 0.01 0.03 ± 0.01
C5:1-DC Glutaconylcarnitine * 0.02 ± 0.01
C6 (C4:1-DC) Hexanoylcarnitine 0.09 ± 0.03 0.07 ± 0.03
C6:1 Hexenoylcarnitine 0.02 ± 0.01 0.02 ± 0.01
C7-DC Pimelylcarnitine 0.05 ± 0.02 0.05 ± 0.02
C8 Octanoylcarnitine 0.26 ± 0.10 0.22 ± 0.09
C8:1 Octenoylcarnitine ∼ 0.09 ± 0.04
C9 Nonaylcarnitine 0.04 ± 0.02 0.05 ± 0.02
C10 Decanoylcarnitine 0.38 ± 0.17 0.36 ± 0.15
C10:1 Decenoylcarnitine 0.18 ± 0.06 0.17 ± 0.06
C10:2 Decadienylcarnitine 0.04 ± 0.01 0.04 ± 0.01
C12 Dodecanoylcarnitine 0.16 ± 0.06 0.13 ± 0.05
C12-DC Dodecanedioylcarnitine 0.07 ± 0.01 0.06 ± 0.01
C12:1 Dodecenoylcarnitine 0.17 ± 0.06 0.15 ± 0.05
C14 Tetradecanoylcarnitine 0.06 ± 0.02 0.05 ± 0.01
C14:1 Tetradecenoylcarnitine 0.15 ± 0.05 0.15 ± 0.05
C14:1-OH Hydroxytetradecenoylcarnitine 0.02 ± 0.01 0.01 ± 0.00
C14:2 Tetradecadienylcarnitine 0.04 ± 0.02 0.03 ± 0.01
C14:2-OH Hydroxytetradecadienylcarnitine * 0.01 ± 0.00
C16 Hexadecanoylcarnitine 0.14 ± 0.03 0.12 ± 0.03
C16-OH Hydroxyhexadecanoylcarnitine * *
C16:1 Hexadecenoylcarnitine 0.04 ± 0.01 0.04 ± 0.01
C16:1-OH Hydroxyhexadecenoylcarnitine * 0.01 ± 0.00
C16:2 Hexadecadienylcarnitine * *
C16:2-OH Hydroxyhexadecadienylcarnitine * 0.01 ± 0.00
C18 Octadecanoylcarnitine 0.06 ± 0.01 0.05 ± 0.01
C18:1 Octadecenoylcarnitine 0.14 ± 0.04 0.13 ± 0.04
C18:1-OH Hydroxyoctadecenoylcarnitine * *
C18:2 Octadecadienylcarnitine 0.05 ± 0.02 0.05 ± 0.01
Ala Alanine 417.99 ± 101.4 ∼
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Mean ± SD Mean ± SD
Arg Arginine 126.87 ± 26.78 115.67 ± 17.45
Asn Asparagine 46.18 ± 8.31 ∼
Asp Aspartate 29.76 ± 9.77 ∼
Cit Citrulline 34.64 ± 9.16 ∼
Gln Glutamine 581.2 ± 113.95 627.31 ± 91.44
Glu Glutamate 80.13 ± 32.04 ∼
Gly Glycine 264.35 ± 73.19 314.88 ± 83.47
His Histidine 82.87 ± 14.75 99.86 ± 16.47
Ile Isoleucine 72.14 ± 20.22 ∼
Leu Leucine 160.51 ± 44.33 ∼
Lys Lysine 166.44 ± 36.59 ∼
Met Methionine 23.86 ± 5.21 32.01 ± 5.69
Orn Ornithine 58.97 ± 14.83 81.5 ± 18.59
Phe Phenylalanine 76.73 ± 17.19 61.17 ± 10.20
Pro Proline 193.96 ± 58.92 171.51 ± 51.25
Ser Serine 127.36 ± 28.85 130.82 ± 24.44
Thr Threonine 120.75 ± 31.79 107.56 ± 24.41
Trp Tryptophan 60.17 ± 12.43 83.28 ± 9.85
Tyr Tyrosine 72.09 ± 20.06 84.6 ± 17.27
Val Valine 227.26 ± 53.13 273.25 ± 59.21
xLeu Leucine/Isoleucine ∼ 210.42 ± 43.19
Ac Orn Acetylornithine 0.74 ± 0.41 ∼
ADMA Asymmetric dimethylarginine# 0.56 ± 0.13 ∼
SDMA Symmetric Dimethylarginine 0.76 ± 0.24 ∼
total DMA Sum of ADMA and SDMA 1.21 ± 0.23 ∼
alpha AAA alpha-Aminoadipic acid 0.68 ± 0.27 ∼
Carnosine Carnosine * ∼
Creatinine Creatinine 75.04 ± 18.99 ∼
Histamine Histamine# 0.4 ± 0.17 ∼
Kynurenine Kynurenine 2.88 ± 0.69 ∼
Met SO Methioninesulfoxide 0.78 ± 0.24 ∼
Nitro-Tyr Nitrotyrosine * ∼
OH-Pro Hydroxyproline * ∼
PEA Phenylethylamine * ∼
Putrescine Putrescine# 0.15 ± 0.05 ∼
Sarcosine Sarcosine * ∼
Serotonin Serotonin# 0.7 ± 0.34 ∼
Spermidine Spermidine 0.27 ± 0.07 ∼
Spermine Spermine * ∼
Taurine Taurine 93.66 ± 23.95 ∼
PC aa C24:0 Phosphatidylcholine diacyl C24:0# 0.09 ± 0.04 0.15 ± 0.08
PC aa C26:0 Phosphatidylcholine diacyl C26:0 0.74 ± 0.24 1.06 ± 0.49
PC aa C28:1 Phosphatidylcholine diacyl C28:1 3.62 ± 0.84 3.43 ± 0.79
PC aa C30:0 Phosphatidylcholine diacyl C30:0 5.95 ± 1.67 4.83 ± 1.54
PC aa C30:2 Phosphatidylcholine diacyl C30:2 * *
PC aa C32:0 Phosphatidylcholine diacyl C32:0 14.98 ± 2.78 15.39 ± 3.43
PC aa C32:1 Phosphatidylcholine diacyl C32:1 21.17 ± 10.62 21.95 ± 11.38
PC aa C32:2 Phosphatidylcholine diacyl C32:2 4.42 ± 1.63 4.05 ± 1.72
PC aa C32:3 Phosphatidylcholine diacyl C32:3 0.55 ± 0.14 0.49 ± 0.12
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Abbrevation Full biochemical name KORA S4 KORA F4
Mean ± SD Mean ± SD
PC aa C34:1 Phosphatidylcholine diacyl C34:1 223.91 ± 46.33 243.79 ± 61.88
PC aa C34:2 Phosphatidylcholine diacyl C34:2 367.86 ± 48.54 400.11 ± 93.65
PC aa C34:3 Phosphatidylcholine diacyl C34:3 18.5 ± 5.14 18.42 ± 5.45
PC aa C34:4 Phosphatidylcholine diacyl C34:4 2.21 ± 0.77 2.29 ± 0.82
PC aa C36:0 Phosphatidylcholine diacyl C36:0 3.00 ± 0.77 2.76 ± 0.86
PC aa C36:1 Phosphatidylcholine diacyl C36:1 54.06 ± 13.95 54.48 ± 13.27
PC aa C36:2 Phosphatidylcholine diacyl C36:2 256.73 ± 42.39 235.95 ± 42.37
PC aa C36:3 Phosphatidylcholine diacyl C36:3 153.12 ± 29.82 151.14 ± 32.7
PC aa C36:4 Phosphatidylcholine diacyl C36:4 208.91 ± 44.39 219.15 ± 54.41
PC aa C36:5 Phosphatidylcholine diacyl C36:5 30.8 ± 14.81 29.88 ± 14.32
PC aa C36:6 Phosphatidylcholine diacyl C36:6 1.13 ± 0.43 1.15 ± 0.46
PC aa C38:0 Phosphatidylcholine diacyl C38:0 3.37 ± 0.87 3.30 ± 0.89
PC aa C38:1 Phosphatidylcholine diacyl C38:1 1.38 ± 0.41 *
PC aa C38:3 Phosphatidylcholine diacyl C38:3 57.77 ± 14.01 53.25 ± 12.82
PC aa C38:4 Phosphatidylcholine diacyl C38:4 117.93 ± 29.14 117.39 ± 28.78
PC aa C38:5 Phosphatidylcholine diacyl C38:5 63.10 ± 14.94 63.04 ± 15.64
PC aa C38:6 Phosphatidylcholine diacyl C38:6 90.3 ± 26.3 91.23 ± 27.32
PC aa C40:1 Phosphatidylcholine diacyl C40:1 0.42 ± 0.09 0.47 ± 0.10
PC aa C40:2 Phosphatidylcholine diacyl C40:2 0.37 ± 0.10 0.36 ± 0.10
PC aa C40:3 Phosphatidylcholine diacyl C40:3 0.69 ± 0.15 0.66 ± 0.15
PC aa C40:4 Phosphatidylcholine diacyl C40:4 4.16 ± 1.2 4.13 ± 1.16
PC aa C40:5 Phosphatidylcholine diacyl C40:5 12.79 ± 3.53 11.52 ± 3.14
PC aa C40:6 Phosphatidylcholine diacyl C40:6 32.3 ± 10.00 28.37 ± 9.35
PC aa C42:0 Phosphatidylcholine diacyl C42:0 0.56 ± 0.16 0.61 ± 0.17
PC aa C42:1 Phosphatidylcholine diacyl C42:1 0.27 ± 0.07 0.30 ± 0.08
PC aa C42:2 Phosphatidylcholine diacyl C42:2 0.20 ± 0.05 0.22 ± 0.06
PC aa C42:4 Phosphatidylcholine diacyl C42:4 0.21 ± 0.04 0.22 ± 0.05
PC aa C42:5 Phosphatidylcholine diacyl C42:5 0.44 ± 0.13 0.43 ± 0.13
PC aa C42:6 Phosphatidylcholine diacyl C42:6 0.60 ± 0.13 0.63 ± 0.14
PC ae C30:0 Phosphatidylcholine acyl-akyl C30:0 0.46 ± 0.13 0.48 ± 0.14
PC ae C30:1 Phosphatidylcholine acyl-akyl C30:1 * *
PC ae C30:2 Phosphatidylcholine acyl-akyl C30:2 0.13 ± 0.04 0.16 ± 0.04
PC ae C32:1 Phosphatidylcholine acyl-akyl C32:1 2.83 ± 0.55 2.95 ± 0.62
PC ae C32:2 Phosphatidylcholine acyl-akyl C32:2 0.72 ± 0.16 0.77 ± 0.17
PC ae C34:0 Phosphatidylcholine acyl-akyl C34:0 1.69 ± 0.43 1.77 ± 0.46
PC ae C34:1 Phosphatidylcholine acyl-akyl C34:1 10.58 ± 2.21 10.83 ± 2.39
PC ae C34:2 Phosphatidylcholine acyl-akyl C34:2 12.19 ± 2.95 13.16 ± 3.39
PC ae C34:3 Phosphatidylcholine acyl-akyl C34:3 7.66 ± 2.14 8.74 ± 2.45
PC ae C36:0 Phosphatidylcholine acyl-akyl C36:0 0.93 ± 0.25 1.08 ± 0.34
PC ae C36:1 Phosphatidylcholine acyl-akyl C36:1 8.91 ± 2.08 8.51 ± 1.96
PC ae C36:2 Phosphatidylcholine acyl-akyl C36:2 15.33 ± 3.88 15.72 ± 4.00
PC ae C36:3 Phosphatidylcholine acyl-akyl C36:3 8.04 ± 1.85 8.83 ± 2.10
PC ae C36:4 Phosphatidylcholine acyl-akyl C36:4 20.11 ± 4.74 21.07 ± 5.53
PC ae C36:5 Phosphatidylcholine acyl-akyl C36:5 13.02 ± 3.2 14.02 ± 3.60
PC ae C38:0 Phosphatidylcholine acyl-akyl C38:0 2.24 ± 0.67 2.55 ± 0.78
PC ae C38:1 Phosphatidylcholine acyl-akyl C38:1 0.63 ± 0.26 0.83 ± 0.29
PC ae C38:2 Phosphatidylcholine acyl-akyl C38:2 2.14 ± 0.48 2.20 ± 0.51
PC ae C38:3 Phosphatidylcholine acyl-akyl C38:3 4.29 ± 0.99 4.35 ± 0.94
PC ae C38:4 Phosphatidylcholine acyl-akyl C38:4 15.49 ± 3.16 15.88 ± 3.38
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PC ae C38:5 Phosphatidylcholine acyl-akyl C38:5 19.36 ± 3.83 20.17 ± 4.55
PC ae C38:6 Phosphatidylcholine acyl-akyl C38:6 8.77 ± 2.11 8.82 ± 2.21
PC ae C40:0 Phosphatidylcholine acyl-akyl C40:0 # ∼ 10.31 ± 1.66
PC ae C40:1 Phosphatidylcholine acyl-akyl C40:1 1.60 ± 0.37 1.72 ± 0.40
PC ae C40:2 Phosphatidylcholine acyl-akyl C40:2 2.14 ± 0.49 2.12 ± 0.48
PC ae C40:3 Phosphatidylcholine acyl-akyl C40:3 1.20 ± 0.24 1.16 ± 0.23
PC ae C40:4 Phosphatidylcholine acyl-akyl C40:4 2.71 ± 0.51 2.62 ± 0.48
PC ae C40:5 Phosphatidylcholine acyl-akyl C40:5 3.71 ± 0.70 3.62 ± 0.65
PC ae C40:6 Phosphatidylcholine acyl-akyl C40:6 5.48 ± 1.35 5.16 ± 1.31
PC ae C42:0 Phosphatidylcholine acyl-akyl C42:0 0.52 ± 0.10 0.51 ± 0.12
PC ae C42:1 Phosphatidylcholine acyl-akyl C42:1 0.38 ± 0.09 0.38 ± 0.09
PC ae C42:2 Phosphatidylcholine acyl-akyl C42:2 0.64 ± 0.14 0.69 ± 0.15
PC ae C42:3 Phosphatidylcholine acyl-akyl C42:3 0.85 ± 0.19 0.90 ± 0.20
PC ae C42:4 Phosphatidylcholine acyl-akyl C42:4 0.96 ± 0.22 1.04 ± 0.24
PC ae C42:5 Phosphatidylcholine acyl-akyl C42:5 2.21 ± 0.46 2.40 ± 0.49
PC ae C44:3 Phosphatidylcholine acyl-akyl C44:3 0.13 ± 0.04 0.11 ± 0.03
PC ae C44:4 Phosphatidylcholine acyl-akyl C44:4 0.38 ± 0.10 0.44 ± 0.11
PC ae C44:5 Phosphatidylcholine acyl-akyl C44:5 1.75 ± 0.47 2.16 ± 0.54
PC ae C44:6 Phosphatidylcholine acyl-akyl C44:6 1.26 ± 0.34 1.40 ± 0.37
lysoPC a C14:0 lysoPhosphatidylcholine acyl C14:0# 6.29 ± 0.79 3.23 ± 0.86
lysoPC a C16:0 lysoPhosphatidylcholine acyl C16:0 122.98 ± 25.91 96.65 ± 20.18
lysoPC a C16:1 lysoPhosphatidylcholine acyl C16:1 3.72 ± 1.17 2.97 ± 1.04
lysoPC a C17:0 lysoPhosphatidylcholine acyl C17:0 2.10 ± 0.68 1.81 ± 0.52
lysoPC a C18:0 lysoPhosphatidylcholine acyl C18:0 32.73 ± 8.09 26.91 ± 6.16
lysoPC a C18:1 lysoPhosphatidylcholine acyl C18:1 21.61 ± 6.10 20.26 ± 5.87
lysoPC a C18:2 lysoPhosphatidylcholine acyl C18:2 28.46 ± 9.04 29.29 ± 9.85
lysoPC a C6:0 lysoPhosphatidylcholine acyl C6:0 ∼ *
lysoPC a C20:3 lysoPhosphatidylcholine acyl C20:3 2.28 ± 0.66 2.46 ± 0.73
lysoPC a C20:4 lysoPhosphatidylcholine acyl C20:4 6.14 ± 1.83 6.94 ± 2.19
lysoPC a C24:0 lysoPhosphatidylcholine acyl C24:0 0.20 ± 0.06 0.37 ± 0.11
lysoPC a C26:0 lysoPhosphatidylcholine acyl C26:0# 0.30 ± 0.14 *
lysoPC a C26:1 lysoPhosphatidylcholine acyl C26:1# 1.67 ± 0.17 2.02 ± 0.25
lysoPC a C28:0 lysoPhosphatidylcholine acyl C28:0# 0.33 ± 0.11 0.50 ± 0.21
lysoPC a C28:1 lysoPhosphatidylcholine acyl C28:1 0.47 ± 0.15 0.63 ± 0.22
SM C16:0 Sphingomyelin C16:0 151.19 ± 23.84 108.15 ± 21.38
SM C16:1 Sphingomyelin C16:1 23.93 ± 4.67 16.07 ± 3.61
SM C18:0 Sphingomyelin C18:0 33.23 ± 6.89 23.23 ± 5.00
SM C18:1 Sphingomyelin C18:1 16.75 ± 4.16 11.25 ± 2.98
SM C20:2 Sphingomyelin C20:2 0.67 ± 0.23 0.38 ± 0.12
SM C22:3 Sphingomyelin C22:3 * *
SM C24:0 Sphingomyelin C24:0 30.53 ± 5.71 22.14 ± 5.13
SM C24:1 Sphingomyelin C24:1 76.96 ± 14.39 53.14 ± 12.02
SM C26:0 Sphingomyelin C26:0# * 0.18 ± 0.05
SM C26:1 Sphingomyelin C26:1 0.64 ± 0.19 0.42 ± 0.13
SM (OH) C14:1 Hydroxysphingomyelin C14:1 9.54 ± 2.56 6.38 ± 1.86
SM (OH) C16:1 Hydroxysphingomyelin C16:1 5.19 ± 1.37 3.42 ± 0.89
SM (OH) C22:1 Hydroxysphingomyelin C22:1 20.42 ± 4.61 13.83 ± 3.50
SM (OH) C22:2 Hydroxysphingomyelin C22:2 16.56 ± 4.17 11.74 ± 3.14
SM (OH) C24:1 Hydroxysphingomyelin C24:1 2.00 ± 0.49 1.37 ± 0.36
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Abbrevation Full biochemical name KORA S4 KORA F4
Mean ± SD Mean ± SD
H1 Hexose 5300.07 ± 891.29 5005.34 ± 670.72
Metabolites excluded from the analyses are marked with * and their mean and standard deviation are not
given. Metabolites marked with ∼ were not part of the other kit. # results with these metabolites require
careful interpretation since the number of samples below detection and/or the coefficient of variation across
all plates is relatively high.
LX Appendix
Table B2: Metabolic traits significantly associated with FFMIa in a linear regression model
adjusted for age, and sex (α = 5%, p-gain > 170) in the KORA S4 sample
(Jourdan et al., 2012).
Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
Val 227.26 53.13 0.15 2.97x10−18 4.75x10−16 0.16
Glu 80.13 32.04 0.15 7.60x10−18 1.22x10−15 0.11
Ile 72.14 20.22 0.12 1.23x10−13 1.96x10−11 0.22
Tyr 72.09 20.06 0.13 2.98x10−12 4.77x10−10 0.06
Leu 160.51 44.33 0.11 1.61x10−10 2.57x10−08 0.18
Phe 76.73 17.19 0.11 1.58x10−09 2.53x10−07 0.05
Ala 417.99 101.4 0.10 5.59x10−08 8.95x10−06 0.03
Trp 60.17 12.43 0.07 4.85x10−05 7.77x10−03 0.07
Pro 193.96 58.92 0.08 1.23x10−05 1.97x10−03 0.14
Met 23.86 5.21 0.07 1.17x10−04 1.86x10−02 0.08
Lys 166.44 36.59 0.07 1.18x10−04 1.88x10−02 0.01
Σ BCAAs 459.91 113.06 0.13 1.30x10−15 2.07x10−13 0.19
Σ aromatic AAs 208.98 43.75 0.12 2.11x10−11 3.37x10−09 0.07
Gln/Val 2.64 0.6 -0.19 4.48x10−28 7.17x10−26 0.18 6.63x10+09
Asn/Val 0.21 0.05 -0.18 1.12x10−26 1.80x10−24 0.17 2.65x10+08
His/Val 0.38 0.07 -0.17 1.22x10−23 1.95x10−21 0.21 2.43x10+05
Glu/Gly 0.33 0.17 0.16 4.77x10−22 7.64x10−20 0.19 1.59x10+04
Asn/Ile 0.68 0.19 -0.16 5.17x10−22 8.27x10−20 0.23 2.37x10+08
Asn/Glu 0.67 0.29 -0.17 1.17x10−21 1.87x10−19 0.11 6.49x10+03
Gln/Tyr 8.47 2.16 -0.17 1.83x10−21 2.93x10−19 0.10 1.63x10+09
Asn/Tyr 0.68 0.18 -0.17 6.16x10−21 9.85x10−19 0.10 4.85x10+08
Gln/Ile 8.53 2.37 -0.15 1.20x10−20 1.92x10−18 0.23 1.02x10+07
Asn/Leu 0.30 0.08 -0.15 1.75x10−18 2.81x10−16 0.19 9.15x10+07
Gly/Tyr 3.89 1.38 -0.15 7.44x10−18 1.19x10−15 0.17 4.01x10+05
Gly/Phe 3.55 1.08 -0.14 1.03x10−17 1.65x10−15 0.19 1.53x10+08
Gln/Leu 3.81 1.02 -0.14 3.20x10−17 5.12x10−15 0.19 5.02x10+06
Asn/Phe 0.62 0.14 -0.15 4.14x10−17 6.62x10−15 0.08 3.82x10+07
Gly/Ile 3.96 1.64 -0.13 1.00x10−16 1.61x10−14 0.30 1.22x10+03
His/Tyr 1.20 0.27 -0.14 5.94x10−16 9.51x10−14 0.09 5.02x10+03
Ala/Asn 9.20 2.38 0.15 8.82x10−16 1.41x10−13 0.07 6.34x10+07
Gly/Leu 1.76 0.69 -0.12 9.16x10−15 1.46x10−12 0.29 1.75x10+04
Gln/Phe 7.83 1.85 -0.14 3.55x10−14 5.69x10−12 0.06 4.44x10+04
Asn/Met 1.98 0.37 -0.13 5.83x10−13 9.32x10−11 0.11 2.00x10+08
Ala/Gly 1.68 0.57 0.12 7.14x10−12 1.14x10−09 0.11 7.83x10+03
Gln/Lys 3.57 0.71 -0.12 7.34x10−12 1.17x10−09 0.05 1.60x10+07
Asn/Lys 0.29 0.06 -0.12 7.36x10−11 1.18x10−08 0.04 1.60x10+06
Ala/Gln 0.74 0.20 0.12 9.21x10−11 1.47x10−08 0.04 6.07x10+02
Gly/Trp 4.53 1.43 -0.11 1.91x10−10 3.06x10−08 0.20 2.54x10+05
Gln/Met 24.99 5.09 -0.11 2.70x10−10 4.31x10−08 0.09 4.32x10+05
Gln/Pro 3.19 0.87 -0.11 3.22x10−10 5.16x10−08 0.13 3.82x10+04
Asn/Trp 0.79 0.17 -0.11 3.76x10−10 6.02x10−08 0.06 1.29x10+05
Gly/Lys 1.64 0.50 -0.11 5.33x10−10 8.52x10−08 0.10 2.21x10+05
Gly/Pro 1.47 0.59 -0.10 7.17x10−10 1.15x10−07 0.24 1.72x10+04
Gly/Met 11.46 3.64 -0.10 7.94x10−10 1.27x10−07 0.22 1.47x10+05
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
Asn/Pro 0.25 0.07 -0.11 8.12x10−10 1.30x10−07 0.13 1.52x10+04
Gln/Trp 9.91 2.26 -0.11 1.32x10−09 2.12x10−07 0.07 3.67x10+04
Asp/Gly 0.12 0.04 0.10 7.07x10−09 1.13x10−06 0.06 6.18x10+04
Asn/Asp 1.72 0.67 -0.09 1.66x10−06 2.66x10−04 0.03 9.48x10+02
Gln/Orn 10.22 2.28 -0.08 2.22x10−05 3.55x10−03 0.02 6.32x10+02
Gln/His 7.07 1.08 -0.08 3.01x10−05 4.82x10−03 0.03 4.66x10+02
Arg/Gln 0.22 0.04 0.07 5.45x10−05 8.72x10−03 0.02 2.58x10+02
Asn/Orn 0.82 0.20 -0.07 8.86x10−05 1.42x10−02 0.03 4.40x10+02
Arg/Asn 2.80 0.64 0.07 1.37x10−04 2.19x10−02 0.02 2.85x10+02
Σ BCAAs/ Σ glucogenic AAs 0.58 0.14 0.10 9.34x10−11 1.49x10−08 0.26
C5 0.16 0.06 0.09 2.18x10−07 3.49x10−05 0.17
C3 0.47 0.15 0.09 3.03x10−07 4.85x10−05 0.13
C0 40.52 8.49 0.07 7.45x10−05 1.19x10−02 0.13
C18 0.06 0.01 -0.06 2.47x10−04 3.96x10−02 0.10
C18/C5 0.37 0.14 -0.12 9.00x10−12 1.44x10−09 0.08 2.42x10+04
C18/C3 0.13 0.05 -0.12 2.28x10−11 3.65x10−09 0.05 1.33x10+04
C0/C18 769.01 221.78 0.11 3.40x10−09 5.44x10−07 0.05 2.19x10+04
C18/C5:1 1.22 0.43 -0.09 1.31x10−06 2.10x10−04 0.05 1.89x10+02
Single PCs
PC aa C42:0 0.56 0.16 -0.12 2.43x10−11 3.89x10−09 0.06
PC aa C42:1 0.27 0.07 -0.11 4.40x10−10 7.04x10−08 0.05
PC aa C42:2 0.20 0.05 -0.11 1.82x10−09 2.91x10−07 0.03
PC aa C38:3 57.77 14.01 0.1 4.39x10−08 7.02x10−06 0.06
PC aa C40:1 0.42 0.09 -0.08 1.55x10−05 2.47x10−03 0.02
PC aa C40:2 0.37 0.10 -0.08 1.57x10−05 2.52x10−03 0.02
PC ae C42:3 0.85 0.19 -0.16 3.19x10−20 5.10x10−18 0.10
PC ae C36:2 15.33 3.88 -0.14 1.51x10−17 2.42x10−15 0.19
PC ae C42:4 0.96 0.22 -0.12 5.26x10−12 8.42x10−10 0.06
PC ae C34:3 7.66 2.14 -0.12 6.28x10−12 1.00x10−09 0.12
PC ae C40:6 5.48 1.35 -0.12 2.60x10−11 4.16x10−09 0.09
PC ae C44:6 1.26 0.34 -0.12 3.18x10−11 5.09x10−09 0.05
PC ae C38:2 2.14 0.48 -0.11 8.21x10−11 1.31x10−08 0.10
PC ae C40:5 3.71 0.70 -0.11 5.67x10−10 9.08x10−08 0.06
PC ae C42:5 2.21 0.46 -0.11 1.09x10−09 1.75x10−07 0.05
PC ae C42:2 0.64 0.14 -0.11 1.86x10−09 2.97x10−07 0.06
PC ae C32:1 2.83 0.55 -0.1 3.65x10−09 5.84x10−07 0.09
PC ae C44:4 0.38 0.10 -0.11 4.23x10−09 6.76x10−07 0.04
PC ae C36:1 8.91 2.08 -0.1 1.19x10−08 1.91x10−06 0.15
PC ae C44:5 1.75 0.47 -0.1 1.22x10−08 1.96x10−06 0.03
PC ae C40:3 1.20 0.24 -0.1 1.46x10−08 2.33x10−06 0.17
PC ae C32:2 0.72 0.16 -0.09 1.81x10−08 2.90x10−06 0.19
PC ae C34:2 12.19 2.95 -0.1 2.29x10−08 3.67x10−06 0.14
PC ae C34:1 10.58 2.21 -0.09 8.47x10−08 1.35x10−05 0.14
PC ae C34:0 1.69 0.43 -0.09 1.28x10−07 2.04x10−05 0.08
PC ae C44:3 0.13 0.04 -0.1 2.03x10−07 3.24x10−05 0.03
PC ae C40:1 1.60 0.37 -0.09 3.80x10−07 6.08x10−05 0.03
PC ae C40:4 2.71 0.51 -0.08 6.01x10−06 9.62x10−04 0.05
PC ae C40:2 2.14 0.49 -0.08 7.35x10−06 1.18x10−03 0.09
PC ae C30:0 0.46 0.13 -0.08 1.50x10−05 2.40x10−03 0.09
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC ae C38:1 0.63 0.26 -0.08 2.00x10−05 3.19x10−03 0.02
PC ae C36:3 8.04 1.85 -0.07 2.08x10−05 3.33x10−03 0.10
PC ae C38:0 2.24 0.67 -0.07 1.16x10−04 1.86x10−02 0.07
Σ PC ae 181.45 30.52 -0.09 8.61x10−07 1.38x10−04 0.10
lysoPC a C18:2 28.46 9.04 -0.15 5.12x10−18 8.19x10−16 0.16
lysoPC a C17:0 2.10 0.68 -0.13 2.68x10−13 4.29x10−11 0.07
lysoPC a C18:1 21.61 6.10 -0.13 1.44x10−12 2.30x10−10 0.11
Σ lysoPC a 229.29 47.21 -0.08 2.72x10−06 4.36x10−04 0.07
PC aa/PC aa Ratios
PC aa C38:3/PC aa C42:6 97.71 21.87 0.16 6.52x10−20 1.04x10−17 0.09 6.73x10+11
PC aa C38:3/PC aa C42:2 297.65 96.51 0.16 1.07x10−18 1.72x10−16 0.10 1.69x10+09
PC aa C36:2/PC aa C38:3 4.59 0.87 -0.16 1.65x10−18 2.65x10−16 0.09 2.65x10+10
PC aa C38:3/PC aa C42:0 111.66 41.58 0.16 6.60x10−18 1.06x10−15 0.07 3.68x10+06
PC aa C38:3/PC aa C42:1 228.35 80.97 0.15 3.81x10−17 6.09x10−15 0.07 1.15x10+07
PC aa C36:1/PC aa C38:3 0.95 0.19 -0.15 6.36x10−16 1.02x10−13 0.08 6.90x10+07
PC aa C38:3/PC aa C40:3 85.86 19.98 0.14 8.33x10−16 1.33x10−13 0.08 5.27x10+07
PC aa C38:3/PC aa C42:4 282.32 70.15 0.14 3.18x10−15 5.08x10−13 0.09 1.38x10+07
PC aa C32:0/PC aa C38:3 0.27 0.06 -0.14 3.42x10−15 5.47x10−13 0.09 1.28x10+07
PC aa C38:3/PC aa C40:2 164.64 48.82 0.14 8.28x10−15 1.32x10−12 0.07 5.30x10+06
PC aa C34:2/PC aa C38:3 6.64 1.37 -0.14 8.98x10−15 1.44x10−12 0.08 4.88x10+06
PC aa C34:3/PC aa C38:3 0.33 0.09 -0.14 1.09x10−14 1.75x10−12 0.07 4.01x10+06
PC aa C36:3/PC aa C38:3 2.71 0.40 -0.14 1.52x10−14 2.43x10−12 0.07 2.89x10+06
PC aa C34:1/PC aa C38:3 3.99 0.83 -0.13 7.06x10−14 1.13x10−11 0.09 6.21x10+05
PC aa C38:4/PC aa C42:1 462.94 156.72 0.14 7.51x10−14 1.20x10−11 0.06 5.86x10+03
PC aa C38:4/PC aa C42:0 227.74 87.12 0.14 9.35x10−14 1.50x10−11 0.06 2.60x10+02
PC aa C38:4/PC aa C42:2 607.9 202.09 0.13 4.40x10−13 7.04x10−11 0.06 4.13x10+03
PC aa C38:3/PC aa C38:5 0.94 0.21 0.13 1.16x10−12 1.86x10−10 0.07 3.77x10+04
PC aa C38:3/PC aa C40:1 143.14 43.12 0.13 1.80x10−12 2.88x10−10 0.06 2.44x10+04
PC aa C32:3/PC aa C38:3 0.01 0.00 -0.12 5.26x10−12 8.42x10−10 0.12 8.34x10+03
PC aa C38:4/PC aa C42:6 199.88 47.26 0.12 2.45x10−11 3.92x10−09 0.04 1.96x10+07
PC aa C38:3/PC aa C42:5 138.06 37.74 0.12 4.17x10−11 6.68x10−09 0.05 1.05x10+03
PC aa C38:4/PC aa C38:5 1.89 0.33 0.12 4.73x10−11 7.57x10−09 0.04 1.01x10+07
PC aa C38:0/PC aa C38:3 0.06 0.02 -0.12 4.91x10−11 7.85x10−09 0.04 8.94x10+02
PC aa C38:3/PC aa C40:5 4.62 0.83 0.12 8.49x10−11 1.36x10−08 0.09 5.17x10+02
PC aa C36:0/PC aa C38:3 0.05 0.02 -0.12 9.96x10−11 1.59x10−08 0.05 4.41x10+02
PC aa C38:4/PC aa C42:4 573.40 132.08 0.12 1.08x10−10 1.72x10−08 0.06 4.46x10+06
PC aa C28:1/PC aa C38:3 0.07 0.02 -0.12 1.72x10−10 2.74x10−08 0.06 2.56x10+02
PC aa C38:4/PC aa C40:2 335.71 99.57 0.11 3.34x10−10 5.35x10−08 0.04 4.70x10+04
PC aa C38:4/PC aa C40:1 291.96 89.08 0.1 2.26x10−08 3.62x10−06 0.03 6.82x10+02
PC aa C40:4/PC aa C42:6 6.99 1.64 0.1 2.43x10−08 3.89x10−06 0.04 2.22x10+04
PC aa C38:4/PC aa C40:3 175.95 44.68 0.1 4.75x10−08 7.59x10−06 0.03 1.01x10+04
PC aa C32:0/PC aa C38:4 0.13 0.03 -0.1 5.40x10−08 8.64x10−06 0.04 8.88x10+03
PC aa C36:2/PC aa C38:4 2.27 0.50 -0.1 7.44x10−08 1.19x10−05 0.03 6.45x10+03
PC aa C38:0/PC aa C38:4 0.03 0.01 -0.1 7.96x10−08 1.27x10−05 0.03 6.02x10+03
PC aa C36:0/PC aa C38:4 0.03 0.01 -0.1 1.02x10−07 1.63x10−05 0.03 4.71x10+03
PC aa C34:3/PC aa C34:4 8.81 2.14 -0.1 1.08x10−07 1.73x10−05 0.03 3.80x10+05
PC aa C36:4/PC aa C42:6 355.68 78.78 0.1 1.76x10−07 2.81x10−05 0.03 3.07x10+03
PC aa C38:4/PC aa C38:6 1.38 0.41 0.09 2.82x10−07 4.52x10−05 0.02 1.70x10+03
PC aa C40:4/PC aa C42:4 20.11 4.91 0.09 5.52x10−07 8.83x10−05 0.02 4.26x10+03
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC aa C34:2/PC aa C38:4 3.27 0.75 -0.09 6.59x10−07 1.05x10−04 0.03 7.28x10+02
PC aa C36:4/PC aa C42:4 1020.10 217.04 0.09 8.45x10−07 1.35x10−04 0.05 2.78x10+03
PC aa C32:3/PC aa C38:4 0.00 0.00 -0.08 1.17x10−06 1.87x10−04 0.12 4.09x10+02
PC aa C32:2/PC aa C34:4 2.04 0.48 -0.09 1.36x10−06 2.17x10−04 0.04 4.18x10+04
PC aa C38:6/PC aa C40:6 2.84 0.40 -0.09 1.40x10−06 2.25x10−04 0.05 9.23x10+03
PC aa C38:4/PC aa C42:5 281.77 77.17 0.09 1.73x10−06 2.76x10−04 0.02 2.78x10+02
PC aa C32:0/PC aa C36:4 0.07 0.01 -0.09 1.75x10−06 2.79x10−04 0.06 1.02x10+04
PC aa C34:3/PC aa C36:3 0.12 0.02 -0.08 3.56x10−06 5.70x10−04 0.07 1.15x10+04
PC aa C30:0/PC aa C34:4 2.83 0.72 -0.08 4.20x10−06 6.72x10−04 0.05 1.35x10+04
PC aa C36:4/PC aa C38:5 3.37 0.53 0.08 6.38x10−06 1.02x10−03 0.03 5.28x10+03
PC aa C36:0/PC aa C36:4 0.01 0.00 -0.08 1.22x10−05 1.95x10−03 0.02 2.35x10+02
PC aa C34:3/PC aa C40:4 4.63 1.35 -0.08 1.97x10−05 3.15x10−03 0.09 1.11x10+03
PC aa C32:1/PC aa C34:3 1.12 0.38 0.08 2.24x10−05 3.59x10−03 0.03 1.83x10+03
PC aa C32:0/PC aa C40:4 3.79 0.93 -0.08 2.52x10−05 4.03x10−03 0.02 7.09x10+02
PC aa C40:3/PC aa C40:4 0.17 0.05 -0.08 2.66x10−05 4.26x10−03 0.02 4.62x10+02
PC aa C32:3/PC aa C34:4 0.27 0.09 -0.08 2.77x10−05 4.43x10−03 0.05 5.10x10+02
PC aa C30:0/PC aa C32:1 0.31 0.09 -0.08 3.55x10−05 5.68x10−03 0.02 2.52x10+03
PC aa C34:4/PC aa C36:6 2.05 0.53 0.08 3.97x10−05 6.35x10−03 0.02 1.43x10+03
PC aa C38:5/PC aa C40:4 15.69 3.54 -0.07 4.71x10−05 7.54x10−03 0.04 4.65x10+02
PC aa C36:4/PC aa C38:6 2.45 0.66 0.07 4.86x10−05 7.77x10−03 0.02 2.67x10+02
PC aa C36:4/PC aa C40:3 312.80 74.28 0.07 5.46x10−05 8.74x10−03 0.02 2.25x10+02
PC aa C36:2/PC aa C36:3 1.70 0.22 -0.07 6.29x10−05 1.01x10−02 0.02 1.08x10+03
PC aa C34:2/PC aa C36:4 1.81 0.32 -0.07 6.39x10−05 1.02x10−02 0.03 5.27x10+02
PC aa C34:3/PC aa C36:4 0.09 0.02 -0.07 7.40x10−05 1.18x10−02 0.06 4.55x10+02
PC aa C36:2/PC aa C40:4 65.02 15.19 -0.07 8.91x10−05 1.43x10−02 0.02 2.46x10+02
PC aa C34:2/PC aa C36:3 2.45 0.30 -0.07 1.05x10−04 1.68x10−02 0.04 4.74x10+02
PC aa C40:4/PC aa C42:5 9.87 2.77 0.07 1.22x10−04 1.95x10−02 0.02 1.80x10+02
PC aa C34:4/PC aa C38:5 0.04 0.01 0.07 2.83x10−04 4.53x10−02 0.05 2.00x10+02
PC ae/PC ae Ratios
PC ae C34:3/PC ae C36:5 0.60 0.14 -0.14 1.21x10−14 1.94x10−12 0.12 5.19x10+02
PC ae C34:2/PC ae C36:4 0.62 0.14 -0.13 1.56x10−14 2.50x10−12 0.17 1.47x10+06
PC ae C38:6/PC ae C40:6 1.63 0.28 0.13 7.66x10−14 1.22x10−11 0.08 3.40x10+02
PC ae C36:4/PC ae C40:5 5.50 1.20 0.13 2.22x10−13 3.55x10−11 0.08 2.56x10+03
PC ae C38:5/PC ae C40:5 5.28 0.81 0.13 9.13x10−13 1.46x10−10 0.08 6.21x10+02
PC ae C36:3/PC ae C36:4 0.41 0.08 -0.12 6.91x10−12 1.11x10−09 0.13 3.01x10+06
PC ae C36:4/PC ae C40:1 12.99 3.34 0.11 1.06x10−09 1.70x10−07 0.04 3.57x10+02
PC ae C36:4/PC ae C40:4 7.51 1.62 0.11 1.13x10−09 1.81x10−07 0.07 5.32x10+03
PC ae C36:4/PC ae C38:4 1.31 0.21 0.11 1.99x10−09 3.19x10−07 0.10 3.28x10+06
PC ae C36:4/PC ae C38:5 1.04 0.10 0.09 1.99x10−06 3.19x10−04 0.04 4.50x10+04
PC ae C36:4/PC ae C42:1 53.76 13.14 0.08 7.87x10−06 1.26x10−03 0.03 2.90x10+02
PC ae C36:4/PC ae C38:6 2.34 0.43 0.07 3.84x10−05 6.14x10−03 0.05 2.33x10+03
lysoPC/lysoPC Ratios
lysoPC a C14:0/lysoPC a C18:2 0.24 0.08 0.17 6.49x10−23 1.04x10−20 0.18 7.88x10+04
lysoPC a C14:0/lysoPC a C18:1 0.31 0.08 0.15 2.91x10−18 4.65x10−16 0.13 4.94x10+05
lysoPC a C14:0/lysoPC a C17:0 3.30 1.14 0.16 4.72x10−18 7.55x10−16 0.09 5.69x10+04
lysoPC a C16:0/lysoPC a C18:1 5.87 1.01 0.14 1.63x10−15 2.60x10−13 0.08 8.83x10+02
lysoPC a C14:0/lysoPC a C16:0 0.05 0.01 0.08 4.87x10−06 7.80x10−04 0.07 1.95x10+03
lysoPC a C14:0/lysoPC a C18:0 0.20 0.05 0.08 6.15x10−06 9.85x10−04 0.03 2.56x10+02
PC aa/PC ae Ratios
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC aa C38:3/PC ae C42:3 70.43 21.88 0.20 1.95x10−28 3.12x10−26 0.12 1.63x10+08
PC aa C38:3/PC ae C36:2 3.98 1.36 0.19 5.11x10−27 8.17x10−25 0.13 2.96x10+09
PC aa C38:3/PC ae C38:2 27.89 7.48 0.19 1.47x10−25 2.35x10−23 0.11 5.58x10+14
PC aa C38:3/PC ae C42:2 93.08 24.28 0.19 2.33x10−25 3.73x10−23 0.11 7.97x10+15
PC aa C38:3/PC ae C36:1 6.70 1.85 0.18 1.55x10−24 2.48x10−22 0.12 7.70x10+15
PC aa C38:3/PC ae C34:1 5.59 1.42 0.17 3.86x10−22 6.18x10−20 0.10 1.14x10+14
PC aa C36:3/PC ae C36:2 10.47 2.95 0.17 1.00x10−21 1.60x10−19 0.14 1.51x10+04
PC aa C38:3/PC ae C40:3 49.43 12.96 0.17 2.25x10−21 3.60x10−19 0.10 6.48x10+12
PC ae C36:2/PC ae C38:3 3.60 0.57 -0.17 7.48x10−21 1.20x10−18 0.08 2.02x10+03
PC aa C38:3/PC ae C40:5 15.98 4.41 0.17 1.10x10−20 1.77x10−18 0.09 5.14x10+10
PC aa C38:3/PC ae C40:6 11.11 3.71 0.17 5.16x10−20 8.26x10−18 0.08 5.04x10+08
PC aa C38:3/PC ae C40:1 37.45 10.56 0.16 5.48x10−20 8.77x10−18 0.10 8.01x10+11
PC aa C38:3/PC ae C42:4 63.03 21.22 0.16 7.50x10−20 1.20x10−17 0.08 7.02x10+07
PC aa C38:3/PC ae C32:1 20.97 5.75 0.16 1.21x10−19 1.93x10−17 0.08 3.02x10+10
PC aa C38:3/PC ae C34:0 35.71 10.67 0.16 1.53x10−19 2.44x10−17 0.08 2.87x10+11
PC aa C38:3/PC ae C34:3 8.12 3.05 0.16 1.56x10−19 2.49x10−17 0.09 4.03x10+07
PC aa C38:3/PC ae C38:3 13.77 3.21 0.16 3.61x10−19 5.77x10−17 0.12 1.22x10+11
PC aa C38:4/PC ae C40:1 75.56 17.61 0.16 5.26x10−19 8.42x10−17 0.08 7.22x10+11
PC aa C38:3/PC ae C44:4 158.91 53.81 0.16 8.21x10−19 1.31x10−16 0.08 5.15x10+09
PC aa C38:3/PC ae C32:2 83.58 24.52 0.16 1.87x10−18 3.00x10−16 0.10 9.68x10+09
PC aa C38:3/PC ae C42:1 153.87 36.76 0.16 3.50x10−18 5.60x10−16 0.10 1.25x10+10
PC aa C38:3/PC ae C44:3 477.53 161.71 0.16 8.53x10−18 1.36x10−15 0.08 5.15x10+09
PC aa C38:4/PC ae C40:5 32.36 8.09 0.15 1.65x10−17 2.65x10−15 0.07 3.43x10+07
PC aa C38:3/PC ae C44:6 49.21 18.31 0.15 2.27x10−17 3.63x10−15 0.08 1.40x10+06
PC aa C38:3/PC ae C36:3 7.44 2.10 0.15 2.27x10−17 3.64x10−15 0.08 1.93x10+09
PC ae C34:3/PC ae C36:4 0.39 0.11 -0.15 3.97x10−17 6.35x10−15 0.13 1.58x10+05
PC aa C36:4/PC ae C40:1 133.83 26.17 0.15 6.61x10−17 1.06x10−14 0.07 5.75x10+09
PC aa C38:3/PC ae C34:2 4.99 1.69 0.15 7.01x10−17 1.12x10−14 0.08 3.27x10+08
PC aa C38:3/PC ae C42:5 27.15 8.60 0.15 8.34x10−17 1.33x10−14 0.07 1.31x10+07
PC aa C38:3/PC ae C40:4 21.79 5.83 0.15 1.48x10−16 2.37x10−14 0.07 2.97x10+08
PC aa C38:4/PC ae C40:6 22.55 7.14 0.15 2.40x10−16 3.84x10−14 0.08 1.08x10+05
PC aa C38:3/PC ae C44:5 35.38 12.76 0.15 5.16x10−16 8.25x10−14 0.08 2.37x10+07
PC aa C36:3/PC ae C38:2 73.66 15.81 0.14 1.41x10−15 2.25x10−13 0.08 5.82x10+04
PC aa C38:4/PC ae C42:2 190.68 52.74 0.14 2.65x10−15 4.24x10−13 0.06 7.01x10+05
PC aa C38:3/PC ae C38:0 27.33 8.44 0.14 3.53x10−15 5.65x10−13 0.07 1.24x10+07
PC aa C38:4/PC ae C34:3 16.57 6.42 0.14 6.57x10−15 1.05x10−12 0.08 9.56x10+02
PC aa C38:4/PC ae C44:6 99.78 36.38 0.14 1.29x10−14 2.06x10−12 0.06 2.47x10+03
PC aa C38:3/PC ae C40:2 28.29 9.38 0.14 2.55x10−14 4.09x10−12 0.06 1.72x10+06
PC aa C38:4/PC ae C38:2 57.49 18.01 0.14 2.89x10−14 4.62x10−12 0.07 2.84x10+03
PC aa C38:4/PC ae C42:1 312.06 66.19 0.14 4.18x10−14 6.68x10−12 0.06 1.15x10+10
PC aa C38:4/PC ae C36:1 13.80 4.35 0.13 1.34x10−13 2.15x10−11 0.09 8.89x10+04
PC aa C38:4/PC ae C42:5 55.06 16.83 0.13 1.53x10−13 2.44x10−11 0.05 7.17x10+03
PC aa C38:3/PC ae C42:0 113.47 30.57 0.13 3.88x10−13 6.21x10−11 0.07 1.13x10+05
PC aa C38:3/PC ae C38:4 3.82 1.01 0.13 4.01x10−13 6.41x10−11 0.05 1.10x10+05
PC aa C38:3/PC ae C30:0 135.46 48.03 0.13 3.22x10−13 5.16x10−11 0.06 1.36x10+05
PC aa C36:3/PC ae C36:1 17.74 4.05 0.13 5.23x10−13 8.37x10−11 0.10 2.28x10+04
PC aa C38:4/PC ae C40:4 44.19 10.85 0.13 5.51x10−13 8.81x10−11 0.05 1.09x10+07
PC aa C38:4/PC ae C44:5 71.81 25.07 0.13 8.75x10−13 1.40x10−10 0.05 1.40x10+04
PC aa C38:3/PC ae C38:1 109.71 77.67 0.13 8.97x10−13 1.44x10−10 0.05 4.89x10+04
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC aa C36:4/PC ae C40:5 57.60 13.47 0.13 9.00x10−13 1.44x10−10 0.06 6.30x10+02
PC aa C38:4/PC ae C32:2 170.96 52.95 0.13 1.34x10−12 2.14x10−10 0.10 1.35x10+04
PC aa C38:4/PC ae C32:1 42.98 12.90 0.13 1.67x10−12 2.68x10−10 0.06 2.18x10+03
PC aa C38:4/PC ae C44:3 975.91 336.09 0.13 1.89x10−12 3.03x10−10 0.05 1.07x10+05
PC aa C36:4/PC ae C42:2 338.33 84.46 0.13 2.21x10−12 3.54x10−10 0.05 8.40x10+02
PC aa C38:4/PC ae C38:4 7.71 1.67 0.12 6.82x10−12 1.09x10−09 0.05 7.02x10+07
PC aa C40:4/PC ae C42:2 6.70 1.99 0.12 7.82x10−12 1.25x10−09 0.06 2.37x10+02
PC aa C36:3/PC ae C42:2 247.25 55.47 0.12 8.01x10−12 1.28x10−09 0.05 2.32x10+02
PC aa C38:4/PC ae C40:3 101.79 30.82 0.12 1.02x10−11 1.63x10−09 0.08 1.43x10+03
PC aa C38:4/PC ae C34:1 11.54 3.54 0.12 1.25x10−11 1.99x10−09 0.07 6.79x10+03
PC aa C38:4/PC ae C44:4 327.70 125.99 0.12 1.32x10−11 2.10x10−09 0.04 3.21x10+02
PC aa C38:4/PC ae C34:0 73.64 25.41 0.12 1.47x10−11 2.35x10−09 0.06 8.67x10+03
PC aa C36:3/PC ae C34:1 14.79 2.93 0.12 1.59x10−11 2.55x10−09 0.09 5.31x10+03
PC aa C40:4/PC ae C36:1 0.49 0.17 0.12 1.64x10−11 2.63x10−09 0.12 7.28x10+02
PC aa C36:4/PC ae C36:1 24.42 6.87 0.12 2.28x10−11 3.65x10−09 0.11 5.24x10+02
PC aa C38:4/PC ae C34:2 10.24 3.81 0.12 6.44x10−11 1.03x10−08 0.07 3.56x10+02
PC aa C36:4/PC ae C32:2 302.36 82.77 0.11 1.01x10−10 1.61x10−08 0.13 1.80x10+02
PC aa C38:3/PC ae C36:0 64.84 18.88 0.12 1.33x10−10 2.12x10−08 0.06 3.30x10+02
PC aa C34:4/PC ae C40:1 1.40 0.41 0.11 2.10x10−10 3.36x10−08 0.08 1.81x10+03
PC aa C38:4/PC ae C38:0 55.75 17.01 0.11 2.51x10−10 4.01x10−08 0.06 4.65x10+05
PC aa C36:4/PC ae C44:3 1727.9 547.87 0.12 2.58x10−10 4.13x10−08 0.04 7.85x10+02
PC aa C40:4/PC ae C34:1 0.40 0.13 0.11 3.95x10−10 6.32x10−08 0.10 2.14x10+02
PC aa C40:4/PC ae C40:1 2.68 0.81 0.11 4.30x10−10 6.88x10−08 0.04 8.84x10+02
PC aa C36:4/PC ae C34:0 129.92 39.18 0.11 4.34x10−10 6.94x10−08 0.08 2.94x10+02
PC aa C34:4/PC ae C34:0 1.34 0.44 0.11 4.61x10−10 7.37x10−08 0.05 2.77x10+02
PC aa C36:3/PC ae C34:0 94.54 24.27 0.11 5.19x10−10 8.31x10−08 0.06 2.46x10+02
PC aa C40:4/PC ae C34:0 2.58 0.92 0.11 5.78x10−10 9.26x10−08 0.08 2.21x10+02
PC aa C36:3/PC ae C40:1 99.08 23.05 0.11 6.12x10−10 9.79x10−08 0.05 6.21x10+02
PC aa C38:4/PC ae C36:3 15.34 5.11 0.11 2.21x10−09 3.54x10−07 0.05 9.40x10+03
PC aa C38:4/PC ae C40:2 57.90 19.88 0.11 2.45x10−09 3.92x10−07 0.05 3.00x10+03
PC aa C40:4/PC ae C42:1 10.94 2.43 0.11 2.95x10−09 4.72x10−07 0.04 7.75x10+05
PC aa C36:4/PC ae C42:1 555.46 109.61 0.11 4.33x10−09 6.94x10−07 0.04 5.27x10+05
PC aa C36:4/PC ae C40:4 78.61 17.85 0.11 6.18x10−09 9.89x10−07 0.05 9.73x10+02
PC aa C40:4/PC ae C40:4 1.56 0.47 0.10 7.98x10−09 1.28x10−06 0.05 7.53x10+02
PC aa C38:4/PC ae C38:1 226.20 162.23 0.10 1.06x10−08 1.70x10−06 0.03 1.88x10+03
PC aa C36:4/PC ae C38:0 98.56 26.41 0.10 1.76x10−08 2.82x10−06 0.07 6.61x10+03
PC aa C36:3/PC ae C36:3 19.62 4.36 0.10 2.17x10−08 3.47x10−06 0.05 9.60x10+02
PC aa C38:4/PC ae C42:0 231.10 60.62 0.10 3.25x10−08 5.20x10−06 0.04 1.47x10+04
PC aa C34:4/PC ae C38:0 1.02 0.32 0.10 6.42x10−08 1.03x10−05 0.03 1.81x10+03
PC aa C38:4/PC ae C30:0 281.12 116.99 0.10 7.20x10−08 1.15x10−05 0.05 2.08x10+02
PC aa C36:4/PC ae C38:4 13.73 2.81 0.09 2.19x10−07 3.50x10−05 0.05 2.99x10+04
PC aa C38:4/PC ae C38:3 28.55 8.61 0.09 3.21x10−07 5.13x10−05 0.08 1.49x10+03
PC aa C40:4/PC ae C38:4 0.27 0.08 0.09 1.18x10−06 1.89x10−04 0.05 5.55x10+03
PC aa C38:4/PC ae C38:6 13.87 3.63 0.09 1.81x10−06 2.89x10−04 0.02 2.65x10+02
PC aa C38:4/PC ae C38:5 6.15 1.27 0.09 1.88x10−06 3.01x10−04 0.03 2.54x10+02
PC aa C38:0/PC ae C36:4 0.17 0.05 -0.08 4.24x10−06 6.78x10−04 0.04 3.54x10+02
PC aa C40:4/PC ae C38:3 1.00 0.34 0.08 8.62x10−06 1.38x10−03 0.12 1.48x10+03
PC aa C36:3/PC ae C42:1 409.17 84.37 0.08 9.88x10−06 1.58x10−03 0.03 2.31x10+02
PC aa C34:4/PC ae C42:1 5.83 1.84 0.08 1.10x10−05 1.75x10−03 0.07 2.08x10+02
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC aa C36:3/PC ae C38:3 36.65 7.41 0.07 3.22x10−05 5.15x10−03 0.11 3.96x10+02
PC aa C36:4/PC ae C36:0 234.4 62.39 0.07 1.82x10−04 2.91x10−02 0.01 1.78x10+02
PC/lysoPC Ratios
PC aa C38:3/lysoPC a C18:2 2.27 0.99 0.17 2.10x10−22 3.37x10−20 0.19 2.43x10+04
PC aa C38:3/lysoPC a C18:1 2.87 1.03 0.16 8.65x10−22 1.38x10−19 0.17 1.66x10+09
PC aa C38:3/lysoPC a C17:0 30.75 14.02 0.16 1.73x10−19 2.77x10−17 0.08 1.55x10+06
PC aa C38:4/lysoPC a C18:1 5.85 2.10 0.14 3.80x10−16 6.09x10−14 0.12 3.77x10+03
PC aa C38:3/lysoPC a C18:0 1.85 0.56 0.13 1.56x10−13 2.49x10−11 0.10 2.82x10+05
PC aa C42:2/lysoPC a C26:1 0.12 0.03 -0.12 7.58x10−12 1.21x10−09 0.05 2.40x10+02
PC aa C38:3/lysoPC a C16:0 0.49 0.14 0.12 1.67x10−11 2.67x10−09 0.12 2.63x10+03
PC aa C38:4/lysoPC a C20:4 20.19 5.51 0.10 4.73x10−10 7.57x10−08 0.19 1.01x10+06
PC aa C38:4/lysoPC a C18:0 3.76 1.14 0.11 5.19x10−09 8.30x10−07 0.06 9.24x10+04
PC aa C40:1/lysoPC a C26:1 0.25 0.06 -0.10 5.03x10−08 8.05x10−06 0.04 3.07x10+02
PC aa C36:4/lysoPC a C20:4 35.84 9.27 0.09 3.29x10−07 5.26x10−05 0.18 3.68x10+04
PC aa C38:4/lysoPC a C16:0 0.99 0.28 0.09 7.55x10−07 1.21x10−04 0.07 6.35x10+02
PC aa C42:6/lysoPC a C14:0 0.10 0.02 -0.09 1.04x10−06 1.66x10−04 0.03 5.22x10+02
PC aa C40:4/lysoPC a C18:0 0.13 0.04 0.08 4.76x10−06 7.62x10−04 0.02 3.31x10+02
PC aa C40:4/lysoPC a C20:4 0.72 0.24 0.07 3.62x10−05 5.79x10−03 0.09 3.35x10+02
PC aa C36:4/lysoPC a C16:0 1.75 0.44 0.07 5.22x10−05 8.35x10−03 0.06 1.82x10+02
PC ae C38:2/lysoPC a C14:0 0.34 0.08 -0.14 1.64x10−14 2.62x10−12 0.11 5.01x10+03
PC ae C36:1/lysoPC a C14:0 1.43 0.33 -0.12 7.20x10−13 1.15x10−10 0.16 1.66x10+04
PC ae C34:0/lysoPC a C14:0 0.27 0.06 -0.13 8.82x10−13 1.41x10−10 0.12 1.45x10+05
PC ae C42:2/lysoPC a C14:0 0.10 0.02 -0.13 1.45x10−12 2.32x10−10 0.07 1.28x10+03
PC ae C34:1/lysoPC a C14:0 1.69 0.35 -0.12 1.08x10−11 1.73x10−09 0.15 7.85x10+03
PC ae C40:1/lysoPC a C14:0 0.26 0.06 -0.12 1.54x10−10 2.47x10−08 0.05 2.46x10+03
PC ae C30:0/lysoPC a C14:0 0.07 0.02 -0.11 6.13x10−10 9.80x10−08 0.12 2.44x10+04
PC ae C42:0/lysoPC a C26:1 0.31 0.06 -0.09 1.86x10−06 2.98x10−04 0.02 3.42x10+02
PC ae C36:4/lysoPC a C20:4 3.46 0.97 0.07 2.73x10−05 4.37x10−03 0.12 4.44x10+02
SM C16:0 151.19 23.84 -0.07 2.97x10−05 4.76x10−03 0.07
SM (OH) C14:1 9.54 2.56 -0.07 9.83x10−05 1.57x10−02 0.18
SM (OH) C16:1 5.19 1.37 -0.06 1.08x10−04 1.73x10−02 0.18
SM C16:0/SM C16:1 6.40 0.76 -0.12 9.51x10−14 1.52x10−11 0.29 3.13x10+08
SM (OH) C16:1/SM C18:0 0.16 0.03 -0.12 2.05x10−12 3.28x10−10 0.10 5.27x10+07
SM (OH) C16:1/SM C18:1 0.31 0.06 -0.13 2.19x10−12 3.51x10−10 0.05 4.94x10+07
SM C16:0/SM C18:0 4.64 0.71 -0.11 3.20x10−10 5.11x10−08 0.09 9.30x10+04
SM C16:0/SM C18:1 9.36 1.83 -0.10 3.57x10−10 5.71x10−08 0.24 8.33x10+04
SM (OH) C22:2/SM C18:1 1.00 0.19 -0.11 2.59x10−09 4.14x10−07 0.05 2.93x10+05
SM (OH) C14:1/SM C18:1 0.58 0.14 -0.10 3.40x10−08 5.45x10−06 0.03 2.89x10+03
SM (OH) C14:1/SM C18:0 0.29 0.06 -0.10 6.07x10−08 9.71x10−06 0.06 1.62x10+03
SM (OH) C22:2/SM C16:1 0.69 0.12 -0.09 3.32x10−07 5.31x10−05 0.10 2.29x10+03
SM (OH) C22:2/SM C18:0 0.50 0.10 -0.09 3.59x10−07 5.74x10−05 0.15 2.12x10+03
SM (OH) C14:1/SM C16:1 0.40 0.08 -0.09 4.60x10−07 7.36x10−05 0.03 2.14x10+02
SM C18:1/SM C26:1 27.63 8.81 0.08 9.87x10−06 1.58x10−03 0.14 3.76x10+02
SM (OH) C24:1/SM C18:1 0.12 0.03 -0.08 1.21x10−05 1.94x10−03 0.08 4.27x10+02
SM (OH) C24:1/SM C18:0 0.06 0.01 -0.08 1.59x10−05 2.54x10−03 0.02 3.26x10+02
SM C18:0/SM C26:1 54.77 15.49 0.08 2.17x10−05 3.47x10−03 0.06 1.71x10+02
SM C18:1/SM C24:1 0.22 0.05 0.06 7.06x10−05 1.13x10−02 0.23 4.92x10+02
H1 5300.1 891.29 0.17 2.67x10−21 4.27x10−19 0.14
Kynurenine 2.88 0.69 0.13 1.11x10−13 1.78x10−11 0.11
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
alpha AAA 0.68 0.27 0.09 8.51x10−07 1.36x10−04 0.05
Serotonin 0.70 0.34 -0.08 2.21x10−05 3.54x10−03 0.03
Kynurenine/total DMA 2.43 0.65 0.15 5.16x10−18 8.25x10−16 0.09 2.16x10+04
Serotonin/alpha AAA 2.85 29.44 -0.11 1.24x10−09 1.98x10−07 0.06 6.89x10+02
alpha AAA/total DMA 0.58 0.26 0.11 1.59x10−09 2.54x10−07 0.06 5.37x10+02
Met SO/SDMA 1.19 1.78 0.08 3.47x10−06 5.55x10−04 0.02 1.35x10+03
Met SO/total DMA 0.66 0.23 0.08 8.03x10−06 1.28x10−03 0.02 5.00x10+02
a Fat Free Mass Index; b for multiple testing adjusted p-value; c adjusted R2 of the linear model; d p-gain,
fold decrease in the p-value of association for the pair of metabolites, compared to the lowest of two
p-values for the single metabolites; AAs amino acids; Σ aromatic amino acids is the sum of tyrosine,
phenylalanine, and tryptophan; Σ BCAAs is the sum of valine, isoleucine, and leucine; Σ glucogenic amino
acids is the sum of alanine, glycine, and serine.
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Table B3: Metabolic traits significantly associated with FFMIa in a linear regression model
adjusted for age, sex and batch (α = 5%, p-gain > 150) in the KORA F4
weight stable sample (Jourdan et al., 2012).
Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
xLeu 210.42 43.19 0.13 4.75x10−16 6.80x10−14 0.39
Gly 314.88 83.47 -0.13 6.53x10−12 9.33x10−10 0.14
Val 273.25 59.21 0.11 2.05x10−11 2.94x10−09 0.35
Tyr 84.60 17.27 0.10 1.19x10−07 1.70x10−05 0.10
Ser 130.82 24.44 -0.09 1.65x10−05 2.36x10−03 0.04
Orn 81.50 18.59 0.07 1.17x10−04 1.67x10−02 0.14
Σ BCAAs 483.67 97.47 0.13 1.51x10−14 2.15x10−12 0.38
Σ aromatic AAs 229.04 32.96 0.08 5.37x10−05 7.68x10−03 0.11
Gly/xLeu 1.57 0.57 -0.17 6.01x10−27 8.60x10−25 0.42 7.90x10+10
Gly/Val 1.22 0.46 -0.16 3.71x10−22 5.31x10−20 0.39 1.76x10+10
Gly/Tyr 3.87 1.30 -0.17 5.22x10−21 7.47x10−19 0.25 1.25x10+09
Ser/xLeu 0.65 0.18 -0.16 9.84x10−21 1.41x10−18 0.35 4.83x10+04
Ser/Val 0.50 0.13 -0.15 2.37x10−20 3.38x10−18 0.36 8.68x10+08
Gln/xLeu 3.07 0.62 -0.16 9.30x10−20 1.33x10−17 0.27 5.11x10+03
Gly/Orn 4.05 1.40 -0.15 8.50x10−19 1.21x10−16 0.31 7.68x10+06
Gln/Val 2.37 0.45 -0.16 1.88x10−18 2.69x10−16 0.21 1.09x10+07
His/xLeu 0.49 0.10 -0.13 2.16x10−18 3.09x10−16 0.52 2.20x10+02
Ser/Tyr 1.60 0.40 -0.15 3.97x10−16 5.68x10−14 0.19 2.99x10+08
Gly/Phe 5.28 1.64 -0.15 2.67x10−15 3.82x10−13 0.21 2.44x10+03
Trp/Val 0.31 0.06 -0.12 3.34x10−14 4.77x10−12 0.43 6.15x10+02
Gln/Tyr 7.64 1.50 -0.14 1.20x10−12 1.72x10−10 0.12 9.88x10+04
Met/Tyr 0.38 0.06 -0.13 6.70x10−12 9.58x10−10 0.21 1.77x10+04
Phe/Ser 0.48 0.10 0.13 1.90x10−11 2.72x10−09 0.14 8.65x10+05
Orn/Ser 0.64 0.17 0.12 2.12x10−11 3.03x10−09 0.22 7.78x10+05
Trp/Tyr 1.01 0.16 -0.12 5.93x10−10 8.48x10−08 0.13 2.00x10+02
Gln/Orn 8.00 1.72 -0.11 1.21x10−08 1.73x10−06 0.06 9.65x10+03
Gln/Phe 10.44 1.79 -0.10 2.50x10−07 3.57x10−05 0.13 4.18x10+03
Σ BCAAs/ Σ glucogenic AAs 1.14 0.34 0.17 2.68x10−27 3.83x10−25 0.43
C8:1 0.09 0.04 0.11 1.39x10−08 1.98x10−06 0.07
C9 0.05 0.02 -0.08 2.37x10−05 3.40x10−03 0.06
C3 0.38 0.12 0.08 3.41x10−05 4.88x10−03 0.14
C5 0.11 0.04 0.08 5.85x10−05 8.36x10−03 0.17
C0 35.05 7.36 0.07 1.17x10−04 1.68x10−02 0.13
C8:1/C9 1.91 1.20 0.15 2.23x10−14 3.18x10−12 0.07 6.23x10+05
C12/C8:1 1.77 0.83 -0.15 7.98x10−14 1.14x10−11 0.06 1.74x10+05
C14:2/C8:1 0.41 0.19 -0.14 3.38x10−13 4.84x10−11 0.08 4.10x10+04
C7-DC/C8:1 0.61 0.28 -0.14 6.24x10−13 8.92x10−11 0.09 2.22x10+04
C10/C8:1 4.79 2.45 -0.14 1.78x10−12 2.55x10−10 0.07 7.78x10+03
C14:1-OH/C8:1 0.20 0.08 -0.14 3.77x10−12 5.40x10−10 0.05 3.68x10+03
C12:1/C8:1 1.97 0.85 -0.14 6.67x10−12 9.53x10−10 0.06 2.08x10+03
C14:1/C8:1 2.08 0.92 -0.13 1.63x10−11 2.33x10−09 0.12 8.53x10+02
C14:2-OH/C8:1 0.13 0.06 -0.13 2.93x10−11 4.19x10−09 0.14 4.74x10+02
C5/C9 2.56 1.17 0.13 3.11x10−11 4.44x10−09 0.15 7.64x10+05
C14/C8:1 0.63 0.28 -0.13 6.95x10−11 9.93x10−09 0.06 2.00x10+02
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
C3/C9 8.46 4.00 0.13 7.71x10−11 1.10x10−08 0.11 3.08x10+05
C0/C9 792.55 331.39 0.12 3.58x10−09 5.12x10−07 0.07 6.64x10+03
C10/C6 (C4:1-DC) 5.07 1.20 -0.12 4.11x10−09 5.88x10−07 0.05 1.42x10+06
C12/C5 1.23 0.55 -0.11 1.52x10−08 2.17x10−06 0.13 3.85x10+03
C14:2-OH/C5 0.09 0.03 -0.10 3.05x10−08 4.36x10−06 0.23 1.92x10+03
C5/C7-DC 2.85 1.29 0.11 3.20x10−08 4.58x10−06 0.10 1.83x10+03
C12/C3 0.37 0.17 -0.11 6.35x10−08 9.07x10−06 0.07 5.38x10+02
C14:1-OH/C5 0.14 0.05 -0.10 9.97x10−08 1.43x10−05 0.13 5.87x10+02
C12/C16 1.12 0.34 -0.10 1.32x10−07 1.89x10−05 0.07 7.85x10+03
C14/C16 0.39 0.06 -0.09 1.86x10−07 2.66x10−05 0.27 3.57x10+05
C12/C6 (C4:1-DC) 1.92 0.52 -0.10 2.23x10−07 3.18x10−05 0.03 4.66x10+03
C10/C5 3.33 1.68 -0.10 3.20x10−07 4.58x10−05 0.13 1.83x10+02
C0/C12 300.33 117.20 0.10 3.40x10−07 4.87x10−05 0.07 3.45x10+02
C12/C18:1 1.02 0.32 -0.10 3.78x10−07 5.41x10−05 0.08 2.74x10+03
C12/C2 0.02 0.01 -0.10 7.38x10−07 1.06x10−04 0.04 1.40x10+03
C10/C8 1.61 0.20 -0.09 7.00x10−06 1.00x10−03 0.05 8.32x10+02
C14:1-OH/C16 0.13 0.03 -0.09 7.38x10−06 1.06x10−03 0.02 3.26x10+03
C16/C7-DC 2.89 0.95 0.08 1.37x10−05 1.96x10−03 0.10 4.52x10+02
C18:1/C7-DC 3.17 1.09 0.08 1.62x10−05 2.32x10−03 0.13 3.82x10+02
C2/C7-DC 192.69 63.81 0.08 1.90x10−05 2.71x10−03 0.12 3.27x10+02
C10/C10:1 2.14 0.48 -0.08 2.78x10−05 3.98x10−03 0.03 2.09x10+02
C14:1-OH/C18:1 0.12 0.03 -0.08 3.14x10−05 4.49x10−03 0.03 7.66x10+02
C14:1/C18:1 1.20 0.31 -0.07 8.34x10−05 1.19x10−02 0.35 7.25x10+02
C14:2/C18:2 0.68 0.22 -0.07 1.05x10−04 1.51x10−02 0.13 2.16x10+02
C14:2/C18:1 0.24 0.08 -0.08 1.09x10−04 1.56x10−02 0.10 2.09x10+02
C12:1/C18:1 1.14 0.29 -0.08 1.16x10−04 1.66x10−02 0.08 3.81x10+02
C14/C18:1 0.36 0.07 -0.07 1.26x10−04 1.80x10−02 0.20 5.30x10+02
C12:1/C16 1.25 0.34 -0.08 1.34x10−04 1.91x10−02 0.06 3.31x10+02
C6 (C4:1-DC)/C8 0.33 0.06 0.08 1.36x10−04 1.95x10−02 0.01 1.03x10+03
C16/C16:1-OH 10.99 2.14 0.07 1.69x10−04 2.41x10−02 0.25 6.79x10+02
C14:1/C16 1.31 0.34 -0.06 1.95x10−04 2.78x10−02 0.30 3.11x10+02
C16/C18 2.34 0.43 0.07 2.76x10−04 3.94x10−02 0.06 4.16x10+02
Single PC
PC aa C42:0 0.61 0.17 -0.15 9.14x10−15 1.31x10−12 0.11
PC aa C42:1 0.30 0.08 -0.14 8.48x10−13 1.21x10−10 0.08
PC aa C38:3 53.25 12.82 0.14 3.20x10−12 4.58x10−10 0.11
PC aa C42:2 0.22 0.06 -0.11 3.22x10−08 4.60x10−06 0.05
PC aa C38:4 117.39 28.78 0.10 1.86x10−06 2.66x10−04 0.05
PC aa C40:1 0.47 0.10 -0.09 4.32x10−06 6.18x10−04 0.09
PC aa C40:4 4.13 1.16 0.08 5.63x10−05 8.05x10−03 0.02
PC aa C42:6 0.63 0.14 -0.08 1.01x10−04 1.45x10−02 0.03
PC aa C40:2 0.36 0.10 -0.08 1.37x10−04 1.96x10−02 0.04
PC ae C42:3 0.90 0.20 -0.16 1.00x10−15 1.44x10−13 0.10
PC ae C42:4 1.04 0.24 -0.15 2.27x10−14 3.25x10−12 0.12
PC ae C44:4 0.44 0.11 -0.14 7.20x10−13 1.03x10−10 0.10
PC ae C44:6 1.40 0.37 -0.14 7.50x10−13 1.07x10−10 0.08
PC ae C42:5 2.40 0.49 -0.14 2.84x10−12 4.07x10−10 0.10
PC ae C36:2 15.72 4.00 -0.13 3.67x10−12 5.24x10−10 0.20
PC ae C40:5 3.62 0.65 -0.13 2.70x10−11 3.86x10−09 0.08
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC ae C44:5 2.16 0.54 -0.13 1.47x10−10 2.10x10−08 0.06
PC ae C40:6 5.16 1.31 -0.12 2.10x10−10 3.00x10−08 0.13
PC ae C30:0 0.48 0.14 -0.12 3.05x10−10 4.37x10−08 0.20
PC ae C38:2 2.20 0.51 -0.12 1.76x10−09 2.52x10−07 0.11
PC ae C40:3 1.16 0.23 -0.11 3.29x10−09 4.70x10−07 0.19
PC ae C44:3 0.11 0.03 -0.12 4.64x10−09 6.63x10−07 0.05
PC ae C34:0 1.77 0.46 -0.11 9.30x10−09 1.33x10−06 0.14
PC ae C42:2 0.69 0.15 -0.11 5.43x10−08 7.77x10−06 0.11
PC ae C36:1 8.51 1.96 -0.10 8.57x10−08 1.22x10−05 0.14
PC ae C34:1 10.83 2.39 -0.10 1.47x10−07 2.11x10−05 0.18
PC ae C34:3 8.74 2.45 -0.10 4.66x10−07 6.66x10−05 0.07
PC ae C40:4 2.62 0.48 -0.10 9.74x10−07 1.39x10−04 0.07
PC ae C32:2 0.77 0.17 -0.09 1.20x10−06 1.71x10−04 0.15
PC ae C40:2 2.12 0.48 -0.09 1.70x10−06 2.43x10−04 0.16
PC ae C40:1 1.72 0.40 -0.10 2.00x10−06 2.86x10−04 0.03
PC ae C32:1 2.95 0.62 -0.09 4.72x10−06 6.74x10−04 0.13
PC ae C34:2 13.16 3.39 -0.08 1.06x10−05 1.52x10−03 0.13
PC ae C38:0 2.55 0.78 -0.08 5.20x10−05 7.43x10−03 0.05
PC ae C40:0 10.31 1.66 -0.07 1.83x10−04 2.62x10−02 0.13
Σ PC ae 199.62 34.61 -0.08 3.29x10−05 4.71x10−03 0.11
lysoPC a C17:0 1.81 0.52 -0.15 1.28x10−14 1.84x10−12 0.10
lysoPC a C18:1 20.26 5.87 -0.13 1.64x10−12 2.35x10−10 0.16
lysoPC a C18:2 29.29 9.85 -0.13 2.36x10−12 3.37x10−10 0.19
lysoPC a C28:1 0.63 0.22 -0.08 2.48x10−05 3.55x10−03 0.06
Σ lysoPC 194.05 40.53 -0.09 1.19x10−06 1.70x10−04 0.14
PC aa/PC aa Ratios
PC aa C38:3/PC aa C42:6 85.92 19.67 0.21 3.67x10−29 5.25x10−27 0.19 8.71x10+16
PC aa C38:3/PC aa C42:1 187.87 67.29 0.20 4.04x10−24 5.77x10−22 0.13 2.10x10+11
PC aa C38:3/PC aa C42:0 95.48 37.12 0.20 4.59x10−24 6.56x10−22 0.14 1.99x10+09
PC aa C38:4/PC aa C42:1 410.11 138.19 0.19 2.58x10−21 3.69x10−19 0.11 3.28x10+08
PC aa C38:3/PC aa C42:2 263.42 87.32 0.19 4.50x10−21 6.43x10−19 0.10 7.11x10+08
PC aa C38:3/PC aa C42:4 243.89 55.88 0.18 1.40x10−20 2.01x10−18 0.11 2.28x10+08
PC aa C38:4/PC aa C42:0 209.21 80.15 0.18 1.84x10−20 2.63x10−18 0.12 4.98x10+05
PC aa C36:3/PC aa C38:3 2.89 0.49 -0.15 1.20x10−19 1.71x10−17 0.35 2.68x10+07
PC aa C28:1/PC aa C38:3 0.07 0.02 -0.18 1.87x10−19 2.68x10−17 0.11 1.71x10+07
PC aa C30:0/PC aa C38:3 0.09 0.03 -0.17 2.70x10−19 3.86x10−17 0.18 1.19x10+07
PC aa C38:3/PC aa C40:1 116.93 35.7 0.17 2.69x10−18 3.85x10−16 0.15 1.19x10+06
PC aa C32:0/PC aa C38:3 0.30 0.07 -0.17 2.81x10−18 4.02x10−16 0.16 1.14x10+06
PC aa C38:3/PC aa C40:2 155.08 45.98 0.17 3.44x10−18 4.93x10−16 0.10 9.29x10+05
PC aa C38:3/PC aa C42:5 129.66 33.97 0.17 3.88x10−18 5.55x10−16 0.10 8.24x10+05
PC aa C38:4/PC aa C42:6 189.31 43.84 0.17 4.26x10−18 6.09x10−16 0.11 4.36x10+11
PC aa C36:1/PC aa C38:3 1.04 0.19 -0.17 2.50x10−17 3.58x10−15 0.09 1.28x10+05
PC aa C40:4/PC aa C42:6 6.62 1.51 0.17 6.51x10−17 9.31x10−15 0.10 8.65x10+11
PC aa C32:3/PC aa C38:3 0.01 0.00 -0.16 8.02x10−17 1.15x10−14 0.14 3.99x10+04
PC aa C38:4/PC aa C42:2 578.15 187.71 0.16 3.79x10−16 5.42x10−14 0.07 8.49x10+07
PC aa C34:3/PC aa C38:3 0.35 0.10 -0.15 6.22x10−16 8.89x10−14 0.17 5.15x10+03
PC aa C38:3/PC aa C38:5 0.87 0.20 0.16 6.62x10−16 9.47x10−14 0.14 4.83x10+03
PC aa C40:4/PC aa C42:1 14.58 5.79 0.16 7.57x10−16 1.08x10−13 0.09 1.12x10+03
PC aa C38:4/PC aa C38:5 1.89 0.32 0.15 2.79x10−15 3.99x10−13 0.13 6.65x10+08
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC aa C36:2/PC aa C38:3 4.59 0.98 -0.14 4.80x10−15 6.87x10−13 0.21 6.66x10+02
PC aa C38:4/PC aa C42:4 534.83 111.92 0.16 6.55x10−15 9.36x10−13 0.07 2.84x10+08
PC aa C40:5/PC aa C42:6 18.36 3.65 0.15 4.28x10−14 6.12x10−12 0.10 2.36x10+09
PC aa C38:4/PC aa C40:3 181.57 42.79 0.15 5.40x10−14 7.73x10−12 0.07 3.44x10+07
PC aa C38:4/PC aa C40:1 256.42 74.82 0.14 1.30x10−13 1.86x10−11 0.11 1.43x10+07
PC aa C38:4/PC aa C40:2 339.98 94.47 0.15 1.65x10−13 2.36x10−11 0.07 1.13x10+07
PC aa C38:6/PC aa C40:6 3.28 0.49 -0.13 4.37x10−13 6.25x10−11 0.25 1.80x10+11
PC aa C40:4/PC aa C42:2 20.46 7.50 0.14 1.66x10−12 2.37x10−10 0.05 1.94x10+04
PC aa C38:4/PC aa C42:5 285.15 73.15 0.14 6.36x10−12 9.09x10−10 0.06 2.92x10+05
PC aa C40:4/PC aa C42:4 18.76 4.34 0.14 6.99x10−12 1.00x10−09 0.07 8.05x10+06
PC aa C40:3/PC aa C40:4 0.17 0.05 -0.14 8.95x10−12 1.28x10−09 0.06 6.29x10+06
PC aa C30:0/PC aa C40:4 1.21 0.39 -0.13 3.65x10−11 5.23x10−09 0.13 1.54x10+06
PC aa C40:6/PC aa C42:2 135.72 41.45 0.13 4.42x10−11 6.32x10−09 0.08 7.28x10+02
PC aa C36:4/PC aa C42:2 1074.77 332.11 0.13 6.30x10−11 9.01x10−09 0.10 5.11x10+02
PC aa C32:0/PC aa C38:4 0.14 0.03 -0.13 8.37x10−11 1.20x10−08 0.10 2.22x10+04
PC aa C28:1/PC aa C38:4 0.03 0.01 -0.13 8.53x10−11 1.22x10−08 0.08 2.18x10+04
PC aa C40:4/PC aa C42:5 9.99 2.63 0.13 9.76x10−11 1.40x10−08 0.06 5.76x10+05
PC aa C40:2/PC aa C40:4 0.09 0.03 -0.13 1.17x10−10 1.68x10−08 0.05 4.79x10+05
PC aa C38:0/PC aa C38:4 0.03 0.01 -0.13 1.28x10−10 1.83x10−08 0.07 1.45x10+04
PC aa C30:0/PC aa C38:4 0.04 0.01 -0.12 2.60x10−10 3.71x10−08 0.11 7.15x10+03
PC aa C40:1/PC aa C40:4 0.12 0.04 -0.12 9.92x10−10 1.42x10−07 0.07 4.36x10+03
PC aa C32:3/PC aa C38:4 0.00 0.00 -0.12 1.68x10−09 2.41x10−07 0.11 1.10x10+03
PC aa C38:5/PC aa C40:4 15.68 3.34 -0.12 1.85x10−09 2.65x10−07 0.06 3.03x10+04
PC aa C32:0/PC aa C40:4 3.89 0.96 -0.12 2.09x10−09 2.99x10−07 0.08 2.69x10+04
PC aa C36:4/PC aa C42:6 353.04 80.73 0.12 2.42x10−09 3.46x10−07 0.09 4.18x10+04
PC aa C28:1/PC aa C40:4 0.88 0.26 -0.11 5.64x10−09 8.07x10−07 0.10 9.97x10+03
PC aa C40:5/PC aa C42:5 27.62 6.19 0.12 6.12x10−09 8.75x10−07 0.05 2.05x10+06
PC aa C36:0/PC aa C38:4 0.02 0.01 -0.11 6.83x10−09 9.77x10−07 0.08 2.72x10+02
PC aa C38:4/PC aa C38:6 1.36 0.39 0.12 7.67x10−09 1.10x10−06 0.06 2.42x10+02
PC aa C40:3/PC aa C40:5 0.06 0.02 -0.11 2.11x10−08 3.01x10−06 0.04 5.79x10+04
PC aa C36:3/PC aa C42:6 244.39 51.71 0.11 5.69x10−08 8.13x10−06 0.06 1.78x10+03
PC aa C40:2/PC aa C40:5 0.03 0.01 -0.11 6.11x10−08 8.74x10−06 0.03 2.24x10+03
PC aa C32:3/PC aa C40:4 0.13 0.04 -0.10 6.75x10−08 9.66x10−06 0.13 8.33x10+02
PC aa C40:6/PC aa C42:6 44.99 11.65 0.10 7.36x10−08 1.05x10−05 0.15 1.37x10+03
PC aa C36:4/PC aa C40:2 633.22 172.28 0.11 9.52x10−08 1.36x10−05 0.09 1.44x10+03
PC aa C34:3/PC aa C40:4 4.62 1.36 -0.10 1.07x10−07 1.52x10−05 0.11 5.28x10+02
PC aa C38:0/PC aa C40:6 0.12 0.03 -0.10 1.29x10−07 1.85x10−05 0.11 1.11x10+04
PC aa C30:0/PC aa C40:5 0.43 0.14 -0.10 1.35x10−07 1.93x10−05 0.11 1.59x10+04
PC aa C30:0/PC aa C36:3 0.03 0.01 -0.10 2.06x10−07 2.94x10−05 0.05 1.04x10+04
PC aa C30:0/PC aa C36:4 0.02 0.01 -0.10 2.85x10−07 4.07x10−05 0.06 7.54x10+03
PC aa C32:0/PC aa C36:4 0.07 0.01 -0.10 3.07x10−07 4.39x10−05 0.10 8.52x10+04
PC aa C36:4/PC aa C42:4 998.53 211.75 0.10 3.74x10−07 5.35x10−05 0.16 4.53x10+04
PC aa C36:4/PC aa C40:3 338.74 79.41 0.10 5.07x10−07 7.25x10−05 0.10 2.41x10+03
PC aa C38:5/PC aa C40:5 5.56 0.89 -0.10 8.94x10−07 1.28x10−04 0.07 1.57x10+04
PC aa C36:6/PC aa C40:6 0.04 0.01 -0.10 1.12x10−06 1.61x10−04 0.06 1.02x10+04
PC aa C40:5/PC aa C42:4 52.43 12.16 0.10 1.29x10−06 1.85x10−04 0.03 1.09x10+04
PC aa C30:0/PC aa C32:1 0.25 0.07 -0.09 1.73x10−06 2.48x10−04 0.06 1.24x10+03
PC aa C36:6/PC aa C40:5 0.10 0.04 -0.09 3.42x10−06 4.89x10−04 0.06 3.36x10+03
PC aa C30:0/PC aa C34:4 2.22 0.57 -0.09 3.69x10−06 5.28x10−04 0.10 5.82x10+02
LXXII Appendix
Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC aa C36:0/PC aa C40:6 0.10 0.03 -0.09 3.81x10−06 5.45x10−04 0.14 3.19x10+03
PC aa C40:6/PC aa C42:5 67.18 16.98 0.09 3.83x10−06 5.47x10−04 0.08 3.28x10+03
PC aa C28:1/PC aa C36:3 0.02 0.01 -0.09 4.02x10−06 5.75x10−04 0.15 4.21x10+02
PC aa C28:1/PC aa C40:5 0.31 0.09 -0.09 4.04x10−06 5.78x10−04 0.07 4.19x10+02
PC aa C36:3/PC aa C40:3 234.08 48.61 0.09 4.65x10−06 6.65x10−04 0.08 2.62x10+02
PC aa C28:1/PC aa C36:4 0.02 0.00 -0.09 5.82x10−06 8.33x10−04 0.15 2.91x10+02
PC aa C36:4/PC aa C38:0 69.93 21.54 0.09 8.88x10−06 1.27x10−03 0.05 1.61x10+02
PC aa C36:4/PC aa C42:5 533.12 140.27 0.09 9.54x10−06 1.36x10−03 0.08 1.32x10+03
PC aa C36:4/PC aa C38:5 3.52 0.54 0.09 9.81x10−06 1.40x10−03 0.11 2.66x10+03
PC aa C36:4/PC aa C36:6 213.15 79.58 0.09 1.11x10−05 1.58x10−03 0.11 1.04x10+03
PC aa C34:4/PC aa C36:6 2.09 0.54 0.09 1.30x10−05 1.86x10−03 0.03 8.82x10+02
PC aa C32:0/PC aa C40:5 1.39 0.33 -0.09 1.36x10−05 1.95x10−03 0.06 1.03x10+03
PC aa C34:3/PC aa C36:3 0.12 0.02 -0.08 1.63x10−05 2.33x10−03 0.09 4.82x10+03
PC aa C32:3/PC aa C36:4 0.00 0.00 -0.08 2.65x10−05 3.79x10−03 0.20 6.37x10+02
PC aa C32:3/PC aa C36:3 0.00 0.00 -0.08 2.78x10−05 3.97x10−03 0.20 6.08x10+02
PC aa C32:0/PC aa C36:3 0.10 0.02 -0.08 2.98x10−05 4.26x10−03 0.06 2.31x10+03
PC aa C36:0/PC aa C36:4 0.01 0.00 -0.08 3.04x10−05 4.34x10−03 0.03 3.99x10+02
PC aa C32:3/PC aa C40:5 0.04 0.01 -0.08 3.29x10−05 4.70x10−03 0.12 4.27x10+02
PC aa C36:3/PC aa C42:4 693.57 146.97 0.08 6.76x10−05 9.67x10−03 0.10 2.50x10+02
PC aa C36:4/PC aa C38:6 2.53 0.68 0.08 1.10x10−04 1.57x10−02 0.07 2.38x10+02
PC aa C32:2/PC aa C34:4 1.78 0.50 -0.07 2.05x10−04 2.93x10−02 0.21 9.21x10+02
PC ae/PC ae Ratios
PC ae C36:4/PC ae C44:6 15.71 5.02 0.16 1.10x10−15 1.58x10−13 0.12 6.80x10+02
PC ae C36:4/PC ae C42:5 8.95 2.36 0.16 2.13x10−15 3.05x10−13 0.11 1.33x10+03
PC ae C36:4/PC ae C40:6 4.24 1.20 0.15 1.61x10−14 2.31x10−12 0.14 1.30x10+04
PC ae C34:2/PC ae C36:4 0.64 0.15 -0.14 4.48x10−14 6.41x10−12 0.18 2.36x10+08
PC ae C36:4/PC ae C44:5 10.14 3.12 0.15 7.90x10−14 1.13x10−11 0.08 1.86x10+03
PC ae C38:6/PC ae C40:6 1.73 0.29 0.14 1.30x10−13 1.86x10−11 0.18 1.62x10+03
PC ae C34:3/PC ae C36:4 0.43 0.12 -0.14 7.63x10−13 1.09x10−10 0.14 6.10x10+05
PC ae C36:4/PC ae C40:4 8.11 1.88 0.14 1.61x10−12 2.31x10−10 0.15 6.04x10+05
PC ae C36:4/PC ae C38:5 1.04 0.10 0.13 1.30x10−11 1.86x10−09 0.08 2.55x10+09
PC ae C36:3/PC ae C36:4 0.43 0.08 -0.12 1.09x10−10 1.56x10−08 0.14 3.67x10+07
PC ae C36:4/PC ae C40:1 12.62 3.46 0.13 1.21x10−10 1.73x10−08 0.07 1.65x10+04
PC ae C36:4/PC ae C42:2 31.47 8.87 0.13 2.24x10−10 3.20x10−08 0.07 2.43x10+02
PC ae C34:3/PC ae C36:5 0.64 0.15 -0.12 3.43x10−10 4.90x10−08 0.15 1.36x10+03
PC ae C36:4/PC ae C38:4 1.33 0.22 0.12 6.24x10−10 8.92x10−08 0.13 5.32x10+07
PC ae C34:1/PC ae C36:4 0.54 0.15 -0.12 8.22x10−10 1.18x10−07 0.13 1.79x10+02
PC ae C32:1/PC ae C36:4 0.15 0.04 -0.12 8.80x10−10 1.26x10−07 0.10 5.36x10+03
PC ae C32:2/PC ae C36:4 0.04 0.01 -0.11 4.64x10−09 6.64x10−07 0.16 2.58x10+02
PC ae C36:4/PC ae C38:6 2.43 0.49 0.09 9.05x10−07 1.29x10−04 0.17 3.66x10+04
lysoPC/lysoPC Ratios
lysoPC a C18:1/lysoPC a C20:3 8.41 1.74 -0.18 1.47x10−19 2.10x10−17 0.09 1.12x10+07
PC aa/PC ae Ratios
PC aa C38:3/PC ae C42:3 61.98 19.51 0.22 1.09x10−31 1.55x10−29 0.18 9.25x10+15
PC aa C38:3/PC ae C40:3 47.15 12.34 0.22 9.19x10−31 1.31x10−28 0.21 3.48x10+18
PC aa C38:3/PC ae C36:1 6.45 1.72 0.22 4.41x10−30 6.31x10−28 0.16 7.25x10+17
PC aa C38:3/PC ae C38:3 12.44 2.77 0.21 1.83x10−29 2.62x10−27 0.19 1.75x10+17
PC aa C38:3/PC ae C38:2 25.07 6.88 0.22 1.90x10−29 2.71x10−27 0.17 1.69x10+17
PC aa C38:3/PC ae C42:2 79.82 21.99 0.21 3.58x10−29 5.12x10−27 0.23 8.95x10+16
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC aa C38:3/PC ae C44:4 128.33 43.91 0.21 5.73x10−29 8.20x10−27 0.20 1.25x10+16
PC aa C38:3/PC ae C40:5 15.04 4.11 0.22 3.05x10−28 4.36x10−26 0.14 1.05x10+16
PC aa C38:3/PC ae C42:4 53.97 18.28 0.21 3.54x10−28 5.06x10−26 0.20 6.42x10+13
PC aa C38:3/PC ae C34:1 5.08 1.40 0.20 4.06x10−28 5.81x10−26 0.24 7.88x10+15
PC aa C38:3/PC ae C36:2 3.60 1.31 0.20 2.47x10−27 3.53x10−25 0.21 1.29x10+15
PC aa C38:3/PC ae C34:0 31.53 9.70 0.20 5.34x10−27 7.64x10−25 0.19 5.99x10+14
PC aa C38:3/PC ae C44:3 494.02 150.03 0.20 1.18x10−26 1.69x10−24 0.17 2.71x10+14
PC aa C38:4/PC ae C40:5 32.85 7.81 0.21 2.24x10−26 3.20x10−24 0.12 1.21x10+15
PC aa C38:3/PC ae C40:1 32.11 9.03 0.21 3.73x10−26 5.33x10−24 0.15 8.58x10+13
PC aa C38:4/PC ae C40:1 69.92 15.87 0.20 1.76x10−25 2.51x10−23 0.13 1.06x10+19
PC aa C38:3/PC aa C40:3 82.26 18.55 0.20 5.11x10−25 7.30x10−23 0.14 6.27x10+12
PC aa C38:3/PC ae C42:5 23.09 7.35 0.19 2.10x10−24 3.01x10−22 0.17 1.35x10+12
PC aa C38:3/PC ae C40:4 20.79 5.57 0.20 2.72x10−24 3.89x10−22 0.16 1.18x10+12
PC aa C38:4/PC ae C42:3 136.35 42.29 0.20 5.01x10−24 7.16x10−22 0.14 2.01x10+08
PC aa C38:3/PC ae C30:0 119.06 43.89 0.18 6.82x10−24 9.75x10−22 0.25 4.69x10+11
PC aa C38:3/PC ae C40:6 10.95 3.83 0.19 1.56x10−23 2.22x10−21 0.15 2.06x10+11
PC aa C38:3/PC ae C44:5 26.19 9.39 0.19 9.10x10−23 1.30x10−20 0.15 3.52x10+10
PC aa C38:3/PC ae C44:6 40.69 15.40 0.19 9.65x10−23 1.38x10−20 0.13 7.76x10+09
PC aa C36:2/PC ae C36:2 15.60 3.46 0.18 2.99x10−22 4.28x10−20 0.20 1.23x10+10
PC aa C38:3/PC ae C40:0 5.24 1.29 0.18 7.03x10−22 1.01x10−19 0.20 4.55x10+09
PC aa C38:4/PC ae C42:5 50.50 15.17 0.18 1.81x10−21 2.58x10−19 0.15 1.57x10+09
PC aa C38:4/PC ae C42:4 118.88 41.13 0.18 2.49x10−21 3.56x10−19 0.15 9.11x10+06
PC aa C38:3/PC ae C40:2 26.13 7.85 0.19 5.27x10−21 7.53x10−19 0.11 6.08x10+08
PC aa C38:3/PC ae C32:2 72.26 22.14 0.18 6.54x10−21 9.35x10−19 0.15 4.89x10+08
PC aa C38:3/PC ae C32:1 18.71 5.60 0.18 1.43x10−20 2.04x10−18 0.17 2.24x10+08
PC aa C38:4/PC ae C40:4 45.49 11.00 0.18 1.52x10−20 2.17x10−18 0.13 6.43x10+13
PC aa C38:4/PC ae C40:6 23.87 7.46 0.18 1.71x10−20 2.45x10−18 0.14 1.22x10+10
PC aa C38:4/PC ae C44:6 88.79 32.11 0.18 2.17x10−20 3.11x10−18 0.12 3.45x10+07
PC aa C36:2/PC ae C38:2 109.88 18.12 0.18 3.02x10−20 4.32x10−18 0.18 5.83x10+10
PC aa C38:3/PC ae C38:0 22.23 6.96 0.18 3.52x10−20 5.03x10−18 0.10 9.09x10+07
PC aa C38:3/PC ae C42:1 144.58 33.32 0.17 8.59x10−20 1.23x10−17 0.15 3.73x10+07
PC aa C38:4/PC ae C42:2 175.65 47.68 0.17 9.18x10−20 1.31x10−17 0.17 5.92x10+11
PC aa C36:3/PC ae C36:2 10.05 2.86 0.17 2.12x10−19 3.03x10−17 0.17 1.73x10+07
PC aa C38:4/PC ae C44:5 57.29 19.78 0.17 3.76x10−19 5.38x10−17 0.12 3.91x10+08
PC aa C38:4/PC ae C44:4 284.94 107.16 0.17 6.67x10−19 9.54x10−17 0.13 1.08x10+06
PC aa C40:4/PC ae C40:5 1.16 0.34 0.18 1.11x10−18 1.59x10−16 0.10 2.43x10+07
PC aa C40:4/PC ae C42:4 4.18 1.63 0.17 1.18x10−18 1.68x10−16 0.13 1.93x10+04
PC aa C38:4/PC ae C36:2 7.97 3.01 0.17 1.60x10−18 2.29x10−16 0.16 2.29x10+06
PC aa C40:4/PC ae C42:3 4.82 1.73 0.17 2.17x10−18 3.10x10−16 0.11 4.64x10+02
PC aa C34:2/PC ae C36:2 26.32 6.53 0.14 2.57x10−18 3.68x10−16 0.38 1.42x10+06
PC aa C40:6/PC ae C40:6 5.58 1.57 0.16 4.10x10−18 5.87x10−16 0.19 5.11x10+07
PC aa C36:3/PC ae C42:3 174.42 45.25 0.17 5.62x10−18 8.03x10−16 0.10 1.79x10+02
PC aa C36:2/PC ae C42:3 272.07 61.81 0.17 6.60x10−18 9.44x10−16 0.10 1.52x10+02
PC aa C40:4/PC ae C44:4 9.98 4.04 0.17 8.47x10−18 1.21x10−15 0.12 8.49x10+04
PC aa C38:4/PC ae C40:3 104.47 29.93 0.17 8.54x10−18 1.22x10−15 0.14 3.85x10+08
PC aa C36:3/PC ae C38:2 70.54 15.38 0.16 9.88x10−18 1.41x10−15 0.16 1.78x10+08
PC aa C36:4/PC ae C40:1 129.94 27.23 0.16 1.33x10−17 1.90x10−15 0.15 1.50x10+11
PC aa C38:3/PC ae C34:2 4.32 1.60 0.16 1.51x10−17 2.16x10−15 0.17 2.12x10+05
PC aa C38:4/PC ae C44:3 1091.87 351.39 0.17 2.13x10−17 3.04x10−15 0.11 2.18x10+08
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC aa C38:3/PC ae C36:0 52.49 15.87 0.16 2.16x10−17 3.09x10−15 0.14 1.48x10+05
PC aa C38:3/PC ae C34:3 6.58 2.54 0.17 2.38x10−17 3.41x10−15 0.11 1.34x10+05
PC aa C40:4/PC ae C42:2 6.16 1.80 0.16 3.46x10−17 4.95x10−15 0.14 1.57x10+09
PC aa C38:4/PC ae C38:2 55.70 17.18 0.17 4.37x10−17 6.25x10−15 0.11 4.03x10+07
PC aa C38:3/PC ae C36:3 6.30 1.93 0.16 5.16x10−17 7.38x10−15 0.20 6.20x10+04
PC aa C38:4/PC ae C34:0 69.86 22.89 0.16 5.83x10−17 8.34x10−15 0.13 1.60x10+08
PC aa C40:4/PC ae C36:2 0.28 0.12 0.16 6.42x10−17 9.17x10−15 0.16 5.71x10+04
PC aa C38:4/PC ae C36:1 14.32 4.26 0.16 1.09x10−16 1.55x10−14 0.10 7.88x10+08
PC ae C36:4/PC ae C40:5 5.87 1.39 0.16 1.38x10−16 1.97x10−14 0.18 1.96x10+05
PC aa C40:4/PC ae C38:2 1.95 0.64 0.16 1.52x10−16 2.18x10−14 0.12 1.16x10+07
PC aa C40:4/PC ae C40:4 1.60 0.47 0.16 2.65x10−16 3.79x10−14 0.11 3.68x10+09
PC aa C38:3/PC ae C42:0 107.87 30.84 0.15 2.71x10−16 3.87x10−14 0.19 1.18x10+04
PC aa C38:4/PC ae C38:4 7.52 1.73 0.15 3.51x10−16 5.01x10−14 0.20 5.30x10+09
PC aa C40:4/PC ae C36:1 0.50 0.16 0.16 3.61x10−16 5.16x10−14 0.13 2.38x10+08
PC aa C40:4/PC ae C34:1 0.39 0.12 0.15 4.01x10−16 5.74x10−14 0.17 3.67x10+08
PC aa C40:4/PC ae C34:0 2.45 0.85 0.16 4.35x10−16 6.22x10−14 0.14 2.14x10+07
PC aa C40:4/PC ae C40:1 2.47 0.71 0.16 5.93x10−16 8.49x10−14 0.07 3.37x10+09
PC aa C38:3/PC ae C38:4 3.46 0.99 0.15 8.80x10−16 1.26x10−13 0.19 3.64x10+03
PC aa C40:4/PC ae C42:5 1.78 0.63 0.16 1.13x10−15 1.61x10−13 0.11 2.52x10+03
PC aa C40:4/PC ae C44:3 38.28 12.76 0.16 1.23x10−15 1.77x10−13 0.09 3.76x10+06
PC aa C34:2/PC ae C38:2 186.71 44.17 0.12 1.78x10−15 2.55x10−13 0.46 9.89x10+05
PC aa C38:4/PC ae C34:1 11.27 3.44 0.15 2.11x10−15 3.02x10−13 0.15 6.97x10+07
PC aa C40:4/PC ae C40:3 3.67 1.19 0.15 2.53x10−15 3.62x10−13 0.15 1.30x10+06
PC aa C42:1/PC ae C36:4 0.02 0.00 -0.15 2.54x10−15 3.63x10−13 0.12 3.34x10+02
PC aa C36:3/PC ae C44:4 360.79 104.54 0.16 2.68x10−15 3.83x10−13 0.09 2.69x10+02
PC aa C40:4/PC ae C44:6 3.15 1.33 0.16 2.86x10−15 4.09x10−13 0.09 2.62x10+02
PC aa C36:4/PC ae C40:5 61.46 15.62 0.15 3.15x10−15 4.51x10−13 0.18 8.57x10+03
PC aa C40:4/PC ae C30:0 9.27 3.93 0.15 3.33x10−15 4.76x10−13 0.18 9.18x10+04
PC aa C36:3/PC ae C34:1 14.24 2.82 0.15 5.47x10−15 7.83x10−13 0.14 2.69x10+07
PC aa C38:4/PC ae C38:0 48.82 14.76 0.16 7.17x10−15 1.03x10−12 0.08 2.59x10+08
PC aa C36:3/PC ae C36:1 18.24 4.14 0.14 8.26x10−15 1.18x10−12 0.22 1.04x10+07
PC aa C38:3/PC ae C38:1 70.46 26.94 0.16 9.26x10−15 1.32x10−12 0.07 3.46x10+02
PC aa C40:4/PC ae C44:5 2.02 0.80 0.15 9.37x10−15 1.34x10−12 0.09 1.57x10+04
PC aa C38:4/PC ae C30:0 264.99 107.03 0.15 9.92x10−15 1.42x10−12 0.17 3.08x10+04
PC aa C38:4/PC ae C32:2 159.11 49.29 0.15 1.06x10−14 1.51x10−12 0.12 1.13x10+08
PC aa C38:4/PC ae C40:0 11.5 2.65 0.15 1.22x10−14 1.75x10−12 0.14 1.52x10+08
PC aa C38:4/PC ae C40:2 57.61 17.37 0.15 1.78x10−14 2.55x10−12 0.09 9.55x10+07
PC aa C38:4/PC ae C32:1 41.25 12.65 0.15 2.22x10−14 3.18x10−12 0.13 8.36x10+07
PC aa C40:5/PC ae C42:2 17.08 4.43 0.15 2.47x10−14 3.54x10−12 0.15 2.20x10+06
PC aa C36:3/PC ae C34:0 88.54 21.38 0.15 3.18x10−14 4.55x10−12 0.11 2.92x10+05
PC aa C40:4/PC ae C40:6 0.85 0.34 0.15 5.04x10−14 7.20x10−12 0.11 4.16x10+03
PC aa C38:4/PC ae C42:1 316.84 65.17 0.15 6.00x10−14 8.58x10−12 0.10 3.10x10+07
PC aa C38:4/PC ae C34:3 14.45 5.52 0.15 1.62x10−13 2.32x10−11 0.09 2.87x10+06
PC aa C36:4/PC ae C40:6 44.41 13.52 0.14 1.74x10−13 2.49x10−11 0.11 1.20x10+03
PC aa C34:1/PC ae C34:1 22.79 4.59 0.13 2.55x10−13 3.65x10−11 0.22 5.77x10+05
PC aa C36:3/PC ae C42:2 224.74 48.80 0.15 3.17x10−13 4.54x10−11 0.06 1.71x10+05
PC aa C36:4/PC ae C42:2 325.38 79.48 0.15 3.33x10−13 4.76x10−11 0.08 1.63x10+05
PC aa C36:4/PC ae C34:0 128.93 37.64 0.14 4.17x10−13 5.96x10−11 0.12 2.23x10+04
PC aa C36:3/PC ae C30:0 332.08 98.14 0.14 4.49x10−13 6.42x10−11 0.11 6.80x10+02
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC aa C36:3/PC ae C40:3 133.46 30.09 0.14 5.82x10−13 8.33x10−11 0.18 5.65x10+03
PC aa C40:5/PC ae C40:1 6.87 1.77 0.14 1.12x10−12 1.60x10−10 0.07 1.79x10+06
PC aa C40:5/PC ae C40:6 2.35 0.82 0.14 1.27x10−12 1.81x10−10 0.10 1.66x10+02
PC aa C40:5/PC ae C34:0 6.79 2.21 0.14 1.27x10−12 1.82x10−10 0.12 7.31x10+03
PC aa C40:6/PC ae C38:0 11.37 2.82 0.14 2.06x10−12 2.95x10−10 0.11 2.52x10+07
PC aa C40:4/PC ae C32:1 1.45 0.50 0.14 2.32x10−12 3.31x10−10 0.11 2.03x10+06
PC aa C36:1/PC ae C36:1 6.54 1.57 0.13 2.36x10−12 3.37x10−10 0.14 3.63x10+04
PC aa C38:4/PC ae C34:2 9.51 3.57 0.14 3.02x10−12 4.32x10−10 0.13 6.15x10+05
PC aa C40:5/PC ae C44:3 106.36 33.39 0.14 3.31x10−12 4.73x10−10 0.09 1.40x10+03
PC aa C34:2/PC ae C34:0 233.74 58.43 0.12 8.33x10−12 1.19x10−09 0.31 1.12x10+03
PC aa C40:4/PC ae C42:1 11.08 2.34 0.14 1.22x10−11 1.74x10−09 0.07 4.62x10+06
PC aa C36:3/PC ae C44:3 1398.09 384.63 0.13 1.52x10−11 2.18x10−09 0.07 3.04x10+02
PC aa C40:5/PC ae C36:1 1.40 0.42 0.13 1.69x10−11 2.41x10−09 0.11 5.08x10+03
PC aa C40:4/PC ae C32:2 5.62 2.01 0.13 1.82x10−11 2.60x10−09 0.12 6.59x10+04
PC aa C36:1/PC ae C34:0 31.89 8.56 0.12 1.93x10−11 2.77x10−09 0.20 4.81x10+02
PC aa C36:3/PC ae C40:1 90.72 21.49 0.13 2.20x10−11 3.15x10−09 0.08 9.09x10+04
PC aa C36:4/PC ae C34:1 20.78 5.50 0.13 2.27x10−11 3.25x10−09 0.12 6.49x10+03
PC aa C38:4/PC ae C36:0 115.73 35.3 0.13 2.28x10−11 3.27x10−09 0.09 8.13x10+04
PC aa C36:4/PC ae C36:1 26.67 7.79 0.12 3.61x10−11 5.17x10−09 0.19 2.37x10+03
PC aa C36:2/PC ae C34:0 138.87 31.74 0.13 3.89x10−11 5.56x10−09 0.08 2.39x10+02
PC aa C34:1/PC ae C34:0 141.93 35.69 0.13 4.12x10−11 5.89x10−09 0.14 2.26x10+02
PC aa C36:2/PC ae C42:2 351.86 69.37 0.13 4.31x10−11 6.17x10−09 0.05 1.26x10+03
PC aa C40:4/PC ae C34:3 0.51 0.22 0.13 4.62x10−11 6.60x10−09 0.08 1.01x10+04
PC aa C38:4/PC ae C38:3 27.78 7.79 0.13 5.18x10−11 7.40x10−09 0.09 3.59x10+04
PC aa C40:4/PC ae C38:0 1.73 0.62 0.13 5.37x10−11 7.68x10−09 0.07 9.67x10+05
PC aa C34:2/PC ae C34:1 37.62 7.99 0.11 6.10x10−11 8.72x10−09 0.36 2.41x10+03
PC aa C36:2/PC ae C36:1 28.60 6.02 0.12 6.15x10−11 8.80x10−09 0.18 1.39x10+03
PC aa C36:4/PC ae C40:4 84.85 20.53 0.13 7.00x10−11 1.00x10−08 0.13 1.39x10+04
PC aa C36:1/PC ae C34:1 5.14 1.19 0.11 7.80x10−11 1.12x10−08 0.29 1.89x10+03
PC aa C40:4/PC ae C34:2 0.34 0.14 0.13 8.37x10−11 1.20x10−08 0.11 1.27x10+05
PC aa C40:5/PC ae C34:1 1.10 0.33 0.12 1.12x10−10 1.60x10−08 0.14 1.32x10+03
PC aa C38:4/PC ae C42:0 237.08 66.26 0.12 1.46x10−10 2.09x10−08 0.13 1.27x10+04
PC aa C40:4/PC ae C36:0 4.06 1.30 0.13 2.07x10−10 2.96x10−08 0.07 2.71x10+05
PC aa C40:4/PC ae C38:4 0.27 0.08 0.12 2.36x10−10 3.38x10−08 0.12 2.38x10+05
PC aa C34:1/PC ae C36:1 29.37 7.64 0.11 2.90x10−10 4.15x10−08 0.29 2.95x10+02
PC aa C40:4/PC ae C38:3 0.97 0.30 0.12 3.42x10−10 4.90x10−08 0.13 1.64x10+05
PC aa C38:4/PC ae C38:5 5.93 1.30 0.12 3.58x10−10 5.12x10−08 0.15 5.18x10+03
PC aa C36:4/PC ae C32:1 76.06 20.02 0.12 3.60x10−10 5.15x10−08 0.08 1.31x10+04
PC aa C40:4/PC ae C40:2 2.05 0.75 0.12 3.72x10−10 5.32x10−08 0.10 4.57x10+03
PC aa C38:4/PC ae C36:3 13.93 4.52 0.12 3.87x10−10 5.54x10−08 0.13 4.80x10+03
PC aa C40:5/PC ae C38:0 4.76 1.44 0.12 4.42x10−10 6.32x10−08 0.07 1.17x10+05
PC aa C40:4/PC ae C40:0 0.41 0.11 0.12 5.26x10−10 7.52x10−08 0.09 1.07x10+05
PC aa C36:4/PC ae C38:0 90.74 26.10 0.12 5.89x10−10 8.43x10−08 0.14 8.82x10+04
PC aa C36:2/PC ae C34:1 22.38 4.35 0.12 6.07x10−10 8.69x10−08 0.09 2.42x10+02
PC aa C38:4/PC ae C38:1 156.15 63.36 0.12 7.08x10−10 1.01x10−07 0.04 2.62x10+03
PC aa C36:2/PC ae C34:3 28.47 7.42 0.12 1.18x10−09 1.68x10−07 0.07 3.96x10+02
PC aa C38:5/PC ae C40:1 37.09 6.37 0.12 1.35x10−09 1.93x10−07 0.05 1.48x10+03
PC aa C36:4/PC ae C32:2 295.14 84.94 0.11 1.42x10−09 2.03x10−07 0.15 8.43x10+02
PC aa C38:4/PC ae C38:6 13.79 3.62 0.12 1.50x10−09 2.15x10−07 0.04 1.24x10+03
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC aa C40:6/PC ae C40:1 16.77 4.89 0.12 2.14x10−09 3.05x10−07 0.13 9.37x10+02
PC aa C36:4/PC ae C34:3 26.70 9.31 0.12 2.38x10−09 3.41x10−07 0.09 1.95x10+02
PC aa C36:2/PC ae C40:1 142.13 31.74 0.12 2.42x10−09 3.47x10−07 0.08 8.25x10+02
PC aa C40:4/PC ae C36:3 0.49 0.17 0.12 2.87x10−09 4.10x10−07 0.11 1.96x10+04
PC aa C36:3/PC ae C32:1 52.49 11.97 0.12 3.48x10−09 4.98x10−07 0.05 1.35x10+03
PC aa C40:5/PC ae C40:4 4.49 1.33 0.11 5.77x10−09 8.25x10−07 0.08 1.69x10+02
PC aa C40:4/PC ae C38:1 5.47 2.25 0.12 7.38x10−09 1.06x10−06 0.04 7.63x10+03
PC aa C36:4/PC ae C40:2 107.63 32.61 0.11 8.06x10−09 1.15x10−06 0.21 2.11x10+02
PC aa C36:2/PC ae C34:2 18.66 4.22 0.11 9.04x10−09 1.29x10−06 0.08 1.17x10+03
PC aa C36:3/PC ae C34:2 12.04 3.46 0.11 2.31x10−08 3.30x10−06 0.07 4.59x10+02
PC aa C40:5/PC ae C32:1 4.04 1.36 0.11 2.92x10−08 4.17x10−06 0.10 1.62x10+02
PC aa C40:4/PC ae C42:0 8.36 2.61 0.11 3.18x10−08 4.55x10−06 0.09 1.77x10+03
PC aa C36:3/PC ae C38:0 63.00 17.9 0.11 5.51x10−08 7.88x10−06 0.09 9.42x10+02
PC aa C38:0/PC ae C36:4 0.16 0.04 -0.11 5.72x10−08 8.18x10−06 0.08 2.50x10+04
PC aa C36:4/PC ae C34:2 17.54 5.88 0.11 5.80x10−08 8.30x10−06 0.07 1.83x10+02
PC aa C36:4/PC ae C36:0 213.53 57.08 0.11 8.78x10−08 1.26x10−05 0.04 7.26x10+03
PC aa C38:5/PC ae C38:0 25.56 5.29 0.10 9.73x10−08 1.39x10−05 0.09 5.34x10+02
PC aa C40:5/PC ae C40:0 1.12 0.27 0.10 1.43x10−07 2.04x10−05 0.10 1.28x10+03
PC aa C40:5/PC ae C36:0 11.29 3.44 0.10 1.87x10−07 2.67x10−05 0.06 3.41x10+03
PC aa C36:4/PC ae C40:0 21.34 4.43 0.10 2.16x10−07 3.09x10−05 0.05 8.49x10+02
PC aa C36:3/PC ae C38:3 35.36 7.00 0.09 2.36x10−07 3.38x10−05 0.24 6.27x10+04
PC aa C36:4/PC ae C38:4 13.98 2.94 0.10 3.93x10−07 5.62x10−05 0.05 6.65x10+04
PC aa C40:2/PC ae C36:4 0.02 0.01 -0.10 8.13x10−07 1.16x10−04 0.06 1.68x10+02
PC aa C40:5/PC ae C38:1 15.20 5.95 0.10 1.75x10−06 2.51x10−04 0.03 3.59x10+02
PC aa C40:5/PC ae C42:1 31.02 6.78 0.09 3.24x10−06 4.64x10−04 0.05 4.33x10+03
PC aa C36:3/PC ae C36:0 147.54 35.81 0.10 5.64x10−07 8.06x10−05 0.03 1.13x10+03
PC aa C36:3/PC ae C36:3 17.63 4.00 0.09 4.29x10−06 6.13x10−04 0.04 9.33x10+02
PC aa C40:5/PC ae C42:0 23.16 6.57 0.09 6.25x10−06 8.93x10−04 0.10 4.76x10+02
PC aa C36:0/PC ae C36:4 0.13 0.04 -0.09 9.53x10−06 1.36x10−03 0.05 1.27x10+03
PC aa C40:5/PC ae C38:3 2.72 0.82 0.08 1.45x10−05 2.07x10−03 0.09 9.69x10+02
PC aa C36:4/PC ae C36:3 25.72 7.39 0.09 1.53x10−05 2.18x10−03 0.04 2.62x10+02
PC aa C36:4/PC ae C42:1 591.88 126.66 0.08 2.30x10−05 3.29x10−03 0.08 1.14x10+03
PC aa C42:4/PC ae C36:4 0.01 0.00 -0.08 2.77x10−05 3.96x10−03 0.10 6.11x10+02
PC aa C36:4/PC ae C38:3 51.94 15.10 0.08 4.65x10−05 6.66x10−03 0.17 3.19x10+02
PC aa C36:4/PC ae C38:6 25.75 6.77 0.07 1.69x10−04 2.42x10−02 0.12 1.55x10+02
PC/lysoPC Ratios
PC aa C38:3/lysoPC a C17:0 32.4 14.58 0.20 3.41x10−24 4.87x10−22 0.12 3.77x10+09
PC aa C38:3/lysoPC a C18:1 2.86 1.12 0.19 1.58x10−23 2.26x10−21 0.21 1.04x10+11
PC aa C38:3/lysoPC a C18:2 2.07 0.97 0.17 3.61x10−19 5.16x10−17 0.21 6.54x10+06
PC aa C38:4/lysoPC a C17:0 71.31 31.03 0.17 3.19x10−18 4.56x10−16 0.09 4.03x10+03
PC aa C38:4/lysoPC a C18:1 6.28 2.45 0.16 7.03x10−18 1.00x10−15 0.16 2.34x10+05
PC aa C40:4/lysoPC a C18:1 0.22 0.08 0.16 2.74x10−17 3.91x10−15 0.14 6.01x10+04
PC aa C38:3/lysoPC a C16:0 0.57 0.17 0.15 8.84x10−16 1.26x10−13 0.16 3.62x10+03
PC aa C38:4/lysoPC a C18:2 4.54 2.14 0.15 3.95x10−15 5.66x10−13 0.18 5.97x10+02
PC aa C38:4/lysoPC a C20:4 18.05 5.67 0.12 1.29x10−11 1.84x10−09 0.27 1.44x10+05
PC aa C38:4/lysoPC a C16:0 1.26 0.38 0.12 6.64x10−10 9.49x10−08 0.11 2.80x10+03
PC aa C38:4/lysoPC a C28:1 206.89 85.78 0.12 1.23x10−09 1.76x10−07 0.06 1.51x10+03
PC aa C38:4/lysoPC a C18:0 4.55 1.46 0.12 5.00x10−09 7.15x10−07 0.07 3.71x10+02
PC aa C40:4/lysoPC a C16:0 0.04 0.01 0.11 6.95x10−09 9.95x10−07 0.08 8.09x10+03
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Trait Mean SD Beta P-Value Adj. Adj.c P-Gaind
(µmol/l) P-Valueb R2
PC aa C40:4/lysoPC a C28:1 7.30 3.31 0.11 2.15x10−08 3.08x10−06 0.07 1.15x10+03
PC aa C40:4/lysoPC a C18:0 0.16 0.05 0.11 9.06x10−08 1.30x10−05 0.04 6.21x10+02
PC aa C40:4/lysoPC a C20:4 0.64 0.23 0.10 1.38x10−07 1.97x10−05 0.15 4.08x10+02
PC aa C36:4/lysoPC a C20:4 33.77 11.69 0.08 5.25x10−06 7.50x10−04 0.22 3.95x10+03
PC aa C40:5/lysoPC a C16:0 0.12 0.04 0.09 1.15x10−05 1.65x10−03 0.09 2.13x10+02
PC aa C40:5/lysoPC a C18:0 0.44 0.14 0.08 7.43x10−05 1.06x10−02 0.04 1.89x10+02
PC ae C36:4/lysoPC a C20:4 3.24 1.10 0.08 5.17x10−05 7.39x10−03 0.15 4.01x10+02
SM (OH) C14:1 6.38 1.86 -0.12 1.60x10−11 2.28x10−09 0.29
SM C16:0 108.15 21.38 -0.10 1.14x10−08 1.63x10−06 0.26
SM (OH) C22:2 11.74 3.14 -0.10 2.36x10−08 3.38x10−06 0.31
SM (OH) C16:1 3.42 0.89 -0.09 1.41x10−07 2.01x10−05 0.24
SM C26:0 0.18 0.05 -0.07 2.97x10−04 4.24x10−02 0.06
SM (OH) C16:1/SM C18:1 0.31 0.06 -0.18 8.49x10−22 1.21x10−19 0.16 1.66x10+14
SM (OH) C14:1/SM C18:1 0.58 0.13 -0.19 1.15x10−21 1.65x10−19 0.10 1.39x10+10
SM (OH) C22:2/SM C18:1 1.06 0.19 -0.19 1.44x10−21 2.06x10−19 0.12 1.64x10+13
SM (OH) C16:1/SM C18:0 0.15 0.02 -0.17 3.75x10−19 5.36x10−17 0.14 3.76x10+11
SM C16:0/SM C16:1 6.81 0.75 -0.16 5.19x10−19 7.42x10−17 0.23 2.20x10+10
SM C16:0/SM C18:1 9.91 1.8 -0.16 1.26x10−18 1.80x10−16 0.20 9.07x10+09
SM (OH) C14:1/SM C18:0 0.28 0.06 -0.17 6.21x10−18 8.88x10−16 0.14 2.57x10+06
SM (OH) C14:1/SM C16:1 0.4 0.08 -0.17 3.13x10−17 4.47x10−15 0.08 5.10x10+05
SM (OH) C22:2/SM C16:1 0.73 0.11 -0.15 1.25x10−15 1.78x10−13 0.15 1.90x10+07
SM C16:0/SM C18:0 4.73 0.72 -0.15 2.92x10−15 4.18x10−13 0.11 3.90x10+06
SM (OH) C22:2/SM C18:0 0.51 0.10 -0.15 4.15x10−15 5.94x10−13 0.17 5.70x10+06
SM (OH) C16:1/SM C16:1 0.21 0.04 -0.12 8.20x10−10 1.17x10−07 0.09 1.72x10+02
SM C18:1/SM C26:1 28.13 7.96 0.11 9.08x10−09 1.30x10−06 0.13 6.29x10+04
SM (OH) C22:1/SM C18:1 1.26 0.26 -0.11 7.11x10−08 1.02x10−05 0.07 2.74x10+04
SM C18:1/SM C26:0 66.47 24.74 0.09 1.58x10−07 2.26x10−05 0.24 1.87x10+03
SM (OH) C24:1/SM C18:1 0.12 0.03 -0.10 1.62x10−07 2.32x10−05 0.08 5.50x10+03
SM C18:1/SM C24:1 0.21 0.04 0.09 6.49x10−07 9.28x10−05 0.18 3.81x10+04
SM C18:0/SM C26:1 58.18 14.21 0.10 7.30x10−07 1.04x10−04 0.10 7.82x10+02
SM (OH) C22:1/SM C24:0 0.63 0.09 -0.09 2.79x10−06 3.99x10−04 0.22 6.97x10+02
SM (OH) C22:1/SM C18:0 0.60 0.11 -0.09 3.82x10−06 5.46x10−04 0.07 5.09x10+02
SM (OH) C24:1/SM C18:0 0.06 0.01 -0.09 4.93x10−06 7.05x10−04 0.07 1.81x10+02
SM C16:1/SM C18:1 1.45 0.19 -0.09 1.19x10−05 1.71x10−03 0.05 2.59x10+03
H1 5005.34 670.72 0.10 3.34x10−07 4.77x10−05 0.13
a Fat Free Mass Index; b for multiple testing adjusted p-value; c adjusted R2 of the linear model; d p-gain,
fold decrease in the p-value of association for the pair of metabolites, compared to the lowest of two
p-values for the single metabolites; AAs amino acids; Σ aromatic amino acids is the sum of tyrosine,
phenylalanine, and tryptophan; Σ BCAAs is the sum of valine, isoleucine, and leucine; Σ glucogenic amino
acids is the sum of alanine, glycine, and serine.
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Table B4: List of selected SNPs, which were significantly associated in genome wide
association studies with anthropometric characteristic as outcomes and tested
in the present study for associations with metabolomics data (Jourdan et al.,
2012).
rs6265 rs988748 rs2568958 rs4923457 rs7635103 rs10871777
rs12321 rs991790 rs2605097 rs4923460 rs7647305 rs10913469
rs29941 rs1011731 rs2605100 rs4923461 rs7766106 rs10938397
rs29942 rs1052486 rs2736172 rs4929949 rs7828207 rs10968576
rs206936 rs1055144 rs2736176 rs6054427 rs7832552 rs11030107
rs368794 rs1077393 rs2815752 rs6499640 rs7928842 rs11075987
rs464553 rs1294420 rs2815752 rs6548238 rs8044769 rs11075989
rs487720 rs1294421 rs2820446 rs6784615 rs8049439 rs11075990
rs506589 rs1350341 rs2844479 rs6795735 rs8050136 rs11084753
rs543874 rs1421085 rs2867125 rs6861681 rs8051591 rs11127491
rs545608 rs1443512 rs2890652 rs6864049 rs8055982 rs11165643
rs571312 rs1460943 rs2893221 rs6874626 rs9491696 rs11664883
rs633265 rs1514175 rs3101336 rs6905288 rs9816226 rs11721286
rs663129 rs1514176 rs3101336 rs7081678 rs9826482 rs11785269
rs713586 rs1555543 rs3751812 rs7085067 rs9931989 rs11847697
rs713587 rs1558902 rs3810291 rs7132908 rs9939609 rs12016871
rs718314 rs1800437 rs3817334 rs7138803 rs10145154 rs12324805
rs734597 rs1813006 rs3888190 rs7178753 rs10150332 rs12444979
rs747472 rs1822438 rs4074134 rs7187333 rs10184004 rs12446228
rs763712 rs1900273 rs4752857 rs7187776 rs10195252 rs12446554
rs887912 rs2049045 rs4771122 rs7189927 rs10501087 rs12641981
rs925946 rs2076529 rs4776375 rs7190492 rs10767658 rs12970134
rs925947 rs2076530 rs4788102 rs7203521 rs10767664 rs13078807
rs939582 rs2112347 rs4804023 rs7359397 rs10769908 rs13107325
rs975918 rs2145270 rs4823006 rs7428936 rs10835211 rs13393304
rs984222 rs2206277 rs4836133 rs7498665 rs10838738 rs16892496
rs984225 rs2241423 rs4846567 rs7561317 rs10840077 rs16912921






















Figure B1: Gaussian graphical model of serum metabolite concentrations of KORA F4. Each node represents a
metabolite, whereas edges represent significant partial correlations. Nodes were coloured according to the β-estimate
and the p-value from the linear models (red = positive association with fat free mass index; blue = negative
association with fat free mass index; white = not significant association with fat free mass index).
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Table C1: Full biochemical names, abbreviation, mean ± standard deviation of all meta-
bolite concentrations measured in µmol/l with the Biocrates AbsoluteIDQ kit
p150 for KORA F4 (n = 1469) and the KORA F4 weight-stablea subset (WS,
n = 621).
Abbrevation Full biochemical name KORA F4 KORA F4 WS
Mean ± SD Mean ± SD
C0 Carnitine 35.39 ± 7.59 35.36 ± 7.33
C2 Acetylcarnitine 7.86 ± 2.77 8.22 ± 2.93
C3 Propionylcarnitine 0.39 ± 0.12 0.38 ± 0.12
C3-OH Hydroxypropionylcarnitine * *
C3:1 Propenonylcarnitine * *
C4 Butyrylcarnitine 0.22 ± 0.10 0.22 ± 0.10
C4-OH (C3-DC) Hydroxybutyrylcarnitine 0.09 ± 0.05 0.09 ± 0.05
C4:1 Butenylcarnitine * *
C5 Valerylcarnitine 0.12 ± 0.04 0.12 ± 0.04
C5-DC (C6-OH) Glutarylcarnitine 0.03 ± 0.01 0.03 ± 0.01
C5-M-DC Methylglutarylcarnitine 0.03 ± 0.01 0.03 ± 0.01
C5-OH (C3-DC-M) Hydroxyvalerylcarnitine
(Methylmalonylcarnitine)
0.04 ± 0.02 0.04 ± 0.02
C5:1 Tiglylcarnitine 0.03 ± 0.01 0.03 ± 0.01
C5:1-DC Glutaconylcarnitine 0.02 ± 0.01 0.02 ± 0.01
C6 (C4:1-DC) Hexanoylcarnitine 0.07 ± 0.02 0.07 ± 0.03
C6:1 Hexenoylcarnitine 0.02 ± 0.01 0.02 ± 0.01
C7-DC Pimelylcarnitine 0.04 ± 0.02 0.05 ± 0.02
C8 Octanoylcarnitine 0.21 ± 0.09 0.22 ± 0.09
C8:1 Octenoylcarnitine 0.09 ± 0.04 0.09 ± 0.04
C9 Nonaylcarnitine 0.05 ± 0.02 0.05 ± 0.02
C10 Decanoylcarnitine 0.34 ± 0.16 0.35 ± 0.15
C10:1 Decenoylcarnitine 0.16 ± 0.06 0.17 ± 0.06
C10:2 Decadienylcarnitine 0.04 ± 0.01 0.04 ± 0.01
C12 Dodecanoylcarnitine 0.13 ± 0.05 0.13 ± 0.05
C12-DC Dodecanedioylcarnitine 0.06 ± 0.01 0.06 ± 0.01
C12:1 Dodecenoylcarnitine 0.14 ± 0.05 0.15 ± 0.05
C14 Tetradecanoylcarnitine 0.04 ± 0.01 0.05 ± 0.01
C14:1 Tetradecenoylcarnitine 0.14 ± 0.05 0.15 ± 0.05
C14:1-OH Hydroxytetradecenoylcarnitine 0.01 ± 0.00 0.01 ± 0.00
C14:2 Tetradecadienylcarnitine 0.03 ± 0.01 0.03 ± 0.01
C14:2-OH Hydroxytetradecadienylcarnitine 0.01 ± 0.00 0.01 ± 0.00
C16 Hexadecanoylcarnitine 0.12 ± 0.03 0.12 ± 0.03
C16-OH Hydroxyhexadecanoylcarnitine * *
C16:1 Hexadecenoylcarnitine 0.04 ± 0.01 0.04 ± 0.01
C16:1-OH Hydroxyhexadecenoylcarnitine 0.01 ± 0.00 0.01 ± 0.00
C16:2 Hexadecadienylcarnitine * *
C16:2-OH Hydroxyhexadecadienylcarnitine 0.01 ± 0.00 0.01 ± 0.00
C18 Octadecanoylcarnitine 0.05 ± 0.01 0.05 ± 0.01
C18:1 Octadecenoylcarnitine 0.13 ± 0.04 0.13 ± 0.04
C18:1-OH Hydroxyoctadecenoylcarnitine * *
C18:2 Octadecadienylcarnitine 0.05 ± 0.01 0.05 ± 0.01
Arg Arginine 115.36 ± 18.30 115.92 ± 17.14
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Abbrevation Full biochemical name KORA F4 KORA F4 WS
Mean ± SD Mean ± SD
Gln Glutamine 615.65 ± 95.73 628.17 ± 88.52
Gly Glycine 311.88 ± 81.53 314.48 ± 82.98
His Histidine 101.79 ± 17.07 100.80 ± 16.22
Met Methionine 31.83 ± 6.06 32.07 ± 5.65
Orn Ornithine 79.80 ± 18.99 81.77 ± 18.61
Phe Phenylalanine 61.61 ± 10.68 61.36 ± 10.48
Pro Proline 174.95 ± 52.78 173.83 ± 50.94
Ser Serine 129.71 ± 24.66 131.28 ± 24.13
Thr Threonine 108.75 ± 26.37 108.03 ± 23.89
Trp Tryptophan 83.95 ± 10.45 83.66 ± 10.07
Tyr Tyrosine 85.12 ± 18.24 85.04 ± 17.68
Val Valine 272.65 ± 58.67 274.27 ± 59.16
xLeu Leucine/Isoleucine 213.31 ± 45.27 213.69 ± 44.87
PC aa C24:0 Phosphatidylcholine diacyl C24:0 0.15 ± 0.09 0.15 ± 0.09
PC aa C26:0 Phosphatidylcholine diacyl C26:0 1.10 ± 0.55 1.08 ± 0.52
PC aa C28:1 Phosphatidylcholine diacyl C28:1 3.33 ± 0.78 3.38 ± 0.80
PC aa C30:0 Phosphatidylcholine diacyl C30:0 4.75 ± 1.55 4.80 ± 1.55
PC aa C30:2 Phosphatidylcholine diacyl C30:2 * *
PC aa C32:0 Phosphatidylcholine diacyl C32:0 15.13 ± 3.28 15.45 ± 3.48
PC aa C32:1 Phosphatidylcholine diacyl C32:1 21.69 ± 11.29 21.96 ± 11.57
PC aa C32:2 Phosphatidylcholine diacyl C32:2 4.01 ± 1.66 4.00 ± 1.70
PC aa C32:3 Phosphatidylcholine diacyl C32:3 0.48 ± 0.12 0.48 ± 0.12
PC aa C34:1 Phosphatidylcholine diacyl C34:1 244.39 ± 62.55 245.49 ± 63.35
PC aa C34:2 Phosphatidylcholine diacyl C34:2 405.97 ± 91.46 403.1 ± 91.63
PC aa C34:3 Phosphatidylcholine diacyl C34:3 18.17 ± 5.39 18.34 ± 5.47
PC aa C34:4 Phosphatidylcholine diacyl C34:4 2.26 ± 0.83 2.27 ± 0.82
PC aa C36:0 Phosphatidylcholine diacyl C36:0 2.72 ± 0.82 2.76 ± 0.85
PC aa C36:1 Phosphatidylcholine diacyl C36:1 53.44 ± 13.59 54.13 ± 13.63
PC aa C36:2 Phosphatidylcholine diacyl C36:2 235.38 ± 44.17 235.45 ± 42.57
PC aa C36:3 Phosphatidylcholine diacyl C36:3 151.34 ± 32.52 150.96 ± 32.57
PC aa C36:4 Phosphatidylcholine diacyl C36:4 221.37 ± 56.11 221.63 ± 55.24
PC aa C36:5 Phosphatidylcholine diacyl C36:5 29.07 ± 13.77 30.12 ± 14.83
PC aa C36:6 Phosphatidylcholine diacyl C36:6 1.11 ± 0.45 1.14 ± 0.46
PC aa C38:0 Phosphatidylcholine diacyl C38:0 3.27 ± 0.86 3.30 ± 0.87
PC aa C38:1 Phosphatidylcholine diacyl C38:1 * *
PC aa C38:3 Phosphatidylcholine diacyl C38:3 52.87 ± 12.89 52.76 ± 12.73
PC aa C38:4 Phosphatidylcholine diacyl C38:4 116.72 ± 29.35 117.65 ± 29.28
PC aa C38:5 Phosphatidylcholine diacyl C38:5 62.18 ± 15.28 63.4 ± 16.05
PC aa C38:6 Phosphatidylcholine diacyl C38:6 90.04 ± 26.79 91.32 ± 27.71
PC aa C40:1 Phosphatidylcholine diacyl C40:1 0.47 ± 0.10 0.48 ± 0.10
PC aa C40:2 Phosphatidylcholine diacyl C40:2 0.35 ± 0.10 0.36 ± 0.10
PC aa C40:3 Phosphatidylcholine diacyl C40:3 0.65 ± 0.15 0.66 ± 0.15
PC aa C40:4 Phosphatidylcholine diacyl C40:4 4.12 ± 1.21 4.13 ± 1.18
PC aa C40:5 Phosphatidylcholine diacyl C40:5 11.38 ± 3.16 11.52 ± 3.24
PC aa C40:6 Phosphatidylcholine diacyl C40:6 27.79 ± 9.07 28.25 ± 9.51
PC aa C42:0 Phosphatidylcholine diacyl C42:0 0.60 ± 0.17 0.61 ± 0.17
PC aa C42:1 Phosphatidylcholine diacyl C42:1 0.30 ± 0.08 0.30 ± 0.08
PC aa C42:2 Phosphatidylcholine diacyl C42:2 0.21 ± 0.06 0.22 ± 0.06
PC aa C42:4 Phosphatidylcholine diacyl C42:4 0.22 ± 0.05 0.22 ± 0.05
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Abbrevation Full biochemical name KORA F4 KORA F4 WS
Mean ± SD Mean ± SD
PC aa C42:5 Phosphatidylcholine diacyl C42:5 0.42 ± 0.12 0.43 ± 0.13
PC aa C42:6 Phosphatidylcholine diacyl C42:6 0.63 ± 0.14 0.63 ± 0.14
PC ae C30:0 Phosphatidylcholine acyl-akyl C30:0 52.87 ± 12.89 52.76 ± 12.73
PC ae C30:1 Phosphatidylcholine acyl-akyl C30:1 * *
PC ae C30:2 Phosphatidylcholine acyl-akyl C30:2 0.48 ± 0.14 0.48 ± 0.14
PC ae C32:1 Phosphatidylcholine acyl-akyl C32:1 0.16 ± 0.04 0.16 ± 0.04
PC ae C32:2 Phosphatidylcholine acyl-akyl C32:2 2.90 ± 0.61 2.94 ± 0.60
PC ae C34:0 Phosphatidylcholine acyl-akyl C34:0 0.75 ± 0.17 0.76 ± 0.17
PC ae C34:1 Phosphatidylcholine acyl-akyl C34:1 1.72 ± 0.46 1.76 ± 0.47
PC ae C34:2 Phosphatidylcholine acyl-akyl C34:2 10.62 ± 2.39 10.76 ± 2.41
PC ae C34:3 Phosphatidylcholine acyl-akyl C34:3 13.07 ± 3.45 13.15 ± 3.42
PC ae C36:0 Phosphatidylcholine acyl-akyl C36:0 8.59 ± 2.42 8.70 ± 2.44
PC ae C36:1 Phosphatidylcholine acyl-akyl C36:1 1.05 ± 0.33 1.07 ± 0.34
PC ae C36:2 Phosphatidylcholine acyl-akyl C36:2 8.21 ± 1.96 8.41 ± 1.98
PC ae C36:3 Phosphatidylcholine acyl-akyl C36:3 15.3 ± 3.96 15.58 ± 3.95
PC ae C36:4 Phosphatidylcholine acyl-akyl C36:4 8.86 ± 2.15 8.85 ± 2.10
PC ae C36:5 Phosphatidylcholine acyl-akyl C36:5 21.41 ± 5.58 21.34 ± 5.42
PC ae C38:0 Phosphatidylcholine acyl-akyl C38:0 13.92 ± 3.50 14.13 ± 3.56
PC ae C38:1 Phosphatidylcholine acyl-akyl C38:1 2.48 ± 0.76 2.54 ± 0.77
PC ae C38:2 Phosphatidylcholine acyl-akyl C38:2 0.81 ± 0.28 0.83 ± 0.28
PC ae C38:3 Phosphatidylcholine acyl-akyl C38:3 2.14 ± 0.49 2.18 ± 0.50
PC ae C38:4 Phosphatidylcholine acyl-akyl C38:4 4.26 ± 0.96 4.30 ± 0.93
PC ae C38:5 Phosphatidylcholine acyl-akyl C38:5 15.79 ± 3.38 15.92 ± 3.32
PC ae C38:6 Phosphatidylcholine acyl-akyl C38:6 20.29 ± 4.48 20.42 ± 4.45
PC ae C40:0 Phosphatidylcholine acyl-akyl C40:0 8.73 ± 2.13 8.84 ± 2.17
PC ae C40:1 Phosphatidylcholine acyl-akyl C40:1 10.27 ± 1.63 10.35 ± 1.66
PC ae C40:2 Phosphatidylcholine acyl-akyl C40:2 1.69 ± 0.40 1.73 ± 0.40
PC ae C40:3 Phosphatidylcholine acyl-akyl C40:3 2.05 ± 0.48 2.10 ± 0.48
PC ae C40:4 Phosphatidylcholine acyl-akyl C40:4 1.13 ± 0.23 1.15 ± 0.23
PC ae C40:5 Phosphatidylcholine acyl-akyl C40:5 2.58 ± 0.50 2.61 ± 0.48
PC ae C40:6 Phosphatidylcholine acyl-akyl C40:6 3.55 ± 0.66 3.62 ± 0.65
PC ae C42:0 Phosphatidylcholine acyl-akyl C42:0 5.06 ± 1.26 5.15 ± 1.27
PC ae C42:1 Phosphatidylcholine acyl-akyl C42:1 0.51 ± 0.12 0.51 ± 0.11
PC ae C42:2 Phosphatidylcholine acyl-akyl C42:2 0.38 ± 0.09 0.38 ± 0.09
PC ae C42:3 Phosphatidylcholine acyl-akyl C42:3 0.68 ± 0.15 0.69 ± 0.15
PC ae C42:4 Phosphatidylcholine acyl-akyl C42:4 0.88 ± 0.20 0.90 ± 0.20
PC ae C42:5 Phosphatidylcholine acyl-akyl C42:5 1.02 ± 0.24 1.04 ± 0.24
PC ae C44:3 Phosphatidylcholine acyl-akyl C44:3 2.39 ± 0.49 2.41 ± 0.48
PC ae C44:4 Phosphatidylcholine acyl-akyl C44:4 0.11 ± 0.03 0.11 ± 0.03
PC ae C44:5 Phosphatidylcholine acyl-akyl C44:5 0.43 ± 0.11 0.44 ± 0.11
PC ae C44:6 Phosphatidylcholine acyl-akyl C44:6 2.15 ± 0.55 2.18 ± 0.54
lysoPC a C14:0 lysoPhosphatidylcholine acyl C14:0 3.23 ± 0.84 3.24 ± 0.86
lysoPC a C16:0 lysoPhosphatidylcholine acyl C16:0 95.47 ± 20.39 97.05 ± 20.04
lysoPC a C16:1 lysoPhosphatidylcholine acyl C16:1 2.92 ± 1.00 2.99 ± 1.03
lysoPC a C17:0 lysoPhosphatidylcholine acyl C17:0 1.73 ± 0.51 1.80 ± 0.53
lysoPC a C18:0 lysoPhosphatidylcholine acyl C18:0 26.47 ± 6.22 26.94 ± 6.10
lysoPC a C18:1 lysoPhosphatidylcholine acyl C18:1 19.77 ± 5.79 20.49 ± 5.82
lysoPC a C18:2 lysoPhosphatidylcholine acyl C18:2 28.98 ± 9.98 29.86 ± 9.82
lysoPC a C6:0 lysoPhosphatidylcholine acyl C6:0 * *
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Abbrevation Full biochemical name KORA F4 KORA F4 WS
Mean ± SD Mean ± SD
lysoPC a C20:3 lysoPhosphatidylcholine acyl C20:3 2.42 ± 0.71 2.49 ± 0.73
lysoPC a C20:4 lysoPhosphatidylcholine acyl C20:4 6.94 ± 2.18 7.10 ± 2.18
lysoPC a C24:0 lysoPhosphatidylcholine acyl C24:0 0.37 ± 0.11 0.37 ± 0.11
lysoPC a C26:0 lysoPhosphatidylcholine acyl C26:0 * *
lysoPC a C26:1 lysoPhosphatidylcholine acyl C26:1 2.00 ± 0.23 2.01 ± 0.24
lysoPC a C28:0 lysoPhosphatidylcholine acyl C28:0 0.50 ± 0.23 0.50 ± 0.22
lysoPC a C28:1 lysoPhosphatidylcholine acyl C28:1 0.62 ± 0.23 0.62 ± 0.23
SM C16:0 Sphingomyelin C16:0 104.63 ± 20.10 106.72 ± 21.40
SM C16:1 Sphingomyelin C16:1 15.55 ± 3.32 15.78 ± 3.55
SM C18:0 Sphingomyelin C18:0 22.7 ± 4.76 22.85 ± 4.94
SM C18:1 Sphingomyelin C18:1 10.87 ± 2.70 10.99 ± 2.89
SM C20:2 Sphingomyelin C20:2 0.39 ± 0.13 0.38 ± 0.12
SM C22:3 Sphingomyelin C22:3 * *
SM C24:0 Sphingomyelin C24:0 21.62 ± 4.97 21.88 ± 5.07
SM C24:1 Sphingomyelin C24:1 51.98 ± 11.37 52.70 ± 12.00
SM C26:0 Sphingomyelin C26:0 0.18 ± 0.05 0.18 ± 0.05
SM C26:1 Sphingomyelin C26:1 0.41 ± 0.12 0.42 ± 0.13
SM (OH) C14:1 Hydroxysphingomyelin C14:1 6.03 ± 1.73 6.21 ± 1.83
SM (OH) C16:1 Hydroxysphingomyelin C16:1 3.28 ± 0.84 3.34 ± 0.88
SM (OH) C22:1 Hydroxysphingomyelin C22:1 13.30 ± 3.31 13.52 ± 3.43
SM (OH) C22:2 Hydroxysphingomyelin C22:2 11.24 ± 2.94 11.46 ± 3.11
SM (OH) C24:1 Hydroxysphingomyelin C24:1 1.31 ± 0.34 1.34 ± 0.35
H1 Hexose 4960.71 ± 627.09 4991.31 ± 628.32
a weight-stable subjects of KORA F4, whose weight gain or loss did not exceed more than 0.5% per year
since their body weight was measured in KORA S4 (seven years prior); Metabolites excluded from the
analyses are marked with * and their mean and standard deviation are not given.
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Table C2: Metabolic traits significantly associated with FT4 in a linear regression model
adjusted for age, sex, BMI, and batch in the KORA F4 sample.
Trait Mean SD Beta P-Value Adj.c P-Gaind
(µmol/l) R2
His/Ser 0.81 0.18 -0.08 6.60x10−09 0.20 3.26x10+04
His/Phe 1.68 0.29 -0.07 3.07x10−07 0.20 3.34x10+03
Phe/Trp 0.73 0.09 0.08 4.79x10−07 0.08 7.02x10+04
Σ AC-DC 0.38 0.10 0.06 3.95x10−05 0.10
Σ AC 10.81 3.24 0.11 3.15x10−13 0.14
Σ even AC 9.97 3.16 0.11 3.27x10−13 0.14
Σ long AC 0.40 0.09 0.11 3.34x10−13 0.21
Σ med. AC 1.12 0.36 0.09 9.88x10−09 0.14
Σ mono AC 1.73 0.46 0.10 6.71x10−11 0.16
Σ poly AC 8.32 2.85 0.11 6.09x10−13 0.13
C18:1 0.13 0.04 0.12 1.80x10−16 0.18
C16:1 0.04 0.01 0.11 1.50x10−13 0.17
C2 7.86 2.77 0.11 1.13x10−12 0.13
C14:2 0.03 0.01 0.11 1.25x10−12 0.14
C18:2 0.05 0.01 0.09 2.48x10−09 0.18
C14:1-OH 0.01 0.00 0.09 2.85x10−09 0.13
C12:1 0.14 0.05 0.09 3.86x10−09 0.12
C16:2-OH 0.01 0.00 0.09 4.01x10−09 0.15
C6 (C4:1-DC) 0.07 0.02 0.09 4.34x10−09 0.13
C12 0.13 0.05 0.09 5.96x10−09 0.12
C16:1-OH 0.01 0.00 0.08 6.29x10−08 0.20
C14 0.04 0.01 0.08 7.60x10−08 0.20
C10 0.34 0.16 0.08 1.30x10−07 0.10
C16 0.12 0.03 0.07 7.36x10−07 0.19
C10:1 0.16 0.06 0.07 9.50x10−07 0.14
C14:2-OH 0.01 0.00 0.06 9.93x10−07 0.36
C5-DC (C6-OH) 0.03 0.01 0.06 4.69x10−05 0.05
C14:1 0.14 0.05 0.06 5.56x10−05 0.25
C5:1:DC 0.02 0.01 0.06 6.37x10−05 0.09
C7:DC 0.04 0.02 0.06 8.65x10−05 0.12
C8 0.21 0.09 0.06 8.93x10−05 0.10
C2/C0 0.23 0.08 0.11 7.61x10−13 0.15
(C2+C3)/C0 0.24 0.08 0.11 4.15x10−13 0.14
CTP1 0.001 0.001 0.06 8.23x10−05 0.07
PCs
Σ PCs 1985.9 355.32 -0.11 1.28x10−13 0.14
Σ mono PCs 348.23 86.27 -0.11 3.77x10−13 0.07
Σ poly PCs 1593.43 279.51 -0.11 3.30x10−12 0.15
Σ sat. PCs 44.23 7.91 -0.09 9.88x10−09 0.12
Σ sat. mono PCs 348.23 86.27 -0.11 3.77x10−13 0.07
Σ short PCs 759.58 161.54 -0.11 1.25x10−13 0.25
PC aa
Σ PC aa 1788.09 333.4 -0.12 2.91x10−14 0.14
Σ long PC aa 47.14 12.35 -0.06 4.33x10−05 0.07
Σ mono PC aa 323.62 83.10 -0.11 4.36x10−13 0.07
LXXXVI Appendix
Trait Mean SD Beta P-Value Adj.c P-Gaind
(µmol/l) R2
Σ poly PC aa 1436.75 261.65 -0.11 7.81x10−13 0.15
Σ sat. PC aa 27.72 5.60 -0.08 3.32x10−08 0.11
Σ short PC aa 721.28 156.91 -0.11 1.04x10−13 0.25
PC aa C34:4 2.26 0.83 -0.14 7.28x10−19 0.07
PC aa C32:2 4.01 1.66 -0.13 1.53x10−18 0.15
PC aa C36:1 53.44 13.59 -0.13 4.29x10−17 0.10
PC aa C34:3 18.17 5.39 -0.13 2.29x10−16 0.13
PC aa C30:0 4.75 1.55 -0.12 1.35x10−15 0.12
PC aa C36:2 235.38 44.17 -0.12 1.35x10−14 0.10
PC aa C36:6 1.11 0.45 -0.11 2.57x10−12 0.06
PC aa C36:3 151.34 32.52 -0.11 4.48x10−12 0.10
PC aa C38:5 62.18 15.28 -0.11 4.97x10−12 0.05
PC aa C32:1 21.69 11.29 -0.11 5.61x10−12 0.07
PC aa C36:5 29.07 13.77 -0.11 7.91x10−12 0.05
PC aa C34:1 244.39 62.55 -0.10 1.87x10−11 0.10
PC aa C42:6 0.63 0.14 -0.10 2.37x10−10 0.05
PC aa C34:2 405.97 91.46 -0.08 1.62x10−09 0.34
PC aa C40:5 11.38 3.16 -0.09 2.27x10−09 0.06
PC aa C40:4 4.12 1.21 -0.09 3.21x10−08 0.05
PC aa C36:4 221.37 56.11 -0.08 2.24x10−07 0.09
PC aa C32:0 15.13 3.28 -0.08 3.37x10−07 0.10
PC aa C38:3 52.87 12.89 -0.07 1.03x10−06 0.13
PC aa C32:3 0.48 0.12 -0.07 1.91x10−06 0.16
PC aa C40:2 0.35 0.10 -0.07 2.45x10−05 0.07
PC aa C42:5 0.42 0.12 -0.07 3.94x10−05 0.04
PC aa C40:3 0.65 0.15 -0.06 5.15x10−05 0.05
PC ae
Σ mono PC ae 24.61 5.00 -0.07 2.63x10−06 0.17
Σ sat. PC ae 16.51 2.81 -0.08 2.88x10−07 0.12
Σ short PC ae 38.30 8.25 -0.06 3.23x10−05 0.19
PC ae C40:1 1.69 0.40 -0.11 6.43x10−13 0.08
PC ae C38:2 2.14 0.49 -0.10 1.21x10−11 0.17
PC ae C42:2 0.68 0.15 -0.09 1.88x10−09 0.12
PC ae C38:0 2.48 0.76 -0.09 3.78x10−08 0.06
PC ae C38:1 0.81 0.28 -0.07 4.36x10−06 0.05
PC ae C34:0 1.72 0.46 -0.07 6.95x10−06 0.13
PC ae C36:1 8.21 1.96 -0.07 9.39x10−06 0.15
PC ae C36:0 1.05 0.33 -0.07 1.18x10−05 0.04
PC ae C42:1 0.38 0.09 -0.07 1.51x10−05 0.02
PC ae C40:0 10.27 1.63 -0.06 2.89x10−05 0.11
PC ae C34:3 8.59 2.42 -0.06 4.55x10−05 0.13
lysoPC a
Σ lysoPCs 191.41 40.73 -0.08 2.42x10−07 0.19
Σ sat. lysoPCs 127.77 26.44 -0.07 8.15x10−06 0.14
Σ unsat. lysoPCs 63.64 17.36 -0.08 1.03x10−07 0.23
lysoPC a C14:0 3.23 0.84 -0.09 9.92x10−09 0.04
lysoPC a C20:3 2.42 0.71 -0.08 3.44x10−08 0.16
lysoPC a C16:1 2.92 1.00 -0.08 7.64x10−08 0.06
lysoPC a C18:1 19.77 5.79 -0.08 1.34x10−07 0.21
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Trait Mean SD Beta P-Value Adj.c P-Gaind
(µmol/l) R2
lysoPC a C18:2 28.98 9.98 -0.07 3.57x10−06 0.23
lysoPC a C18:0 26.47 6.22 -0.07 1.37x10−05 0.09
lysoPC a C16:0 95.47 20.39 -0.06 2.80x10−05 0.15
PC aa/PC aa Ratios
PC aa C36:6/PC aa C42:0 1.95 0.80 -0.14 5.06x10−18 0.06 5.08x10+05
PC aa C36:5/PC aa C42:0 51.17 24.93 -0.13 1.93x10−16 0.10 4.10x10+04
PC aa C36:6/PC aa C38:0 0.35 0.12 -0.13 2.62x10−16 0.06 9.81x10+03
PC aa C36:6/PC aa C42:1 3.84 1.52 -0.13 6.48x10−16 0.05 3.97x10+03
PC aa C42:0/PC aa C42:2 2.90 0.64 0.12 4.10x10−14 0.09 4.72x10+09
PC aa C42:1/PC aa C42:2 1.45 0.27 0.11 5.58x10−12 0.07 3.46x10+07
PC aa C36:0/PC aa C38:0 0.83 0.13 -0.11 9.76x10−12 0.04 1.51x10+08
PC aa C36:0/PC aa C42:0 4.70 1.30 -0.10 1.77x10−10 0.10 8.36x10+06
PC aa C40:2/PC aa C42:0 0.62 0.18 -0.10 1.91x10−10 0.09 1.28x10+05
PC aa C40:2/PC aa C42:1 1.22 0.30 -0.09 7.26x10−09 0.07 3.38x10+03
PC aa C40:3/PC aa C42:0 1.15 0.32 -0.09 7.28x10−09 0.10 7.07x10+03
PC aa C40:1/PC aa C42:0 0.82 0.16 -0.08 4.30x10−08 0.12 1.74x10+05
PC aa C42:0/PC aa C42:4 2.80 0.75 0.08 1.37x10−07 0.08 4.34x10+03
PC aa C36:0/PC aa C42:1 9.28 2.37 -0.08 1.50x10−07 0.08 9.86x10+03
PC ae/PC ae Ratios
PC ae C42:2/PC ae C42:5 0.29 0.06 -0.15 4.31x10−22 0.07 4.37x10+12
PC ae C40:1/PC ae C42:5 0.73 0.18 -0.15 2.55x10−21 0.09 2.53x10+08
PC ae C40:1/PC ae C40:5 0.48 0.10 -0.14 6.88x10−20 0.09 9.35x10+06
PC ae C38:2/PC ae C42:5 0.92 0.22 -0.14 1.33x10−18 0.08 9.04x10+06
PC ae C40:5/PC ae C42:2 5.35 0.92 0.13 1.58x10−18 0.15 1.19x10+09
PC ae C38:2/PC ae C40:3 1.90 0.27 -0.13 1.27x10−17 0.08 9.49x10+05
PC ae C42:2/PC ae C44:5 0.33 0.08 -0.13 7.13x10−17 0.06 2.64x10+07
PC ae C40:1/PC ae C44:5 0.82 0.25 -0.13 1.02x10−16 0.06 6.28x10+03
PC ae C38:2/PC ae C40:5 0.61 0.12 -0.13 4.12x10−16 0.09 2.92x10+04
PC ae C42:2/PC ae C42:4 0.68 0.15 -0.12 6.30x10−15 0.08 2.99x10+05
PC ae C38:0/PC ae C40:6 0.50 0.12 -0.12 1.47x10−14 0.07 2.58x10+06
PC ae C40:4/PC ae C42:2 3.88 0.70 0.12 1.80x10−14 0.08 1.04x10+05
PC ae C42:3/PC ae C42:5 0.37 0.07 -0.12 3.11x10−14 0.07 3.57x10+10
PC ae C42:2/PC ae C44:4 1.61 0.37 -0.12 4.22x10−14 0.07 4.47x10+04
PC ae C42:2/PC ae C44:6 0.51 0.13 -0.12 7.54x10−14 0.07 2.50x10+04
PC ae C38:0/PC ae C42:5 1.07 0.34 -0.11 5.42x10−13 0.05 6.97x10+04
PC ae C42:3/PC ae C44:5 0.42 0.09 -0.11 9.46x10−12 0.05 1.22x10+08
PC ae C34:0/PC ae C42:5 0.74 0.20 -0.11 1.67x10−11 0.06 4.17x10+05
PC ae C38:1/PC ae C42:5 0.35 0.13 -0.10 4.44x10−11 0.05 9.83x10+04
PC ae C34:3/PC ae C42:5 3.66 1.00 -0.10 6.52x10−11 0.05 6.98x10+05
PC ae C42:1/PC ae C42:5 0.16 0.05 -0.10 1.29x10−10 0.05 1.17x10+05
PC ae C36:1/PC ae C42:5 3.53 0.95 -0.10 1.51x10−10 0.09 6.24x10+04
PC ae C34:1/PC ae C42:5 4.54 1.05 -0.10 1.94x10−10 0.07 9.42x10+05
PC ae C36:0/PC ae C42:5 0.45 0.15 -0.10 3.43x10−10 0.04 3.43x10+04
PC ae C42:3/PC ae C44:6 0.65 0.14 -0.10 3.65x10−10 0.03 3.17x10+06
PC ae C34:0/PC ae C40:5 0.49 0.11 -0.09 1.32x10−09 0.09 5.26x10+03
PC ae C36:3/PC ae C42:5 3.79 0.93 -0.10 1.74x10−09 0.04 3.10x10+05
PC ae C34:3/PC ae C44:5 4.15 1.26 -0.10 1.85x10−09 0.05 2.46x10+04
PC ae C42:3/PC ae C42:4 0.87 0.16 -0.09 3.27x10−09 0.03 3.54x10+05
PC ae C42:1/PC ae C44:5 0.18 0.06 -0.09 3.28x10−09 0.03 4.60x10+03
LXXXVIII Appendix
Trait Mean SD Beta P-Value Adj.c P-Gaind
(µmol/l) R2
PC ae C32:1/PC ae C42:5 1.23 0.22 -0.09 4.10x10−09 0.06 2.71x10+05
PC ae C34:3/PC ae C44:6 6.41 1.84 -0.09 5.09x10−09 0.04 8.95x10+03
PC ae C36:5/PC ae C42:5 5.95 1.54 -0.09 5.54x10−09 0.12 2.00x10+05
PC ae C34:2/PC ae C42:5 5.58 1.45 -0.09 2.76x10−08 0.04 4.02x10+04
PC ae C42:3/PC ae C44:4 2.08 0.43 -0.09 3.04x10−08 0.03 3.80x10+04
PC ae C40:3/PC ae C42:5 0.48 0.09 -0.08 4.75x10−08 0.12 2.33x10+04
PC ae C34:1/PC ae C44:5 5.16 1.48 -0.09 4.77x10−08 0.07 3.83x10+03
PC ae C36:3/PC ae C44:5 4.30 1.26 -0.09 8.32x10−08 0.05 6.48x10+03
PC ae C36:5/PC ae C44:5 6.75 2.02 -0.08 1.38x10−07 0.08 2.13x10+04
PC ae C34:2/PC ae C44:5 6.34 1.93 -0.08 4.78x10−07 0.05 4.05x10+03
PC ae C32:1/PC ae C44:5 1.40 0.32 -0.08 5.33x10−07 0.06 9.60x10+03
SM C18:1 10.87 2.70 0.07 4.15x10−06 0.24
SM C20:2 0.39 0.13 0.05 3.96x10−05 0.39
SM (OH) C16:1 3.28 0.84 0.06 1.19x10−04 0.17
SM C18:0 22.70 4.76 0.06 1.32x10−04 0.12
SM C24:0/SM C24:1 0.42 0.06 -0.09 9.48x10−09 0.04 3.37x10+04
a adjusted R2 of the linear model; b p-gain, fold decrease in the p-value association for the pair of metabolites,
compared to the lowest of two p-values for the single metabolites; AC, acylcarnitines; CPT1, carnitine
palmitoyltransferase I; even, even numbered; long, long-chain; med., medium-chain; short, short-chain;
sat., saturated; unsat., unsaturated.
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Table C3: Metabolic traits significantly associated with FT4 in linear regression models
adjusted for age, sex, batch, and FFMIa next to the significantly associated
traits from linear models adjusted for age, sex, batch, and BMI the in the
KORA F4 weight-stableb subsample (n = 621).
Adjusted for FFMI Adjusted for BMI
Trait Beta P-Value Adj.c P-Gaind Beta P-Value Adj.c P-Gaind
R2 R2
His -0.09 1.62x10−05 0.38 -0.09 9.41x10−06 0.38
Ser/Trp 0.12 3.74x10−07 0.20 2.86x10+03 0.12 1.27x10−07 0.20 4.36x10+03
His/Ser -0.14 1.69x10−09 0.25 5.56x10+03
Σ long AC 0.09 5.06x10−05 0.20 0.10 2.38x10−05 0.20
Σ mono AC 0.09 1.72x10−04 0.15 0.09 9.31x10−05 0.15
C18:1 0.11 7.90x10−06 0.16 0.11 3.74x10−06 0.17
C14:1-OH 0.09 1.73x10−04 0.11 0.09 9.89x10−05 0.11
C16:2-OH 0.13 6.68x10−08 0.13 0.13 4.30x10−08 0.13
C6 (C4:1-DC) 0.10 5.80x10−05 0.11 0.10 2.92x10−05 0.12
C10 0.10 8.16x10−05 0.10 0.10 4.22x10−05 0.10
C14:2-OH 0.09 1.02x10−04 0.12
PCs
Σ PCs -0.12 4.78x10−07 0.14 -0.12 1.93x10−07 0.14
Σ mono PCs -0.12 3.00x10−06 0.07 -0.12 1.31x10−06 0.07
Σ poly PCs -0.11 1.95x10−06 0.15 -0.12 8.65x10−07 0.15
Σ sat. PCs -0.10 5.93x10−05 0.14 -0.10 4.96x10−05 0.14
Σ sat. mono PCs -0.12 3.00x10−06 0.07 -0.12 1.31x10−06 0.07
Σ short PCs -0.11 7.90x10−07 0.26 -0.11 3.52x10−07 0.26
PC aa
Σ PC aa -0.12 3.68x10−07 0.14 -0.13 1.45x10−07 0.14
Σ mono PC aa -0.12 3.18x10−06 0.07 -0.12 1.40x10−06 0.07
Σ poly PC aa -0.11 1.75x10−06 0.15 -0.12 7.98x10−07 0.15
Σ sat. PC aa -0.09 2.37x10−04 0.13
Σ short PC aa -0.11 8.32x10−07 0.27 -0.11 3.84x10−07 0.27
PC aa C34:4 -0.16 3.22x10−10 0.08 -0.16 1.31x10−10 0.08
PC aa C32:2 -0.15 3.77x10−10 0.15 -0.15 2.06x10−10 0.15
PC aa C36:1 -0.13 3.21x10−07 0.09 -0.13 1.34x10−07 0.10
PC aa C34:3 -0.12 4.15x10−07 0.10 -0.13 1.39x10−07 0.10
PC aa C30:0 -0.12 5.50x10−07 0.12 -0.12 5.73x10−07 0.12
PC aa C36:2 -0.12 4.67x10−07 0.10 -0.13 2.11x10−07 0.10
PC aa C36:6 -0.13 2.79x10−07 0.08 -0.13 1.74x10−07 0.08
PC aa C36:3 -0.12 3.00x10−06 0.08 -0.12 1.03x10−06 0.08
PC aa C38:5 -0.12 3.37x10−06 0.05 -0.12 1.62x10−06 0.06
PC aa C32:1 -0.12 2.18x10−06 0.06 -0.12 1.58x10−06 0.06
PC aa C36:5 -0.10 4.73x10−05 0.05 -0.11 2.51x10−05 0.05
PC aa C34:1 -0.11 1.04x10−05 0.11 -0.11 4.41x10−06 0.11
PC aa C42:6 -0.13 2.21x10−07 0.06 -0.13 1.94x10−07 0.06
PC aa C34:2 -0.08 4.38x10−05 0.37 -0.09 2.37x10−05 0.37
PC aa C40:5 -0.10 7.82x10−05 0.06 -0.10 5.11x10−05 0.06
PC aa C40:4 -0.11 1.79x10−05 0.06 -0.11 9.96x10−06 0.07
PC aa C36:4 -0.09 0.00012 0.09 -0.10 6.43x10−05 0.09
PC aa C42:2 -0.10 5.52x10−05 0.09 -0.10 6.39x10−05 0.09
XC Appendix
Trait Beta P-Value Adj.c P-Gaind Beta P-Value Adj.c P-Gaind
R2 R2
PC aa C38:3 -0.09 1.27x10−04 0.15
PC ae
Σ sat. PC ae -0.10 3.02x10−05 0.12 -0.10 2.00x10−05 0.13
PC ae C40:1 -0.12 1.65x10−06 0.05 -0.12 1.08x10−06 0.07
PC ae C38:2 -0.13 1.39x10−07 0.15 -0.13 6.11x10−08 0.17
PC ae C42:2 -0.10 1.86x10−05 0.11 -0.11 1.27x10−05 0.13
PC ae C38:0 -0.10 2.59x10−05 0.07 -0.11 1.56x10−05 0.07
PC ae C42:1 -0.10 4.35x10−05 0.03 -0.10 6.10x10−05 0.03
PC ae C40:0 -0.09 0.00015 0.12 -0.09 9.62x10−05 0.13
PC ae C34:3 -0.09 1.44x10−04 0.14
lysoPC a









-0.15 1.50x10−09 0.07 1.24x10+04 -0.16 6.15x10−10 0.07 2.06x10+04
PC ae C42:3/
PC ae C42:5
-0.14 2.92x10−08 0.05 8.03x10+04 -0.14 1.67x10−08 0.06 1.33x10+05
PC ae C32:1/
PC ae C42:5
-0.11 6.85x10−06 0.07 3.50x10+03 -0.12 3.55x10−06 0.07 5.93x10+03
a fat free mass index, b weight-stable subjects of KORA F4, whose weight gain or loss did not exceed more
than 0.5% per year since their body weight was measured in KORA S4 (seven years prior); c adjusted R2
of the linear model; d p-gain, fold decrease in the p-value association for the pair of metabolites, compared
to the lowest of two p-values for the single metabolites; AC, acylcarnitines; even, even numbered; long,
long-chain; med., medium-chain; short, short-chain; sat., saturated; unsat., unsaturated.
C Supplementary Material - Metabolomics and Thyroid Hormones XCI
Table C4: Metabolic traits significantly associated with FT4 in linear regression models
adjusted for age, BMI, sex, batch and stratified by physical activitya in the
KORA F4 sample.
Active (n = 838) Inactive (n = 631)
Trait Beta P-Value Adj.b P-Gainc Beta P-Value Adj.b P-Gainc
R2 R2
Σ poly AC 0.1 2.22x10−06 0.12 0.12 3.01x10−08 0.14
Σ even AC 0.1 2.90x10−06 0.13 0.12 1.22x10−08 0.15
Σ AC 0.1 4.12x10−06 0.13 0.13 7.12x10−09 0.16
Σ long AC 0.09 2.32x10−05 0.18 0.13 1.07x10−09 0.25
Σ mono AC 0.12 7.61x10−09 0.19
Σ AC-DC 0.10 9.94x10−06 0.13
Σ AC-OH 0.08 1.39x10−03 0.13
C18:1 0.11 1.25x10−07 0.16 0.14 1.83x10−10 0.20
C16:1 0.10 1.22x10−06 0.16 0.12 1.63x10−08 0.18
C2 0.10 2.76x10−06 0.12 0.12 4.70x10−08 0.13
C14:2 0.09 2.85x10−05 0.14 0.13 8.38x10−09 0.15
C12:1 0.11 1.36x10−06 0.14
C14 0.09 3.70x10−05 0.22
C18:2 0.11 4.08x10−07 0.19
C16:1:OH 0.09 2.17x10−05 0.21
C12 0.11 6.58x10−07 0.14
C6 (C4:1-DC) 0.11 2.31x10−07 0.15
C14:1:OH 0.12 8.53x10−08 0.14
C16:2:OH 0.12 1.07x10−08 0.17
C10 0.11 1.23x10−06 0.12
C16 0.09 1.10x10−05 0.22
C10:1 0.11 1.09x10−06 0.15
C5:1-DC 0.09 4.64x10−05 0.09
C8 0.09 7.02x10−05 0.14
C14:2-OH 0.11 2.08x10−08 0.35
C7-DC 0.10 5.10x10−06 0.14
C5-DC (C6-OH) 0.12 2.33x10−07 0.08
C18 0.08 1.67x10−04 0.22
C2+C3/C0 0.11 8.00x10−08 0.15 0.11 5.59x10−07 0.14
C2/C0 0.11 9.91x10−08 0.15 0.11 1.06x10−06 0.14
PCs
Σ mono PCs -0.12 1.50x10−08 0.07 -0.11 3.95x10−06 0.08
Σ sat. mono PCs -0.12 1.50x10−08 0.07 -0.11 3.95x10−06 0.07
Σ PCs -0.12 1.72x10−08 0.14 -0.11 1.52x10−06 0.14
Σ short. PCs -0.11 2.76x10−08 0.25 -0.10 1.36x10−06 0.24
Σ poly PCs -0.11 1.38x10−07 0.14 -0.10 5.81x10−06 0.15
Σ sat. PCs -0.10 8.95x10−06 0.145
PC aa
Σ PC aa -0.12 7.48x10−09 0.14 -0.11 8.30x10−07 0.14
Σ mono PC aa -0.12 1.52x10−08 0.07 -0.10 4.27x10−06 0.07
Σ short. PC aa -0.11 2.42x10−08 0.26 -0.10 1.48x10−06 0.24
Σ poly PC aa -0.11 6.30x10−08 0.15 -0.10 3.27x10−06 0.15
PC aa C36:1 -0.15 8.78x10−13 0.11 -0.11 2.04x10−06 0.09
XCII Appendix
Trait Beta P-Value Adj.b P-Gainc Beta P-Value Adj.b P-Gainc
R2 R2
PC aa C36:2 -0.14 4.86x10−11 0.11 -0.10 1.40x10−05 0.09
PC aa C34:4 -0.14 2.94x10−10 0.07 -0.14 6.15x10−10 0.07
PC aa C32:2 -0.13 7.15x10−10 0.16 -0.14 6.79x10−10 0.14
PC aa C34:3 -0.13 7.91x10−10 0.14 -0.12 1.12x10−07 0.11
PC ae C38:2 -0.11 5.08x10−08 0.18 -0.09 6.76x10−05 0.15
PC aa C36:3 -0.12 5.20x10−08 0.10 -0.10 1.93x10−05 0.08
PC aa C30:0 -0.11 8.21x10−08 0.11 -0.13 2.50x10−09 0.13
PC aa C34:1 -0.11 2.46x10−07 0.10 -0.10 1.54x10−05 0.10
PC ae C40:1 -0.11 5.97x10−07 0.07 -0.11 4.28x10−07 0.08
PC aa C32:1 -0.11 1.13x10−06 0.06 -0.11 1.42x10−06 0.07
PC aa C34:2 -0.09 2.82x10−06 0.36
PC aa C40:4 -0.10 2.90x10−06 0.05 -0.08 7.80x10−04 0.04
PC aa C36:6 -0.10 3.18x10−06 0.06 -0.12 3.17x10−07 0.06
PC aa C38:5 -0.10 3.98x10−06 0.04 -0.12 3.55x10−07 0.06
PC aa C40:5 -0.10 6.24x10−06 0.06 -0.09 4.39x10−05 0.05
PC aa C38:3 -0.09 9.96x10−06 0.14
PC aa C36:5 -0.10 1.58x10−05 0.03 -0.12 1.33x10−07 0.07
PC aa C32:3 -0.08 4.13x10−05 0.17
PC aa C42:6 -0.09 6.35x10−05 0.05 -0.11 7.94x10−07 0.05
PC aa C36:4 -0.09 1.03x10−04 0.10
PC aa C32:0 -0.09 1.07x10−04 0.12
PC ae
PC ae C38:1 -0.09 1.54x10−05 0.07
PC ae C34:3 -0.08 8.84x10−05 0.14
PC ae C38:0 -0.09 7.13x10−05 0.05
PC ae C42:2 -0.11 9.87x10−07 0.12
lysoPC
Σ lysoPCs -0.09 3.75x10−06 0.20
Σ sat. lysoPCs -0.09 1.41x10−05 0.16
lysoPC a C14:0 -0.10 4.51x10−06 0.04 -0.08 5.91x10−04 0.05
lysoPC a C16:1 -0.09 1.69x10−05 0.06
lysoPC a C18:0 -0.09 2.57x10−05 0.10
lysoPC a C16:0 -0.08 3.75x10−05 0.17
lysoPC a C18:1 -0.08 4.16x10−05 0.21
lysoPC a C20:3 -0.08 9.00x10−05 0.17 -0.09 6.81x10−05 0.14





-0.15 1.55x10−12 0.09 3.28x10+04
PC ae C40:1/
PC ae C42:5
-0.15 6.50x10−12 0.08 9.19x10+04
PC aa C42:1/
PC ae C40:1
0.15 1.05x10−11 0.08 5.67x10+04
PC aa C42:0/
PC ae C40:1
0.15 1.67x10−11 0.09 3.58x10+04
PC ae C42:2/
PC ae C42:5
-0.14 1.17x10−10 0.05 3.46x10+06 -0.16 1.76x10−12 0.09 5.61x10+05
PC ae C38:2/
PC ae C40:3
-0.13 1.20x10−08 0.08 5.62x10+03
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-0.14 1.44x10−10 0.05 4.15x10+03
PC aa C36:6/
PC aa C42:0
-0.14 3.03x10−10 0.06 1.05x10+04
PC ae C40:1/
PC ae C40:5
-0.15 9.98x10−11 0.10 4.29x10+03
PC aa C36:6/
PC ae C40:6
-0.14 3.47x10−10 0.07 9.18x10+03
PC ae C42:2/
PC ae C44:5
-0.13 1.45x10−09 0.05 2.80x10+05
PC ae C38:1/
PC ae C42:5
-0.13 2.30x10−09 0.06 6.71x10+03
PC aa C42:0/
PC ae C42:2
0.13 4.29x10−09 0.08 9.44x10+04
PC ae C34:3/
PC ae C42:5
-0.13 7.23x10−09 0.06 1.22x10+04
PC aa C42:0/
PC ae C38:0
0.13 1.01x10−08 0.05 3.50x10+04
PC ae C34:3/
PC ae C44:5
-0.13 1.33x10−08 0.06 6.64x10+03
PC aa C42:0/
PC aa C42:2
0.12 3.31x10−08 0.09 4.60x10+05 0.12 1.77x10−07 0.10 1.30x10+04
PC ae C38:0/
PC ae C40:6
-0.12 3.60x10−08 0.05 9.87x10+03
PC aa C42:0/
PC ae C42:3
0.12 5.38x10−08 0.04 2.83x10+05 0.12 2.74x10−07 0.04 1.10x10+04
PC ae C40:5/
PC ae C42:2
0.11 8.31x10−08 0.16 4.88x10+03 0.15 2.93x10−12 0.15 3.37x10+05
PC aa C42:1/
PC ae C42:2
0.12 9.47x10−08 0.08 4.28x10+03
PC aa C42:1/
PC ae C38:0
0.12 1.02x10−07 0.04 3.50x10+03
PC ae C36:3/
PC ae C42:5
-0.12 1.43x10−07 0.05 5.29x10+03
PC aa C42:1/
PC aa C42:2
0.11 1.65x10−07 0.07 1.72x10+05
PC aa C32:0/
PC ae C42:5
-0.11 3.30x10−07 0.10 3.18x10+03
PC aa C40:2/
PC aa C42:0
-0.11 4.09x10−07 0.08 4.83x10+03
PC ae C42:3/
PC ae C44:5
-0.11 5.96x10−07 0.05 1.89x10+04
PC ae C34:1/
PC ae C42:5
-0.11 6.16x10−07 0.06 5.70x10+03
PC aa C40:2/
PC aa C42:1
-0.11 6.91x10−07 0.07 2.86x10+03
PC ae C42:3/
PC ae C42:5
-0.11 7.64x10−07 0.06 9.45x10+03 -0.13 1.39x10−08 0.07 2.16x10+05
PC ae C34:2/
PC ae C42:5
-0.11 9.51x10−07 0.04 3.34x10+03
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-0.10 2.40x10−06 0.13 3.00x10+03
PC ae C42:3/
PC ae C44:6
-0.10 9.58x10−06 0.02 4.30x10+03
PC aa C42:1/
PC ae C42:3
0.10 1.26x10−05 0.03 7.83x10+03
PC aa C36:0/
PC aa C38:0
-0.13 2.86x10−08 0.07 1.73x10+05
SM C18:1 0.09 1.17x10−05 0.25
SM C24:1 0.09 4.66x10−05 0.13
SM C16:0 0.09 2.67x10−05 0.21
a physical activity (active: ≥ 1h sport per week on a regular basis; inactive: less than 1h sport per week); b
adjusted R2 of the linear model; c p-gain, fold decrease in the p-value association for the pair of metabolites,
compared to the lowest of two p-values for the single metabolites; AC, acylcarnitines; even, even numbered;
long, long-chain; med., medium-chain; short, short-chain; sat., saturated; unsat., unsaturated.
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Table C5: Metabolic traits significantly associated with FT4 in linear regression models
adjusted for age, BMI, batch and stratified by gender in the KORA F4 sample.
Male (n = 792) Female (n = 677)
Trait Beta P-Value Adj.a P-Gainb Beta P-Value Adj.a P-Gainb
R2 R2
Σ AC 0.11 2.36x10−08 0.13 0.11 2.46x10−06 0.16
Σ even AC 0.11 2.72x10−08 0.13 0.11 2.14x10−06 0.15
Σ long AC 0.11 2.76x10−08 0.16 0.11 3.60x10−06 0.16
Σ med. AC 0.10 3.54x10−06 0.10
Σ mono AC 0.11 1.74x10−07 0.11 0.09 1.29x10−04 0.16
Σ poly AC 0.11 6.70x10−08 0.12 0.11 2.18x10−06 0.14
C18:1 0.12 1.91x10−09 0.16 0.13 8.35x10−09 0.13
C14:2 0.11 4.62x10−08 0.10 0.10 1.56x10−05 0.14
C18:2 0.08 1.58x10−04 0.12 0.11 7.49x10−06 0.10
C14:1-OH 0.10 3.52x10−07 0.09
C12:1 0.10 2.86x10−06 0.10
C16:2-OH 0.11 3.71x10−08 0.14
C6 (4:1-DC) 0.10 6.43x10−07 0.09
C12 0.10 3.05x10−06 0.08
C16:1-OH 0.09 7.37x10−06 0.15
C14 0.09 1.32x10−05 0.15
C10 0.09 8.88x10−06 0.06
C16 0.09 1.07x10−05 0.12
C10:1 0.08 1.13x10−04 0.09
C14:2-OH 0.08 4.78x10−06 0.36
C2/C0 0.11 1.59x10−07 0.15 0.13 5.81x10−08 0.08
(C2+C3)/C0 0.11 1.09x10−07 0.15 0.13 4.85x10−08 0.08
PCs
Σ PCs -0.11 2.64x10−08 0.14 -0.11 1.11x10−06 0.12
Σ mono PCs -0.10 1.02x10−06 0.08 -0.13 3.56x10−08 0.07
Σ poly PCs -0.11 5.46x10−08 0.15 -0.10 1.72x10−05 0.13
Σ sat. mono PCs -0.10 1.02x10−06 0.08 -0.13 3.56x10−08 0.07
Σ sat. PCs -0.08 3.51x10−05 0.10 -0.09 1.27x10−04 0.11
Σ short PCs -0.10 1.86x10−07 0.24 -0.11 1.23x10−07 0.25
PC aa
Σ mono PC aa -0.10 9.22x10−07 0.08 -0.13 4.92x10−08 0.07
Σ PC aa -0.11 1.52x10−08 0.14 -0.12 4.17x10−07 0.13
Σ poly PC aa -0.11 3.20x10−08 0.16 -0.10 7.51x10−06 0.14
Σ sat. PC aa -0.08 4.72x10−05 0.10
Σ short PC aa -0.10 1.55x10−07 0.24 -0.11 1.46x10−07 0.26
PC aa C34:4 -0.16 1.18x10−13 0.07 -0.13 3.04x10−07 0.04
PC aa C32:2 -0.14 4.82x10−11 0.09 -0.14 6.42x10−09 0.11
PC aa C36:1 -0.13 1.81x10−09 0.07 -0.14 7.82x10−10 0.15
PC aa C34:3 -0.12 4.42x10−08 0.06 -0.15 5.10x10−10 0.08
PC aa C30:0 -0.13 1.87x10−09 0.08 -0.12 3.19x10−07 0.10
PC aa C36:2 -0.12 1.46x10−09 0.11 -0.12 8.57x10−07 0.07
PC aa C36:6 -0.11 5.76x10−07 0.04 -0.12 5.71x10−07 0.06
PC aa C36:3 -0.09 4.87x10−06 0.08 -0.12 1.73x10−07 0.09
PC aa C38:5 -0.10 1.10x10−06 0.04 -0.12 3.64x10−07 0.07
XCVI Appendix
Trait Beta P-Value Adj.a P-Gainb Beta P-Value Adj.a P-Gainb
R2 R2
PC aa C32:1 -0.10 2.28x10−06 0.06 -0.12 1.07x10−06 0.06
PC aa C36:5 -0.09 1.22x10−05 0.03 -0.13 5.69x10−08 0.06
PC aa C34:1 -0.09 7.93x10−06 0.11 -0.12 4.61x10−07 0.10
PC aa C42:6 -0.10 2.75x10−06 0.03 -0.10 5.47x10−05 0.07
PC aa C34:2 -0.08 7.36x10−06 0.33 -0.08 1.08x10−04 0.34
PC aa C40:5 -0.09 8.44x10−06 0.05 -0.10 3.83x10−05 0.08
PC aa C40:4 -0.09 9.50x10−06 0.06
PC aa C36:4 -0.09 3.74x10−06 0.11
PC aa C32:3 -0.08 1.63x10−04 0.02
PC aa C42:5 -0.08 1.47x10−04 0.07
PC ae
Σ mono PC ae -0.09 7.57x10−05 0.10
Σ sat. PC ae -0.09 1.54x10−04 0.10
PC ae C40:1 -0.11 1.58x10−07 0.07 -0.12 2.94x10−07 0.11
PC ae C38:2 -0.10 4.69x10−07 0.08 -0.11 3.08x10−06 0.11
PC ae C42:2 -0.09 5.81x10−06 0.11 -0.10 2.87x10−05 0.10
PC ae C38:0 -0.08 1.30x10−04 0.04 -0.10 3.50x10−05 0.06
lysoPC a
Σ unsat lysoPCs -0.08 1.07x10−04 0.18 -0.10 2.93x10−05 0.16
lysoPC a C14:0 -0.10 4.52x10−06 0.05
lysoPC a C20:3 -0.12 1.97x10−07 0.10
lysoPC a C16:1 -0.08 1.11x10−04 0.04 -0.09 1.36x10−04 0.06
lysoPC a C18:1 -0.10 1.78x10−05 0.17
lysoPC a C18:2 -0.09 1.31x10−04 0.15





-0.15 1.91x10−10 0.07 2.99x10+03
PC aa C42:0/
PC aa C42:2
0.11 1.38x10−07 0.05 7.53x10+03 0.13 5.19x10−08 0.06 1.59x10+05
PC aa C42:1/
PC aa C42:2
0.13 1.43x10−07 0.06 2.95x10+05
PC aa C36:0/
PC aa C38:0
-0.13 8.51x10−08 0.06 5.78x10+05
PC aa C36:0/
PC aa C42:0
-0.12 4.83x10−07 0.06 1.71x10+04
PC aa C36:0/
PC aa C42:1





-0.14 5.52x10−11 0.07 1.05x10+05 -0.18 1.27x10−13 0.09 2.25x10+08
PC ae C40:1/
PC ae C42:5
-0.18 1.90x10−13 0.10 1.55x10+06
PC ae C40:1/
PC ae C40:5
-0.16 1.28x10−11 0.08 2.29x10+04
PC ae C38:2/
PC ae C42:5
-0.16 4.45x10−12 0.11 6.92x10+05
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0.12 1.19x10−09 0.16 4.87x10+03 0.15 7.68x10−11 0.14 3.73x10+05
PC ae C38:2/
PC ae C40:3
-0.15 1.53x10−10 0.08 2.02x10+04
PC ae C42:2/
PC ae C44:5
-0.15 1.72x10−10 0.07 1.67x10+05
PC ae C38:2/
PC ae C40:5
-0.15 8.16x10−10 0.05 3.78x10+03
PC ae C42:2/
PC ae C42:4
-0.15 7.37x10−10 0.08 3.89x10+04
PC ae C38:2/
PC ae C40:4
-0.15 6.03x10−10 0.07 5.12x10+03
PC ae C38:2/
PC ae C42:4
-0.14 1.84x10−09 0.10 1.68x10+03
PC ae C38:0/
PC ae C40:6
-0.15 1.30x10−09 0.07 2.68x10+04
PC ae C40:4/
PC ae C42:2
0.15 1.49x10−09 0.07 1.93x10+04
PC ae C42:3/
PC ae C42:5
-0.10 1.79x10−06 0.06 6.38x10+03 -0.15 1.45x10−09 0.08 7.01x10+05
PC ae C42:2/
PC ae C44:6
-0.15 1.25x10−09 0.07 2.29x10+04
PC ae C38:0/
PC ae C42:5
-0.14 4.57x10−09 0.07 7.65x10+03
PC ae C42:3/
PC ae C44:5
-0.13 1.05x10−07 0.05 5.48x10+04
PC ae C34:0/
PC ae C42:5
-0.13 1.11x10−08 0.11 2.51x10+04
PC ae C38:1/
PC ae C42:5
-0.12 1.94x10−07 0.08 5.22x10+03
PC ae C38:0/
PC ae C42:0
-0.13 1.19x10−08 0.20 2.93x10+03
PC ae C34:3/
PC ae C42:5
-0.14 5.46x10−09 0.07 1.56x10+05
PC ae C36:1/
PC ae C42:5
-0.13 2.32x10−08 0.15 9.23x10+03
PC ae C34:1/
PC ae C42:5
-0.14 2.33x10−09 0.08 2.45x10+05
PC ae C42:3/
PC ae C44:6
-0.13 1.12x10−07 0.04 6.73x10+04
PC ae C36:3/
PC ae C42:5
-0.13 1.47x10−07 0.04 6.92x10+03
PC ae C34:3/
PC ae C44:5
-0.13 1.22x10−07 0.05 6.98x10+03
PC ae C42:3/
PC ae C42:4
-0.12 2.15x10−06 0.03 2.37x10+04
PC ae C32:1/
PC ae C42:5
-0.15 8.65x10−10 0.07 1.17x10+06
PC ae C34:3/
PC ae C44:6
-0.14 2.90x10−08 0.05 2.94x10+04
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-0.12 5.25x10−07 0.06 1.10x10+04
a adjusted R2 of the linear model; b p-gain, fold decrease in the p-value association for the pair of metabolites,
compared to the lowest of two p-values for the single metabolites; AC, acylcarnitines; even, even numbered;
long, long-chain; med., medium-chain; short, short-chain; sat., saturated; unsat., unsaturated.
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Table C6: Metabolic traits significantly associated with FT4 in linear regression models
adjusted for age, BMI, batch and stratified by obesity status in the KORA F4
sample.
Obese (BMI = 30 kg/m2) Non-Obese (BMI < 30 kg/m2)
(n = 286) (n = 1182)
Trait Beta P-Value Adj.a P-Gainb Beta P-Value Adj.a P-Gainb
R2 R2
Σ AC 0.11 5.18x10−10 0.10
Σ even AC 0.11 5.83x10−10 0.10
Σ long AC 0.13 7.86x10−05 0.20 0.10 1.40x10−09 0.20
Σ med. AC 0.08 1.14x10−06 0.10
Σ mono AC 0.09 1.89x10−08 0.20
Σ poly AC 0.10 1.38x10−09 0.10
C18:1 0.13 7.29x10−05 0.18 0.12 1.47x10−12 0.17
C16:1 0.15 7.62x10−06 0.20 0.10 1.06x10−09 0.15
C2 0.10 2.21x10−09 0.11
C14:2 0.14 7.12x10−05 0.15 0.10 4.84x10−09 0.14
C18:2 0.08 1.21x10−06 0.19
C14:1-OH 0.13 1.04x10−04 0.17 0.08 3.27x10−06 0.11
C12:1 0.08 1.48x10−06 0.11
C16:2-OH 0.08 2.70x10−06 0.15
C6 (C4:1-DC) 0.09 7.89x10−08 0.11
C12 0.08 2.53x10−06 0.12
C16:1-OH 0.08 1.01x10−06 0.20
C14 0.07 1.40x10−05 0.20
C10 0.08 2.86x10−06 0.09
C10:1 0.07 2.77x10−05 0.13
C2/C0 0.11 6.77x10−11 0.10
(C2+C3)/C0 0.11 3.20x10−11 0.10
PCs
Σ PCs -0.10 2.72x10−11 0.10
Σ mono PCs -0.10 6.32x10−11 0.10
Σ poly PCs -0.10 3.04x10−10 0.10
Σ sat. PCs -0.10 3.32x10−07 0.10
Σ sat. mono PCs -0.10 6.32x10−11 0.10
Σ short PCs -0.10 2.25x10−10 0.20
PC aa
Σ PC aa -0.10 6.13x10−12 0.10
Σ long PC aa -0.10 3.25x10−05 0.10
Σ mono PC aa -0.10 7.39x10−11 0.10
Σ poly PC aa -0.10 8.31x10−11 0.10
Σ sat. PC aa -0.10 1.50x10−06 0.10
Σ short PC aa -0.10 1.67x10−10 0.20
PC aa C34:4 -0.14 7.37x10−05 0.07 -0.14 1.76x10−14 0.07
PC aa C32:2 -0.15 8.56x10−06 0.16 -0.12 2.02x10−13 0.15
PC aa C36:1 -0.13 1.15x10−14 0.11
PC aa C34:3 -0.14 5.98x10−05 0.14 -0.12 4.04x10−12 0.13
PC aa C30:0 -0.12 1.42x10−12 0.11
PC aa C36:2 -0.12 2.34x10−11 0.09
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Trait Beta P-Value Adj.a P-Gainb Beta P-Value Adj.a P-Gainb
R2 R2
PC aa C36:6 -0.11 1.99x10−10 0.07
PC aa C36:3 -0.11 1.16x10−09 0.08
PC aa C38:5 -0.11 8.45x10−11 0.06
PC aa C32:1 -0.11 2.44x10−10 0.06
PC aa C36:5 -0.12 4.14x10−11 0.06
PC aa C34:1 -0.10 2.22x10−09 0.09
PC aa C42:6 -0.11 2.87x10−09 0.05
PC aa C34:2 -0.07 1.09x10−06 0.35
PC aa C40:5 -0.10 5.65x10−09 0.06
PC aa C40:4 -0.10 3.46x10−08 0.03
PC aa C36:4 -0.08 5.79x10−06 0.08
PC aa C32:0 -0.08 7.09x10−06 0.10
PC aa C38:3 -0.09 9.12x10−07 0.05
PC aa C32:3 -0.07 5.26x10−05 0.16
PC aa C42:5 -0.07 1.41x10−04 0.05
PC aa C40:3 -0.08 1.39x10−05 0.06
PC ae
Σ mono PC ae -0.10 5.31x10−05 0.10
Σ sat. PC ae -0.10 1.38x10−06 0.10
PC ae C40:1 -0.12 9.56x10−11 0.04
PC ae C38:2 -0.09 2.91x10−08 0.14
PC ae C42:2 -0.10 3.85x10−08 0.08
PC ae C38:0 -0.09 1.47x10−07 0.06
PC ae C38:1 -0.07 7.70x10−05 0.04
PC ae C34:0 -0.07 1.34x10−04 0.11
PC ae C36:0 -0.08 2.65x10−05 0.03
PC ae C42:1 -0.07 5.03x10−05 0.02
PC ae C40:0 -0.07 6.98x10−05 0.09
lysoPC a
Σ lysoPCs -0.10 5.38x10−07 0.20
Σ sat. lysoPCs -0.10 4.57x10−06 0.10
Σ unsat. lysoPCs -0.10 2.27x10−06 0.10
lysoPC a C14:0 -0.10 1.39x10−08 0.05
lysoPC a C20:3 -0.09 2.28x10−08 0.17
lysoPC a C16:1 -0.10 4.72x10−08 0.07
lysoPC a C18:1 -0.08 1.20x10−06 0.13
lysoPC a C18:2 -0.07 1.18x10−04 0.12
lysoPC a C18:0 -0.08 9.36x10−06 0.09





0.11 1.49x10−10 0.08 2.62x10+06
PC aa C42:1/
PC aa C42:2
0.11 5.16x10−10 0.06 7.59x10+05
PC aa C36:0/
PC aa C38:0
-0.10 4.26x10−08 0.03 2.13x10+05
PC aa C36:0/
PC aa C42:0
-0.09 1.09x10−06 0.06 8.28x10+03
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-0.17 2.03x10−06 0.09 3.00x10+03 -0.15 6.47x10−17 0.07 5.94x10+08
PC ae C40:1/
PC ae C42:5
-0.14 4.55x10−16 0.09 2.10x10+05
PC ae C40:1/
PC ae C40:5
-0.14 2.77x10−15 0.07 3.45x10+04
PC ae C38:2/
PC ae C42:5
-0.19 1.47x10−07 0.09 1.39x10+04 -0.12 2.31x10−12 0.08 1.26x10+04
PC ae C40:5/
PC ae C42:2
0.13 3.96x10−15 0.15 9.71x10+06
PC ae C38:2/
PC ae C40:3
-0.19 1.47x10−07 0.13 1.40x10+04 -0.12 4.01x10−11 0.05 7.27x10+02
PC ae C42:2/
PC ae C44:5
-0.12 4.09x10−12 0.05 9.41x10+03
PC ae C38:2/
PC ae C40:5
-0.18 3.14x10−07 0.12 6.53x10+03
PC ae C38:0/
PC ae C40:6
-0.12 1.89x10−12 0.07 7.77x10+04
PC ae C42:3/
PC ae C42:5
-0.12 5.37x10−11 0.05 3.04x10+07
PC ae C42:3/
PC ae C44:5
-0.10 4.28x10−08 0.04 3.82x10+04
PC ae C34:0/
PC ae C42:5
-0.10 3.63x10−08 0.06 3.68x10+03
PC ae C34:3/
PC ae C42:5
-0.09 4.27x10−07 0.04 3.46x10+03
PC ae C34:1/
PC ae C42:5
-0.09 3.00x10−07 0.06 5.96x10+03
PC ae C36:3/
PC ae C42:5
-0.18 9.55x10−07 0.09 6.37x10+03
PC ae C42:3/
PC ae C42:4
-0.09 5.38x10−07 0.03 3.04x10+03
PC ae C32:1/
PC ae C42:5
-0.08 4.01x10−06 0.04 3.47x10+03
PC ae C36:5/
PC ae C42:5
-0.08 3.07x10−06 0.10 2.90x10+03
PC ae C34:2/
PC ae C42:5
-0.19 1.90x10−07 0.10 2.43x10+04
PC ae C40:3/
PC ae C42:5
-0.08 3.84x10−06 0.12 3.62x10+03
PC ae C34:2/
PC ae C44:5
-0.18 8.01x10−07 0.10 5.75x10+03
PC ae C34:2/
PC ae C44:6
-0.18 5.28x10−07 0.11 8.73x10+03
SM C16:0/
SM C24:0
0.08 2.60x10−06 0.10 8.80x10+03
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-0.09 2.04x10−07 0.04 9.58x10+04
a adjusted R2 of the linear model; b p-gain, fold decrease in the p-value association for the pair of metabolites,
compared to the lowest of two p-values for the single metabolites; AC, acylcarnitines; even, even numbered;
long, long-chain; med., medium-chain; short, short-chain; sat., saturated; unsat., unsaturated.
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